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INTRODUCTION 
The autonomic nervous system is to the heart as a maestro is to the orchestra – 
conductor of rhythm and dynamic. When the maestro is stressed it will 
immediately reflect on the music, as it will sound rushed and hurried, while when 
calm the music will be in perfect harmony. Many a factor can cause stress to the 
maestro. He might fall into afflictions of the mind, such as depression or anxiety. 
Or the strain of life and bad habits could get to him, as he enjoys his beers and 
cigarettes on the lazy weekends. The orchestra does not mind when the maestro 
is agitated at times, it keeps them on edge and concentrated. But when this state 
becomes chronic they will endure the consequences of wear and tear.  
Cardiac autonomic activity 
The autonomic nervous system is a division of the peripheral nervous system and 
orchestrates bodily functions to maintain homeostasis. This system is involved in 
the acute human stress response and exists of two branches. The sympathetic 
nervous system is activated during stress and danger to prepare the body for 
action, known as the ‘fight or flight’ response. The parasympathetic nervous 
system regulates the body’s ‘rest and digest’ state. Sympathetic activity stimulates 
an increase in heart rate, blood pressure, pupil dilation, breathing rate, sweat 
production, and energy distribution to the muscles. This happens primarily by 
employing the neurotransmitter norepinephrine to act on α- and β-adrenergic 
receptors on the organs. Parasympathetic activity stimulates a heart rate decrease, 
pupil constriction, digestion, and the restoration of energy level. The nervus vagus 
is its principal nerve and employs acetylcholine to innervate muscarinic receptors 
on the organs.  
Because the autonomic nervous system influences many important vital 
systems in the body, researchers have been interested in measuring its activity. The 
golden standard is to measure this directly, for example by action potentials in the 
nerves or neurotransmitter spillover. Such measurements, however, are highly 
invasive. Therefore, studies have often preferred indirect, non-invasive measures 
of the effect of autonomic activity on the organs – such as the heart. Various 
devices have been developed to measure cardiac autonomic activity by recording 
electrocardiography (ECG) and impedance cardiography (ICG) (Figure 1). 
Combined, these recordings hold a wealth of valuable information on sympathetic 
and parasympathetic functioning. Heart rate (HR) is directly derived from the ECG 
interbeat interval (IBI) time series, and is controlled by both branches of the 
autonomic nervous system.1 Heart rate variability (HRV) mainly reflects parasympathetic 
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activity, also referred to as vagal activity, and can be obtained in several ways by using 
the ECG, sometimes combined with respiratory frequency from the thorax 
impedance.2–5 A combination of the ECG and ICG signals allows for the obtainment 
of the pre-ejection period (PEP), a measure indicating contractility of the heart that 
is under the control of the sympathetic nervous system.1 From the ECG we can also 
derive T-wave amplitude (TWA)6 and HR-corrected QT-interval (QTc),7 two 
measures of cardiac repolarization that are affected by sympathetic activity. 
Sympathetic innervation generally causes an increase in HR, a decrease in HRV, a 
shorter PEP, a lower TWA, and a prolongation of QTc, whereas parasympathetic 
innervation has the opposite effect.   
Figure 1. ICG and ECG recording indicating several cardiac autonomic measures. 
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Mental health and cardiac autonomic activity 
Depressive and anxiety disorders are among the largest contributors to global 
disability.8 People with these mental health disorders have an increased risk of 
cardiovascular disease (CVD).9–13 Researchers have wondered whether the 
autonomic nervous system might be an underlying mechanism in the pathway 
from depression and anxiety to CVD. It is intuitively appealing that depressive and 
anxiety disorders – characterized by distress and fear14 – may be associated with 
negative alterations of the autonomic nervous system (ANS) – a major determinant 
of cardiac functioning15 – and that dysregulation of this system in turn may lead to 
diseases of the heart. Indeed, studies have found depression and anxiety to be 
associated with basal levels of cardiac autonomic activity,16–22 but many questions 
and contradictions remain to be elucidated. For instance, some studies have 
implied altered cardiac autonomic reactivity to stressors among patients with 
depression and anxiety rather than dysregulation at basal levels.23,24 In addition, 
there are indications that measures of cardiac repolarization that are affected by 
sympathetic activity could explain part of the comorbidity between poor mental 
health and cardiovascular disease,25–28 but these measures have not received 
adequate attention in the literature. The most important debate revolves around 
findings from several studies, including those from our own research group, 
indicating that the relationship between cardiac autonomic activity and mental 
health might be attributable to antidepressant use.29–33 However, the effects of 
antidepressants also remain ambiguous, as studies find different results and effect 
sizes for different types of medication. Most studies find large and robust 
associations between the use of tricyclic antidepressants and cardiac autonomic 
dysregulation,34–37 but findings are conflicting for other antidepressants.31,36,38 In 
addition to antidepressant use, there are many factors that may influence the 
association between poor mental health and cardiac autonomic activity. With 
rapid progress in DNA technologies and widespread recognition of the importance 
of genetics, one cannot help but wonder if genetic risk should be taken into 
account when investigating any relationship, including the above. For instance, 
poor mental health might primarily affect cardiac autonomic activity in persons 
with a genetic vulnerability for cardiac autonomic dysregulation, leaving the 
persons with no such vulnerability less affected. Such genetic moderation may 
explain contradicting findings in this field as studies have differed in their sample 
selection. And what about the usual suspects? It is well known that poor mental 
health leads to poorer lifestyle,39 and an impact of lifestyle on cardiac autonomic 
functioning may well explain the relationship of depression and anxiety with 
cardiac autonomic dysregulation. However, previous studies on the relationship of 
cardiac autonomic activity with physical activity,40–49 alcohol use,50–56 and smoking57–59 
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have mostly been conducted cross-sectionally or over short time periods, and there is 
a need for more longitudinal evidence. Given these gaps in the literature, research 
is required to clarify the nature of the relationship between mental health and 
cardiac autonomic activity. 
Cardiac autonomic activity and CVD risk 
One of the mechanisms through which autonomic dysregulation is thought to 
underlie the relationship of depression and anxiety with CVD, is via its associations 
with CVD risk factors. Indeed, studies have linked cardiac autonomic dysregulation 
to components of the metabolic syndrome60: high waist circumference, blood 
pressure, triglycerides, glucose, and/or low high-density lipoprotein cholesterol.61–
70 Recent studies have suggested that markers of systemic inflammation, which are 
part of the immune response to harmful stimuli, might be plausibly included as 
features of the metabolic syndrome and may play a role in the pathogenic 
aggregation of its multiple components.71,72 Congruently, cardiac autonomic 
dysregulation has been associated with increased levels of inflammatory 
markers.73–83 Studies investigating these relationships have mostly been cross-
sectional, whereas few studies have investigated these relationships longitudinally 
to infer directionality. Moreover – circling back to the main question – few studies 
have attempted to investigate the mediating effect of cardiac autonomic activity 
in the pathway between poor mental health and cardiovascular disease risk.  
COHORTS 
The present thesis is mainly based on the Netherlands Study of Depression and 
Anxiety (NESDA), a longitudinal cohort study to examine the long-term course of 
depression and anxiety.84 The NESDA sample includes 2981 participants aged 18-
65 years with a current diagnosis of depression and/or anxiety disorder (according 
to the DSM-IV-based Composite International Diagnostic Interview, version 2.185), 
a prior history of these disorders, and healthy controls. Participants were recruited 
from community, primary care and mental health care in the Netherlands. A four-
hour baseline measurement was conducted by trained research staff between 
September 2004 and February 2007, and follow-up assessments took place 
after two, four, six, and nine years. Demographic, psychiatric and biological 
assessments were included, as well as collection of blood and saliva samples.  
Because NESDA was designed to primarily include persons with 
depressive and/or anxiety disorder, two population-based samples were used to 
replicate and extend some of the research questions in this thesis. The Netherlands 
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Twin Register (NTR) sample included 828 participants who participated in a large 
cardiac ambulatory monitoring study and a large biobank study.86 The Adult 
Health and Behavior (AHAB) study included behavioral and biological 
measurements of 1785 participants.87,88  
 
AIM AND OUTLINE OF THIS THESIS 
 
The main aim of this thesis is to investigate the role of cardiac autonomic activity 
in the pathway from poor mental health to CVD risk, with specific focus on 
influences of antidepressant use, genetics, and lifestyle. This aim is subdivided into 
the following questions: Is poor mental health associated with cardiac autonomic 
dysregulation (Chapter 2 – 6, 9)? Is cardiac autonomic dysregulation associated 
with CVD risk factors (Chapter 7 – 9)? And is cardiac autonomic activity in the 
pathway from poor mental health to CVD risk (Chapter 9)? 
The outline of this thesis is illustrated in Figure 2. Chapter 2 examines 
whether persons with depression and anxiety show a differential stress reactivity 
during two types of stress conditions. Chapter 3 investigates the association of 
depression, anxiety, and antidepressant use with cardiac repolarization. Chapter 4 
focuses on the effect of genetic risk on the association of depression, anxiety, and 
antidepressant use with cardiac autonomic activity. In Chapter 5, we determined 
the influences of lifestyle factors on cardiac autonomic activity over time. Chapter 
6 describes temporal stability of cardiac autonomic measures and investigates the 
most important determinants that drive cardiac autonomic change over time. 
Chapter 7 presents the longitudinal effects of basal cardiac autonomic activity and 
stress reactivity on metabolic syndrome components. Chapter 8 shows the 
bidirectional prospective association between cardiac autonomic activity and 
markers of systemic inflammation. Finally, Chapter 9 investigates the mediating 
role of cardiac vagal activity in the association of depressive and anxious 
symptomatology with metabolic and inflammatory dysregulations. A summary 
and discussion of this thesis will be given in Chapter 10, as well as clinical 
implications and recommendations for future research.  
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ABSTRACT 
 
Objective: It remains unclear whether depressive and anxiety disorders are 
associated with hypo- or hyperreactivity of the autonomic nervous system (ANS) 
and whether deviant reactivity occurs in all types of stressors. This study compared 
ANS reactivity in people with current or remitted depression/anxiety with 
reactivity in healthy controls during two stress conditions.  
Methods: From the Netherlands Study of Depression and Anxiety (NESDA), data 
was available of 804 individuals with current depression/anxiety, 913 individuals 
with remitted depression/anxiety, and 466 healthy controls (mean age=44.1 years; 
66.4% female). Two conditions were used to evoke stress: 1) an n-back task, a 
cognitive challenging stressor, and 2) a psychiatric interview, evoking personal-
emotional stress related to the occurrence of symptoms of depression/anxiety. 
Indicators of ANS activity were heart rate (HR), root mean square of differences 
between successive interbeat intervals (RMSSD), respiratory sinus arrhythmia 
(RSA), and pre-ejection period (PEP).  
Results: As compared to controls, participants with psychopathology had significant 
hyporeactivity of HR (controls=4.1; remitted=3.5; current psychopathology=3.1 
beats/min), RMSSD (controls=-6.2; remitted=-5.4; current psychopathology=-3.5 ms) and 
RSA (controls=-9.3; remitted=-7.4; current psychopathology=-6.9 ms) during the n-back 
task. In contrast, during the psychiatric interview they showed significant hyperreactivity 
of HR (controls=2.7; remitted=3.5; current psychopathology=4.0 beats/min), RMSSD 
(controls=-3.4; remitted=-4.1; current psychopathology=-5.6 ms) and RSA (controls=-3.8; 
remitted=-4.3; current psychopathology=-5.0 ms). The lack of group differences in PEP 
reactivity suggests that the found effects were driven by altered cardiac vagal reactivity 
in depression/anxiety. 
Conclusions: The direction of altered ANS reactivity in depressed/ anxious 
patients is dependent on the type of stressor and only the more ecologically valid 
stressors may evoke hyperreactivity in these patients.     
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INTRODUCTION 
Depressive and anxiety disorders, both important causes of disability-adjusted life 
years (DALYs) according to the World Health Organization, have been associated 
with an increased risk of cardiovascular disease (CVD), the leading cause of 
DALYs.1–5 It is intuitively appealing that depressive and anxiety disorders – 
characterized by distress and fear6 – may be associated with negative alterations 
of the autonomic nervous system (ANS) involved in the human stress response,7 
and that dysregulation of this system in turn may lead to diseases of the heart. The 
existence and nature of these autonomic dysregulations remain debated.3 For 
instance, when Licht et al. investigated sympathetic nervous system (SNS) and 
parasympathetic nervous system (PNS) activity in over 1000 patients with 
depression8–10 and anxiety disorders,9–11 they found no associations between these 
disorders and autonomic dysregulation independent of a robust association with 
use of antidepressants. However, these studies focused on overall levels of ANS 
activity and did not include a contrast between the resting level and a condition 
evoking a stress response, which may explain the lack of evidence for an altered 
ANS in depressed and anxious patients. Several studies have implied altered ANS 
reactivity to stressors among depressed patients rather than ANS dysregulation 
during baseline conditions.12,13 For example, Hughes et al.12 found that depressed 
mood was related to increased heart rate responses and stronger withdrawal of 
parasympathetic cardiac control during stressors, but not to heart rate and vagal 
control at baseline. Interestingly, both hyperreactivity14–16 and hyporeactivity17–24 
have been implied in depression and anxiety. Hyporeactivity was seen in a study 
of 1608 participants by Phillips et al.,17 who found higher depression scores to be 
associated with lower heart rate reactivity to psychological stress. Illustrating the 
lack of unanimity among research in this area, a number of studies have reported 
no relationship at all between ANS stress reactivity and psychiatric disorders.25,26 
A possible explanation for the discrepant findings is that many of the 
above studies were limited by small sample sizes and did not adjust for numerous 
potential confounding factors, such as lifestyle, medication use and chronic 
diseases. In addition, a large proportion of the studies had limited breadth of ANS 
measurements or focused on resting levels of ANS activity and did not include one 
or more specific stress conditions. Besides, the studies that did induce stress used 
different stressors and it is possible that participants with psychopathology do not 
have increased sensitivity to all types of stress. 
The aim of the current study was to investigate stressor-induced 
sympathetic and parasympathetic reactivity in the 2-year follow-up assessment of 
Autonomic stress reactivity in depression and anxiety     23
a large depression and anxiety cohort (the Netherlands Study of Depression and 
Anxiety, NESDA). Four indicators of ANS activity were used: 1) heart rate (HR), 
controlled by both parasympathetic and sympathetic cardiac innervation,27 2) root 
mean square of differences between successive interbeat intervals (RMSSD), an 
index of cardiac vagal control,28 3) respiratory sinus arrhythmia (RSA), a second 
index of cardiac vagal control that combines interbeat intervals with the 
respiration signal,27–29 and 4) pre-ejection period (PEP), an index of cardiac 
sympathetic control.27,30 Hyperreactivity of the ANS is characterized by a greater 
increase in HR and greater decrease in RMSSD, RSA and PEP in people with 
psychopathology compared to controls, whereas hyporeactivity is indicated by a 
smaller increase in HR and smaller decrease in RMSSD, RSA and PEP.  
To evoke ANS reactivity, two types of stressors were used: 1) an n-back 
task, and 2) a psychiatric interview. The n-back task represents the ‘classical’ 
cognitive challenging tasks that are often used to evoke stress in controlled 
laboratory settings. The rationale for using the psychiatric interview is that 
questions about psychiatric symptoms, recent life events, and the reliving of 
anxious and depressing memories are likely to be particularly stress-evoking for 
patients with psychopathology. Ultimately, affective dysregulations are what 
distinguishes people with depression and anxiety from mentally healthy 
individuals. Accordingly, we hypothesized that there is ecological validity behind 
investigating the stress reactivity of people with psychopathology when 
confronted with recalling negative life events and anxious and depressing 
moments. 
NESDA’s large sample size allowed us to consider important covariates, 
and, in response to the research results of Licht et al.,8–11 to specifically examine the 
confounding effects of antidepressants. 
METHODS 
Subjects 
Subjects belonged to the Netherlands Study of Depression and Anxiety 
(NESDA), an ongoing longitudinal cohort study to examine the long-term 
course of depression and anxiety. The NESDA sample includes 2981 participants 
aged 18-65 years with a current diagnosis of depression and/or anxiety disorder, a 
prior history of these disorders, and healthy controls. Participants were 
recruited from community, primary care and mental health care in the Netherlands. A 
four-hour baseline measurement was conducted by specially trained clinical research 
staff between September 2004 and February 2007, and follow-up assessments took 
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place after one, two, four and six years. Demographic, psychiatric and biological 
assessments were included, as well as collection of blood and saliva samples. 
People were excluded when they had a primary clinical diagnosis of other severe 
psychiatric disorders, such as psychotic disorder, obsessive compulsive disorder, 
bipolar disorder, or severe addiction disorder, and when they lacked fluency in 
Dutch. A detailed description of the rationale, objectives and methods of the 
NESDA study can be found elsewhere.31 The study protocol was approved by the 
Ethical Review Board of each participating center, and written informed consent 
was provided by all participants. 
Data for the present study were drawn from the two-year follow-up 
assessment (since the N-back task was not introduced until then) and consisted of 
2596 respondents.32 Participants were divided into three groups according to the 
DSM-IV based Composite International Diagnostic Interview (CIDI), version 2.1: 1) 
a control group with no lifetime history of psychiatric disorders, 2) a remitted 
psychopathology group with major depressive disorder (MDD) or anxiety disorder 
(panic disorder, social phobia and/or generalized anxiety disorder) earlier in life but 
not in the past six months, 3) a current psychopathology group with either MDD, 
anxiety disorder or both in the past six months. Of the participants, 5 individuals 
were excluded from the sample because they did not meet our group criteria (e.g. 
people with solely dysthymia), and 408 individuals were excluded because of 
missing physiological data due to equipment failure during assessment, poor 
electrocardiogram quality or because they did not complete either stress 
conditions. Consequently, we conducted our analyses with 2183 participants, 
including 466 controls, 913 people with remitted psychopathology and 804 
people with current psychopathology. 
Stress conditions 
Stress reactivity was evoked by two types of stressors. First, the n-back task, a well-
validated task for working memory33,34 but also used as a laboratory stressor.35 The 
second stressor consisted of a psychiatric interview, evoking personal-emotional 
stress related to the occurrence of symptoms of anxiety and depression in daily life.  
N-back task stressor 
A spatial variant of the n-back task for which the participant had to remember the 
location of a stimulus presented a certain number ‘n’ of stimuli back was 
administered. A 1-back, a 2-back, and two 3-back conditions were presented to the 
participants, each consisting of 20 trials. The n-back task is stress-evoking due to 
task difficulty and performance pressure. Furthermore, false feedback and 
negative comparisons to other participants were provided to evoke a stronger 
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 stress response. Prior to the n-back task participants were presented with the n-
back rest, during which a series of neutral pictures were shown for approximately 
2 minutes. This rest condition was used as a baseline measurement to compare 
against the n-back task stressor. 
 
Psychiatric interview stressor 
The psychiatric interview lasted approximately 45 minutes and included various 
indicators of presence, symptomatology and history of anxiety and depressive 
disorders, as well as suicide ideation, mood disorder symptoms and experience of 
adverse life events. A general interview of approximately 30 minutes was used as 
a baseline measurement to compare against the psychiatric interview stressor. 
Integrated into this general interview were topics such as smoking behavior, use 
of medication, somatic health, daily functioning and health care utilization. Both 
the general and psychiatric interview have been previously described elsewhere.31 
 
Physiological Measurement 
Physiological data were measured by the ‘Vrije Universiteit Ambulatory Monitoring 
System’ (VU-AMS), a lightweight portable device that records electrocardiograms 
(ECG) and changes in thorax impedance (ICG) from a six-electrode configuration.27 
Recording is unobtrusive and subjects retain full freedom of movement. 
Participants wore the VU-AMS device during most of the assessment at baseline 
and follow-up. An event marker was used to divide the recording into distinct 
assessment conditions. Movement registration through vertical accelerometry 
was used to remove periods where the participants were not sitting (e.g. breaks, 
moving between locations). 
From the VU-AMS recordings the following outcome variables were 
computed: heart rate (HR), the root mean square of successive differences 
(RMSSD), the respiratory sinus arrhythmia (RSA) and the pre-ejection period (PEP). 
HR and RMSSD were directly derived from the interbeat interval (IBI) time series.28 
RSA was obtained by peak-valley estimation that combined the ECG with the 
respiration signal obtained from the thorax impedance.27–29 PEP was extracted 
from the interval between the Q-onset in the ECG, indicating onset of  left 
ventricular electrical activity, and the upstroke (B-point) of the ICG signal, 
indicating the beginning of left ventricular ejection.27,30 
During automated and visual data cleaning, suspicious IBIs and breathing 
cycles were corrected or discarded when displaying irregularities. An automated 
scoring algorithm was also used to detect crucial landmarks in the ICG, which were 
then visually inspected and manually corrected. 
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Covariates 
Since it has been linked to heart rate variability,36,37 respiration rate was included 
as a covariate. Adjustments were also made for sociodemographic characteristics, 
including age, sex, and education in years, as well as for health indicators 
associated with psychopathology and ANS activity, including body mass index 
(BMI), physical activity measured by the International Physical Activity 
Questionnaire,38 current smoking status (yes/no), alcohol use (units per week), self-
reported presence of heart disease (coronary disease, cardiac arrhythmia, angina, 
heart failure, and myocardial infarction) and number count of other chronic 
conditions (epilepsy, diabetes, osteoarthritis, stroke, cancer, chronic lung disease, 
thyroid disease, liver disease, intestinal disorders and ulcer). In addition, we 
adjusted analyses of the n-back task stressor for n-back task performance. 
Participants were required to bring their medication containers to the assessments 
so that medication use could be determined. We adjusted for regular medication 
use, including heart medication (ATC codes C01, C02, C03, C04, C05, C07 and C08), 
but specifically the following antidepressants: tricyclic antidepressants (TCAs, ATC 
code N06AA), selective serotonin reuptake inhibitors (SSRIs, ATC code N06AB), and 
selective serotonin and noradrenalin reuptake inhibitors (SNRIs, ATC code N06AX). 
Statistical Analyses 
Data were analyzed using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp). 
Since preliminary analyses showed that ANS reactivity association results for MDD 
and anxiety were very similar, we chose to merge these psychiatric disorders into 
groups based on the presence of either of the disorders (full details per 
psychopathology group are available in Supplementary tables 1-4). RMSSD and 
RSA values were highly skewed and these values were therefore ln-transformed for 
all analyses. 
Analysis of variance (ANOVA) and χ2 statistics were used to compare sample 
characteristics across the controls, participants with remitted psychopathology and 
participants with current psychopathology. For descriptive purposes, ANOVA was 
also used to outline the differences between ANS baseline and stress values, and 
absolute stress reactivity values across the groups. Absolute stress reactivity values 
for n-back were calculated by subtraction of averaged ANS values during the n-
back rest from averaged ANS values during the n-back task. Similarly, absolute 
stress reactivity values for interview were calculated by subtraction of averaged 
ANS values during the general interview from averaged ANS values during the 
psychiatric interview.  
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To formally examine the differences in HR, RMSSD, RSA and PEP between 
the three psychopathology groups, we conducted linear mixed model analyses. 
Two models were used: one to estimate the main effects of group (remitted 
psychopathology and current psychopathology vs. control) and condition (stress 
vs. baseline), and the other model to additionally estimate the interaction effect of 
group*condition (stress reactivity differences across the psychopathology groups). 
These models were separately run for the n-back conditions and the interview 
conditions. The mixed models were then repeated with adjustments for covariates 
(respiration rate, age, sex, education, BMI, smoking, alcohol use, physical activity, 
heart disease, chronic disease, heart medication and, for analyses of the n-back 
conditions, n-back performance). In addition, adjustments for antidepressants 
were added to the analyses. To entirely rule out effects of antidepressants, we 
conducted sensitivity analyses in which antidepressant-users were excluded. The 
criterion for statistical significance was p<.05.  
RESULTS 
Our sample (n=2183) had a mean age of 44.1 years (±13.2 SD) and 66.4% of the 
participants were female. 
Table 1 shows that, compared to participants without psychopathology, 
individuals with psychopathology were more likely to be female, had fewer years 
of education, were more likely to smoke and less likely to drink, and had higher 
BMIs. In addition, the psychopathology group had lower systolic blood pressure 
but higher diastolic blood pressure, had more chronic diseases, were more likely 
to use antidepressants and had higher severity of depression (Inventory of 
Depressive Symptomatology score, IDS-SR) and anxiety (Beck Anxiety Inventory 
score, BAI). Finally, these patients performed worse and took less time on the n-
back task, and took more time on the general and psychiatric interview.  
Table 2 describes the unadjusted means of ANS data during the n-back 
task and psychiatric interview stressor with their respective baseline and stress 
levels and the reactivity values for the three psychopathology groups. Results of 
the unadjusted and adjusted main and interaction effects of group and condition 
are shown in Table 3 (n-back task stressor) and Table 4 (psychiatric interview 
stressor).  
Table 3 shows that mixed model analyses resulted in significant main 
condition effects: higher HR and lower RMSSD, RSA and PEP were seen for the n-
back task compared to n-back rest (all p-values<.001), indicating that the n-back 
task yielded the expected stress activation. Significant main psychopathology 
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group effects were seen for HR, which was lower in both unadjusted and adjusted 
analyses for the remitted psychopathology group (range p-values=.001 – .012) and 
the current psychopathology group (p≤.001) as compared to controls. In addition, 
RMSSD was lower for participants with remitted psychopathology in the fully 
adjusted model (p=.030), and RSA was lower for patients with current 
psychopathology in the unadjusted (p=.031) and the first adjusted model (p=.029). 
However, as we expected based on earlier findings by Licht et al.,8–11 adjustment 
for antidepressants reduced many of these effects to non-significant, illustrating 
that there were, except for HR, not many general differences in ANS parameters 
across psychopathology groups. Importantly, highly significant results were found 
for the group*condition interaction effects (i.e. differences in stress reactivity 
across the groups). A lower HR reactivity was seen in the remitted (p=.004) and 
current psychopathology group (p<.001), and a lower reactivity of RMSSD (p=.002) 
and RSA (p=.019) in patients with current psychopathology than in controls. The 
fully adjusted significant interaction effects for n-back are illustrated in Figure 1. 
There were no significant interaction effects for PEP. When excluding the 450 
antidepressant users from the analyses, the found effects remained significant and 
of similar magnitude. 
Table 4 shows that similar main condition effects were seen for interview 
as for n-back: HR was significantly higher for the psychiatric interview compared to 
the general interview, and RMSSD, RSA and PEP were significantly lower (all p-
values<.001). Comparable to the results of the n-back conditions, significant group 
effects were found for HR, which was lower for participants with current 
psychopathology than for controls in both the unadjusted (p=.03) and adjusted 
models (range p-values=.001 – .002). Compared to the controls, the remitted 
patients had a lower HR (p=.02), in addition to a shorter PEP (p=.04) only in the fully 
adjusted model. Again, we found highly significant group*condition effects for HR, 
RMSSD and RSA. However, these interaction effects were in the complete opposite 
of the interaction effects found for the n-back task. Comparing the psychiatric 
interview to the general interview condition, a higher HR reactivity was seen for 
both the remitted and current psychopathology group than for the control group 
(p<.001). In addition, a higher reactivity was seen for RMSSD (p<.001) and RSA 
(p=.002) in patients with current psychopathology than in controls. The fully 
adjusted significant interaction effects for the interview conditions are illustrated 
in Figure 1. Again, no significant interaction effects were found for PEP. 
Importantly, all of the results remained comparable after excluding antidepressant 
users from the analyses, suggesting that use of antidepressants was not the main 
driving factor of our findings.  
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 Table 1. Sample characteristics for controls, remitted psychopathology subjects and current psychopathology 
subjects 
 Participants  
 
Characteristics 
Control 
 
n=466 
Remitted 
psychopathology 
n=913 
Current 
psychopathology 
n=804 
 
p-
valuea 
Age, years  43.5 ± 14.7 44.1 ± 13.0 44.5 ± 12.3 .45 
Female sex (%)  60.3 66.8 69.4 .004 
Education, years  13.3 ± 3.3 12.7 ± 3.2 12.1 ± 3.3 <.001 
Smoking (%) 20.6 29.9 38.1 <.001 
Alcohol use      
   Non-drinker (%)  23.6 32.0 36.3  
   Mild/Moderate drinker (%) 61.6 53.3 48.9 <.001 
   Heavy drinker (%)  14.8 14.7 14.8  
Physical activity, median METhours/week  
(IQR)  
62.8 (32.4 – 90.2) 59.8 (29.9 – 90.3) 56.4 (24.4 – 81.6) .30 
Resting respiration rate, breaths/min 16.6 ± 1.3 16.5 ± 1.3 16.5 ± 1.3 .70 
Body Mass Index, kg/m2  25.2 ± 4.7 25.7 ± 4.6 26.0 ± 5.2 .011 
Blood pressure      
   Systolic, mmHg  133.7 ± 18.4 130.7 ± 19.9 130.4 ± 19.4 .007 
   Diastolic, mmHg 78.4 ± 11.04 77.6 ± 11.3 78.9 ± 11.9 .067 
Heart or coronary disease (%)  3.6 4.9 5.7 .26 
Chronic diseases, median No. (IQR) 0.0 (0.0 – 1.0) 0.0 (0.0 – 1.0) 1.0 (0.0 – 1.0) <.001 
Heart or blood pressure medication (%)  14.4 13.9 15.7 .58 
Antidepressant use     
   TCA (%) 0.2 2.1 4.5 <.001 
   SSRI (%)  0.4 14.8 21.3 <.001 
   SNRI (%)  0.0 3.6 7.0 <.001 
Other psychotropic medication (%)  4.7 6.9 5.6 .23 
IDS-SR score  6.4 ± 5.6 12.7 ± 8.3 24.7 ± 12.0 <.001 
BAI-score 3.2 ± 4.0 6.5 ± 6.2 14.3 ± 9.4 <.001 
Current psychopathology     
   Current MDD (%) N.A. N.A. 26.0 N.A. 
   Current anxiety (%)  N.A. N.A. 39.2 N.A. 
   Current comorbid MDD and anxiety (%) N.A. N.A. 34.8 N.A. 
Remitted psychopathology     
   Remitted MDD (%) N.A. 32.2 N.A. N.A. 
   Remitted anxiety (%) N.A. 19.2 N.A. N.A. 
   Remitted MDD and Anxiety (%) N.A. 48.6 N.A. N.A. 
N-back task     
   Reaction time, ms  576.9 ± 206.6 588.1 ± 201.4 588.9 ± 187.2 .53 
   Accuracy (mean %)  44.4 ± 20.2 42.9 ± 19.1 41.3 ± 19.0 .020 
Duration conditionsa      
   N-back rest, min  1.8 ± 0.5 1.8 ± 0.5 1.8 ± 0.6 .14 
   N-back task, min  10.8 ± 2.1 10.8 ± 2.0 10.4 ± 2.0 .001 
   General interview, min  26.2 ± 10.3 31.9 ± 11.7 36.7 ± 11.6 <.001 
   Psychiatric interview, min  25.5 ± 12.8 39.3 ± 20.6 66.1 ± 22.7 <.001 
Note: Values represent mean ± SD unless otherwise indicated. METhours = multiple of resting metabolic rate times 
hours of physical activity per week. IQR = interquartile range. TCA = tricyclic antidepressant. SSRI = selective serotonin 
reuptake inhibitors. SNRI = selective serotonergic and noradrenergic reuptake inhibitors. IDS-SR = Inventory of 
Depressive Symptomatology. BAI = Beck Anxiety Inventory. MDD = Major Depressive Disorder. N.A. = not applicable. 
aComparison using ANOVA analyses (continuous variables) and χ2-statistics (categorical variables).  
Boldface indicates statistical significance (p<.05). 
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Table 2. ANS values during n-back task and psychiatric interview stressor with their respective baseline 
condition and stress reactivity values in controls, remitted psychopathology and current psychopathology 
  Participants   
ANS data during  
n-back rest  
and n-back task 
Control 
n=443 
Remitted 
psychopathology 
n=808 
Current 
psychopathology 
n=703 
 
p-
valuea 
HR (beats/min)     
N-back rest 69.0 ± 9.6 67.9 ± 9.6 67.6 ± 10.2 .043 
N-back task 73.1 ± 9.9 71.3 ± 9.8 70.7 ± 10.5 <.001 
Stress reactivity 4.1 ± 4.2 3.5 ± 3.5 3.1 ± 3.4 <.001 
RMSSD (ms)b     
N-back rest 33.3 ± 27.3 33.1 ± 29.2 30.7 ± 24.8 .038 
N-back task 28.9 ± 21.5 29.6 ± 24.1 28.6 ± 20.9 .48 
Stress reactivity -6.2 ± 14.5 -5.4 ± 17.8 -3.5 ± 15.4 .013 
RSA (ms)b     
N-back rest 42.2 ± 31.0 40.4 ± 28.4 38.3 ± 28.2 .033 
N-back task 36.7 ± 23.7 35.0 ± 21.9 33.8 ± 20.6 .26 
Stress reactivity -9.3 ± 17.0 -7.4 ± 16.5 -6.9 ± 15.0 .044 
PEP (ms)     
N-back rest 123.9 ± 17.0 122.1 ± 18.6 123.0 ± 18.7 .23 
N-back task 121.1 ± 17.0 119.6 ± 18.7 120.6 ± 18.5 .32 
Stress reactivity -2.8 ± 5.8 -2.5 ± 5.0 -2.4 ± 5.3 .34 
  Participants   
ANS data during general 
interview  
and psychiatric interview 
Control 
n=454 
Remitted 
psychopathology 
n=896 
Current 
psychopathology 
n=791 
 
p-
valuea 
HR (beats/min)     
General interview 73.0 ± 9.6 71.9 ± 9.5 71.1 ± 10.3 .005 
Psychiatric interview 75.7 ± 9.6 75.4 ± 9.8 75.1 ± 10.4 .59 
Stress reactivity 2.7 ± 3.4 3.5 ± 3.4 4.0 ± 3.3 <.001 
RMSSD (ms)b     
General interview 32.2 ± 25.0 31.5 ± 24.7 31.5 ± 27.1  .77 
Psychiatric interview 29.0 ± 22.9 27.8 ± 22.4 26.8 ± 22.7 .062 
Stress reactivity -3.4 ± 12.2 -4.1 ± 12.1 -5.6 ± 11.8 .004 
RSA (ms)b     
General interview 39.7 ± 24.6 39.1 ± 22.6 38.0 ± 23.7 .32 
Psychiatric interview 36.1 ± 22.9 35.1 ± 20.9 33.4 ± 21.3 .038 
Stress reactivity -3.8 ± 8.1 -4.3 ± 7.9 -5.0 ± 7.9 .028 
PEP (ms)     
General interview 122.1 ± 16.6 120.5 ± 18.1 121.2 ± 18.4 .28 
Psychiatric interview 120.0 ± 16.0 118.1 ± 17.5 119.0 ± 17.6 .16 
Stress reactivity -2.1 ± 6.0 -2.3 ± 5.9 -2.2 ± 6.3 .75 
Note: Values represent mean ± SD. HR = heart rate. RMSSD = root mean square of successive differences. RSA 
= respiratory sinus arrhythmia. PEP = pre-ejection period. Stress reactivity values represent averaged ANS 
values during the n-back task or psychiatric interview stressor minus their respective averaged baseline 
condition values. aComparison using ANOVA analyses. bValues were ln-transformed for analyses and back-
transformed for representation of the means. Boldface indicates statistical significance (p<.05). 
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Figure 1. Mean HR, RMSSD, and RSA during n-back task or psychiatric interview 
stressor and their respective baseline condition values in controls, remitted 
psychopathology and current psychopathology. * p < .05, ** p < .01, *** p < .001; 
p-values were derived from linear mixed model analyses and represent a
significantly different stress reactivity of the remitted or current psychopathology
group compared to controls. 
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DISCUSSION 
This large-scale cohort study aimed to investigate the nature and direction of ANS 
stress reactivity dysregulation in psychopathology. Interestingly, compared to 
healthy controls, depressed and anxious participants showed a differential stress 
reactivity for HR, RMSSD and RSA in opposite directions for two different stressors: 
1) a hyporeactivity for the n-back task, a cognitive challenging stressor, and 2) a
hyperreactivity for the psychiatric interview, a personal-emotional stressor related 
to the occurrence of symptoms of anxiety and depression. Both stress reactivity
directions for the two stressors were also seen for participants with a remitted
diagnosis but only for HR and with smaller effects. These results are interesting,
since previous studies have suggested both hyporeactivity17–24 and 
hyperreactivity12–16 in depression and anxiety. Those studies have focused on stress
reactivity during mental and speech tasks, sometimes in combination with a cold
pressure task or a postural challenge, but without unequivocal results on the effect
of specific stressors on the ANS reactivity of people with psychopathology.
However, no study has investigated both the effect of a cognitive challenging
stressor and a personal-emotional stressor. The results of hyporeactivity during the
n-back task led to the hypothesis that people with psychopathology who 
symptomatically show disengagement from commitments to difficult to reach
goals39,40 may consequently be less motivated41,42 to perform well in comparison to
healthy controls. This hypothesis is supported by the finding of a significantly
worse performance on the n-back task by depressed and anxious patients (Table
1). Our findings are in line with research by Brinkmann and Gendolla43 indicating
that dysphoric participants showed lower systolic blood pressure reactivity than
non-dysphoric participants when facing a difficult cognitive task. These authors
also concluded that dysphoria is associated with a motivational deficit during
difficult tasks. In contrast, requesting participants to describe depressing and
anxious events during a psychiatric interview may better capture the experiences
of personal-emotional stress in daily life. This stressor evoked a reaction in controls,
who also experienced some negative life events and anxious and depressing
moments. However, it was probably more provocative for patients with
psychopathology, and the heightened physiological reactivity most likely reflects
a higher perceived stress level. We consider this to be representative for real-life
situations where people with depression/anxiety are presumed to be more
affected by recanting and sharing their daily situations and problems than people 
without mental disorder. Since only parameters controlled by the PNS were
affected, the differences in stress reactivity between the psychopathology groups
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were probably caused by differences in vagal withdrawal during stressful 
situations.  
Consistent with NESDA research conducted by Licht et al.,8–11 there were 
few group differences in overall ANS functioning after adjustment for confounding 
factors, including antidepressant medication. However, we did find main group 
effects for HR, which was lower in the current and remitted psychopathology 
groups than in controls during both n-back and interview conditions. These results 
are remarkable, as other studies indicate that HR is higher in patients with 
depressive and anxiety disorders.25,44–46 A possible explanation for this is the down-
regulation of cardiac beta-receptors due to prolonged activation of the SNS. There 
is indeed some evidence that depression and anxiety are associated with 
decreased beta-adrenergic receptor responsiveness.47,48 Since HR, as opposed to 
RMSSD and RSA, is partly controlled by the SNS,27 it would be consistent with the 
theory of down-regulated beta-receptors that we find lower values for HR, but not 
RMSSD and RSA, in our current and remitted psychopathology group. 
Correspondingly, prolonged activation of the SNS would be expected to increase 
cardiac contractility but down-regulation of ventricular beta-receptors would act 
to cancel this effect. This may also be an explanation as to why no group 
differences were seen in the PEP. We note that others did find differences in SNS 
functioning in psychopathology. A study conducted by Salomon et al.23 showed 
that people with MDD showed less PEP reactivity during a speech task than 
controls. Light et al.16 (1998) used both PEP and plasma norepinephrine (NE) as 
indicators of sympathetic activity. Plasma NE showed a significantly greater 
increase during a speech task, suggesting higher SNS nerve spillover in people 
with depressive symptoms. This does not contradict down-regulation of beta-
receptors, as NE spillover, in contrast to PEP, should not be affected by beta-
receptor status. 
Adjusting for confounding factors did not, to a large extent, change our 
results, nor did exclusion of antidepressant-users. We conclude that, in contrast to 
studies by Licht et al.8–11 that focused on general ANS activity, antidepressant-use 
was not the main factor causing patient-control differences in the current study on 
ANS reactivity during stress. 
When interpreting these findings, we need to take some limitations into 
account. For instance, the psychiatric interview is not validated as a stress task in 
literature and one limitation is that this stressor is more susceptible to 
interpersonal variability. This limitation is illustrated by the large differences in 
interview duration between individuals and between groups, which may have 
influenced some of the differences in ANS functioning between groups. In 
addition, the general interview might not have been a neutral reference condition 
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for the psychiatric interview, because it also contains some questions (e.g. somatic 
health and disease) that might have caused arousal. However, since all groups 
showed a stress response from our chosen baseline condition to our chosen stress 
condition, we can assume that the psychiatric interview was generally more stress-
evoking compared to the general interview. It should be mentioned that multiple 
statistical comparisons were performed without pre-specified hypotheses or 
statistical adjustments, increasing the chance of false positives. In addition, 
compared to a meta-analysis published in 2004, suggesting a moderate effect size 
for the relationship between depressive symptoms and stressor-evoked 
cardiovascular reactivity,15 we found only small differences in ANS reactivity. 
However, strong associations are rare in the field of biological psychiatry, as has 
been shown for immuno-inflammatory and HPA-axis dysregulations,3 and the 
absence of large effect sizes does not necessarily mean that the findings are 
immaterial. Smaller studies might have found larger effect sizes, but these studies 
are prone to error from possibly testing atypical samples, whereas our results are 
much more replicable to larger studies. Also, our short-term stressors clearly 
induced a proportionally mild stress reactivity compared to the more chronic and 
intense stress that people experience in daily life. This is a limitation, but we note 
that our aim was to examine potential biological pathways linking psychopathology 
to cardiovascular health, as opposed to providing a clinically useful marker of 
dysfunctional stress reactivity at the level of individual participants. Furthermore, our 
cohort was relatively young with few cardiovascular health problems and we 
cannot rule out that psychopathology has larger effects on ANS functioning in 
older, less healthy populations. Another limitation concerns the potential 
heterogeneity in the type and severity of psychopathology which can be a crucial 
source of variability in biological dysregulation,3,49 and perhaps even crucial in 
determining blunted or exaggerated autonomic responses to stress.50,51 For the 
current study, we chose to merge data of patients with depression and anxiety, 
since preliminary analyses showed very similar results for both psychopathologies 
on ANS activity. However, we have not examined heterogeneity within anxiety 
diagnosis (e.g. panic disorder, social phobia and/or generalized anxiety disorder) 
or severity of psychopathology. Although earlier research did not reveal large basal 
ANS differences across different anxiety patients,11 it would be interesting to study 
such influence of disease character on ANS stress reactivity more in depth during 
further research. Finally, the cross-sectional nature of our data makes it difficult to 
infer causality from the found relationships. Therefore it remains unclear whether 
altered ANS reactivity is a vulnerability factor for developing psychopathology, 
whether having depression and anxiety changes stress reactivity, or whether there 
is a common mechanism that influences both the ANS and depressive symptoms.  
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Despite the limitations, this study has a number of strengths: the findings 
of altered ANS reactivity were robust in our large study sample and inclusion of 
many key confounding factors did not change this. We used stable and reliable 
indicators of both SNS and PNS activity, and we used two types of stressors that 
showed an intuitively appealing discrepancy in reactivity levels between patients 
with psychopathology compared to healthy controls.  
In conclusion, ANS stress reactivity, specifically cardiac vagal reactivity, is 
dysregulated in psychopathology. The results imply a hyporeactivity for people 
with depression and anxiety in response to cognitively challenging stressors and a 
hyperreactivity in response to stressors evoking personal-emotional stress. If the 
interview stressor has captured the response of patients with psychopathology to 
the affective afflictions they are confronted with in daily life, it may be a more 
ecologically valid means of testing ANS stress reactivity in people with depression 
and anxiety compared to the predominantly used laboratory stressors. 
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ABSTRACT 
 
Objectives: Cardiac repolarization may be affected by psychiatric disorders and/or 
antidepressant use, but evidence for this is inconclusive. This study examined the 
relationship between depressive and anxiety disorder and use of antidepressants 
with T-wave amplitude (TWA) and QT-interval. 
Methods: Data was obtained from the Netherlands Study of Depression and 
Anxiety (n=1383). Depression/anxiety was diagnosed with the DSM-IV based 
Composite International Diagnostic Interview. The use of tricyclic antidepressants 
(TCAs), selective serotonin and noradrenalin reuptake inhibitors (SNRIs), and 
selective serotonin reuptake inhibitors (SSRIs) was established. T-wave amplitude 
and QT-interval corrected for heart rate (QTc) were obtained from an ECG 
measured in a type II axis configuration.   
Results: Compared to controls, persons with depression or anxiety disorders did 
not show a significantly different TWA (p = .58; Cohen’s d = 0.046) or QTc (p = .48; 
Cohen’s d = -0.057). In spite of known sympathomimetic effects, TCA use (p = .26; 
Cohen’s d = -.162) and SNRI use (p = .70; Cohen’s d = -0.055) were not significantly 
associated with a lower TWA. TCA use (p = .12; Cohen’s d = 0.225) and SNRI use (p 
= .11; Cohen’s d = 0.227) were also not significantly associated with a prolonged 
QTc.   
Conclusion: We did not find evidence that either depressive/anxiety disorder or 
antidepressant use is associated with abnormalities in TWA or QTc. Earlier found 
sympathomimetic effects of TCAs and SNRIs are not evident in these measures of 
cardiac repolarization. 
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INTRODUCTION 
Depressive and anxiety disorders have been associated with an increased risk of 
cardiovascular disease (CVD),1,2 cardiovascular mortality and sudden death.3
Dysregulation of the autonomic nervous system (ANS) may be part of the 
underlying mechanism linking these psychiatric disorders to unfavourable health 
outcomes.4,5 However, in view of the increasing evidence that the use of 
antidepressants negatively impacts autonomic balance,6,7 it has been suggested 
that the found effects of psychopathology on ANS activity are driven by 
medication use.8  
Studies linking cardiac autonomic dysregulation to mental health and 
antidepressant use have mostly used heart rate variability (HRV) as a measure of 
parasympathetic activity,8–14 and (nor)epinephrine concentrations15,16 or pre-
ejection period17–19 as a measure of sympathetic activity. Less focus is directed to 
measures of repolarization, such as T-wave amplitude (TWA) and QT-interval. TWA 
is the asymmetrical wave in the electrocardiogram following the QRS complex, and 
reflects repolarization of the ventricles.20 Sympathetic stimulation has been 
suggested to lead to a decreased TWA, whereas the role of the parasympathetic 
nervous system remains unclear.21 QT-interval is defined as the interval from the 
onset of the QRS complex (the earliest indication of ventricular depolarization) to 
the end of the T wave (the latest indication of ventricular repolarization).22 Because 
the QT-interval is directly influenced by HR, it is recommended to use a measure 
corrected for HR: QTc.23 Increased sympathetic activity has been found to prolong 
QTc.24,25 Both abnormalities in TWA26,27 and prolonged QTc28,29 have been 
associated with cardiac morbidity and mortality. If these measures are affected by 
psychiatric disorders and/or antidepressant use, they could explain part of the 
comorbidity between poor mental health and cardiovascular disease. Previous 
studies concerning QT variables and psychiatric disorders have tentatively 
confirmed this relationship. One study investigated QTc in relation to depression-
related personality, and found a positive relationship.30 Another study concluded 
that depressive symptoms were non-significantly associated with prolonged 
QTc.31 Studies by the group of Bär and Koschke32,33 have investigated patients with 
schizophrenia and major depressive disorder and found an increase in QT 
variability (dynamic changes in QT-interval duration) in these patients. However, 
they did not report on measures of QT-interval. Both QT variability and QT-interval 
have been associated with increased risk of cardiac mortality.29,34 However, a study 
by Baumert and colleagues (2008) did not find a correlation between these 
measures, suggesting that they reflect different parts of the repolarization 
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dynamics. Interestingly, the same study found a positive correlation between 
norepinephrine spillover and QTc, but not QT variability, in patients with 
depression or panic disorder, providing more evidence that these measures are 
influenced by differential mechanisms. To our knowledge, no study has linked 
basal QTc or TWA to depressive or anxiety disorder. Considering antidepressant 
use, studies have indicated that the use of tricyclic antidepressants (TCA) are 
associated with a lower TWA and a prolonged QTc,35–39 while the effects of selective 
serotonergic and noradrenergic reuptake inhibitors (SNRIs) and selective serotonin 
reuptake inhibitors (SSRIs) are less conclusive.25,40–45  
Whether psychopathology is independently associated with autonomic 
dysregulation or whether this association is driven by antidepressant use, remains 
an ongoing debate.8,46,47 This study aimed to investigate the association between 
depression/anxiety and antidepressant use with TWA and QTc. 
 
METHODS 
 
Subjects 
Data was obtained from NESDA, a longitudinal cohort study including 2981 
subjects recruited from community, primary care, and mental health care in the 
Netherlands. The participants were aged 18 to 65 and consisted of people with a 
current diagnosis of depression and/or anxiety disorder, a history of these 
disorders, and healthy controls. Baseline measurement was conducted between 
2004 and 2007, and follow-up assessments took place after two, four, six and nine 
years. A detailed description of the rationale, objectives and methods of the NESDA 
study can be found elsewhere.48 The study protocol was performed conform the 
declaration of Helsinki and approved by the Ethical Review Board of each 
participating center. All participants provided written informed consent. 
Data were drawn from the nine-year follow-up of the NESDA study 
(n=2069), conducted between 2014 and 2017. Of the total sample, 686 participants 
were excluded because they had missing physiological data (due to telephone or 
at-home interviews without ANS recording, equipment failure during assessment, 
or poor electrocardiogram quality). This resulted in a total of 1383 participants for 
analyses. Excluded participants were older and were more often treated with 
cardiac medication. 
 
Depressive/anxiety disorder 
Participants were diagnosed with the DSM-IV based Composite International 
Diagnostic Interview (CIDI), version 2.1,49 and divided into three groups: 1) a control 
50
group with no lifetime history of psychiatric disorders, 2) a remitted psychopathology 
group with major depressive disorder (MDD) or anxiety disorder (panic disorder, social 
phobia and/or generalized anxiety disorder) earlier in life but not in the past six 
months, 3) a current psychopathology group with either MDD, anxiety disorder, or 
both in the past six months. In addition to diagnosis, the severity of depression and 
anxiety was measured in all participants using the 30-item Inventory of Depressive 
Symptomatology, Self-Report (IDS-SR)50 and the Beck Anxiety Inventory (BAI).51  
 
Antidepressant use 
Medication use was determined by inspection of medication containers that 
participants brought to the assessment. Participants were considered to be 
currently using antidepressants when they reported to have used medication 
frequently (daily or more than 50% of the time) in the past month. We divided the 
participants into four groups: 1) non-users, 2) persons using TCAs (ATC code 
N06AA), 3) persons using SSRIs (ATC code N06AB), and 4) persons using SNRIs (ATC 
code N06AX). There were four persons using TCAs and SSRIs simultaneously, and 
1 person using both TCA and SNRI. Since TCAs have been found to have the 
strongest effect on cardiac autonomic activity,52,53 we decided to group these 
persons under TCA use. There was one person using SNRI and SSRI at the same 
time, whom we grouped under SNRI use, since SNRIs have been found to have a 
stronger effect on cardiac autonomic activity than SSRIs.52,53 A derived daily dose 
for antidepressant use was calculated by dividing the participant’s mean daily dose 
by the daily dose recommended by the World Health Organization.54  
 
Physiological measurements 
Physiological data were recorded with an unobtrusive lightweight portable device 
containing a six-electrode configuration: the ‘Vrije Universiteit Ambulatory 
Monitoring System’ (VU-AMS). This device measures electrocardiograms (ECG) and 
impedance cardiography (ICG).55 Heart rate (HR) was derived from the ECG 
interbeat interval (IBI) time series.56 TWA was calculated by subtracting the 
amplitude of T-offset from the point of highest amplitude of T-wave deflection.21 
QT-interval was defined as the interval from the onset of the QRS complex (the 
earliest indication of ventricular depolarization) to the end of the T wave (the latest 
indication of ventricular repolarization).22 Since the QT-interval is directly 
influenced by HR, a corrected measure was calculated using Bazett’s formula (QTc= 
QT/√RR).23 
VU-AMS software (version 3.8, VU University Amsterdam, www.vu-ams.nl) was 
used for data cleaning. Non-stationary periods were detected by movement registration 
through vertical accelerometry and removed. Bad ECG signal fragments (artifacts) were 
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automatically detected, after which a modified version of the algorithm by Christov57 
was used to detect R-wave peaks. Participants were excluded when their recordings 
showed more than 5% highly suspicious IBIs of the total recording. An event marker 
was used to divide the assessment into four different conditions: a supine rest 
condition with blood pressure measurement (±11 min) and three sitting 
conditions: a psychiatric interview (±45 min), a general interview (±47 min), and 
a computer task (±7 min). The ECG signals were ensemble averaged across these 
conditions by time locking them to the R-wave peaks.21 Exploratory mixed 
model analyses showed that there were no significant interaction effects between 
psychopathology status and assessment condition for TWA (p = .98) or QTc (p 
= .84), nor between antidepressant groups and condition for TWA (p > .99) or QTc 
(p > .99). Therefore, data during the four conditions were collapsed to create a 
single average score of HR, TWA, QT-interval, and QTc, with an average total 
recording duration of ±107 minutes.  
Covariates 
Adjustments were made for sociodemographics: age, sex and years of education. We 
also accounted for health factors: physical activity measured by the 
International Physical Activity Questionnaire,58 alcohol use (units per week), 
number of smoked cigarettes/day, body mass index (BMI), number of treated 
chronic diseases (cardiovascular disease, epilepsy, diabetes, osteoarthritis, stroke, 
cancer, chronic lung disease, thyroid disease, liver disease, intestinal disorders and 
ulcer) and use of cardiac medication (ATC codes C01, C02, C03, C04, C05, C07 and 
C08).  
Statistical analyses
Data were analyzed using SPSS, version 22.0. Characteristics across the 
psychopathology groups were compared using ANOVA analyses, Kruskal-Wallis 
one-way analysis of variance, and χ2-statistics. Analyses of covariance (ANCOVA) 
were used to investigate the relationship between psychopathology diagnosis 
and antidepressant use with cardiac autonomic variables. Cohen’s d effect sizes 
were calculated, defined as the difference in the means of two groups, divided 
by the pooled standard deviation of these groups. Regression analyses were 
used to establish the association between cardiac autonomic activity and IDS-SR 
score, BAI score, and derived daily dose of antidepressant use. ANCOVA and 
regression analyses were adjusted for age, sex and education in a first model, and 
for physical activity, alcohol use, smoking, BMI, number of chronic diseases, and 
cardiac medication in a second model. Analyses with psychopathology were 
additionally corrected for antidepressant use in a third model. The criterion for 
statistical significance was p < .05.  
52
RESULTS 
Our sample (n=1383) had a mean age of 51.0 years (SD=13.1) and 64.4% were 
female. Of the participants, 26.6% had a current depressive/anxiety disorder, 52.4% 
had a history of depression/anxiety, and 19.7% used antidepressants (Table 1).  
Table 2 shows the association between depressive/anxiety disorder and 
ANS values. No significant association was seen between depression/anxiety and 
TWA. Compared to controls, people with remitted (p = .033; Cohen’s d = -0.150) 
and current depression/anxiety (p = .002; Cohen’s d = -0.254) had a significantly 
lower HR in the fully adjusted model. In addition, people with current 
depression/anxiety had a significantly longer QT-interval (fully adjusted model: p 
= .018; Cohen’s d = 0.192). However, this association disappeared after correcting 
QT-interval for HR (QTc). When analyzing the association between IDS-SR and BAI 
score with ANS values (Table 3), no significant results were found after full 
adjustment.  
Table 4 shows the association between antidepressant use and ANS 
values. Although users of TCAs had a lower TWA, this difference was not 
statistically significant (fully adjusted model: p = .26; Cohen’s d = -.162). Compared 
to non-users, TCA users had a significantly higher HR (fully adjusted model: p = 
<.001; Cohen’s d = 1.048) and shorter QT-interval (fully adjusted model: p = <.001; 
Cohen’s d = -0.661). However, after correction for HR, TCA use (fully adjusted 
model: p = .12; Cohen’s d = 0.225) and SNRI use (fully adjusted model: p = .11; 
Cohen’s d = 0.227) were non-significantly associated with a longer QTc-interval. 
When investigating the relationship between antidepressant derived daily dose 
(DDD) and ANS values (Table 5), we found an unexpected lower TWA in subjects
with higher DDD of SSRI (fully adjusted model: β = -.177; p = .022).
To test whether the results were not influenced by differences in signal 
processing, we compared ECG artifacts and respiration rate across the groups. 
When comparing current psychopathology (0.29%), remitted psychopathology 
(0.33%), and healthy controls (0.30%), we found no difference in percentage of ECG 
artifacts (p=.59). A difference was found when comparing ECG artifacts between 
users of TCA (0.60%), SNRI (0.25%), SSRI (0.23%), and non-users (0.32%) (p=.003). 
This difference was caused by a higher percentage of artifacts in TCA users. 
However, even in this group the percentage was still very low, making it unlikely 
that artifacts influenced the results substantially. When comparing respiration rate 
across the different psychopathology and antidepressant groups, we did not find 
a significant difference. In addition, when we corrected for respiration rate in the 
analyses, the results remained similar. 
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DISCUSSION 
The current study did not find an association between depressive/anxiety disorder 
and TWA and QT-interval, two measures of cardiac repolarization that are affected 
by sympathetic activity and associated with cardiac morbidity and mortality.27,28 In 
spite of their known adrenergic effects, TCA and SNRI use were not associated with 
a lower TWA or a prolonged QTc. 
Regarding psychopathology, we did find an association between a 
current depressive/anxiety disorder and a prolonged QT-interval. However, this 
result was driven by a lower HR in these patients, since the association rendered 
non-significant when using the HR-adjusted QTc. Importantly, when investigating 
severity scores of depression and anxiety, we did not find any associations with the 
TWA or QTc measures after adjustment for antidepressants. These null-findings are 
somewhat surprising as previous studies have shown an association between T 
wave59 and QT30,32 abnormalities with depressive and anxious symptomatology. 
However, two of these studies investigated different aspects of these variables ( T 
wave inversion or QT variability), and the third investigated the relationship of QTc 
with depression-related personality. To the best of our knowledge, no study has 
investigated the relationship between TWA and QTc with diagnosed depression 
and anxiety. Our findings are in line with research by Kamphuis and colleagues,31 
indicating that there were no significant associations between QTc and depressive 
symptoms, and with previous NESDA research claiming that psychopathology 
might not have a negative impact on sympathetic activity as assessed using pre-
ejection period, independent from antidepressant use.53  
The current study could not confirm findings suggesting that the use of 
TCAs is associated with a lower TWA and a prolonged QTc.35–38 Most of the previous 
studies investigated the acute effects of short-term medication use on cardiac 
repolarization. In our study, we examined patients who were generally using TCAs 
for a longer term. Perhaps the effect of short-term TCA use on QTc and TWA 
diminishes with chronic use. This theory is in line with a study by Burckhardt and 
colleagues,39 indicating a modest effect of TCA use on TWA and QTc after three 
weeks, which disappeared after 13 months of antidepressant use. Considering 
SNRI use, our results indicate that there is no effect of this group of antidepressants 
on cardiac repolarization, congruent with several studies that found none to minor 
changes in QTc in patients using duloxetine or venlafaxine.42,44,45 These null-
findings of TCA and SNRI use are in contrast to previous NESDA studies suggesting 
strong associations between the use of these antidepressants with higher HR and 
shorter pre-ejection period, indicating increased sympathetic activity.53,60 
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However, it is important to bear in mind that different mechanisms of 
cardiac autonomic activity are in play concerning the investigated variables. 
Whereas HR and pre-ejection period are measures of sympathetic effects on 
sinoatrial node pacemaker activity and contractility of the ventricles respectively, 
TWA and QTc are measures of sympathetic effects on repolarization of the 
ventricles. That these measures do not reflect the exact same mechanism is 
illustrated by a study by Van Lien and colleagues,21 showing a correlation of only .4 
between TWA and pre-ejection period. We suggest that there are 
sympathomimetic effects of TCAs and SNRIs which are apparent in HR and pre-
ejection period, but not in TWA and QTc.  
Studies on the relationship between SSRI use and measures of cardiac 
repolarization have generally concluded that this group of antidepressants has no 
significant effect on QTc or TWA.25,40,43 Our study indicated that SSRI users did not 
differ from controls in repolarization measures, but we found a lower TWA in SSRI 
users that had higher SSRI DDD. An effect of SSRI on repolarization would be 
consistent with a study by Castro and colleagues,41 that found a dose-response 
relationship between several SSRIs (citalopram and escitalopram) with a 
prolonged QTc. However, since there was no general effect of SSRI use on TWA, the 
found association between a higher SSRI DDD and lower TWA might be a chance 
finding. 
Limitations of the study 
In order to interpret the results of the current study, some limitations need to be 
taken into account. We recorded ANS measures during several conditions, but not 
during a true rest condition, rendering this measure prone to all sources of 
variability. However, exploratory mixed model analyses showed that there were no 
significant interaction effects between psychopathology status/antidepressant 
group and assessment condition for TWA or QTc. Also, when comparing 
respiration rate between the psychopathology groups and antidepressant groups 
versus controls, we found no significant differences for any of the conditions. In 
addition, we have shown in a previous study that the average of the conditions has 
good temporal stability for measures of HR, respiratory sinus arrhythmia, and pre-
ejection period,60 suggesting that we are assessing robust and reliable variables. 
Unfortunately, in our study we did not measure other aspects of cardiac 
repolarization, such as QT variability, or T-wave inversions.  Previous studies have 
associated psychopathology with increased QT variability.32,33,61 A study by Whang 
and colleagues59 showed that depressive and anxious symptoms were associated 
with abnormalities in T wave inversions. Similarly, there are many more 
mechanisms of repolarization to be considered, such as spatial and temporal 
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dispersion of repolarization, configuration of the action potential, and early post-
depolarization. For instance, prolongation of the action potential or variations in 
duration can produce lability in the repolarization process, which may manifest as 
variability or dispersion of repolarization duration, or early afterdepolarizations 
that can initiate triggered arrhythmias.62 Investigating these different aspects 
would further the understanding of the underlying mechanisms linking mental 
health to cardiovascular risk. 
Several studies have implied altered ANS reactivity to stressors among 
depressed patients rather than ANS dysregulation during rest conditions.63,64 The 
current study did not contain a stressor or intervention to investigate the 
association between psychopathology or antidepressant use on reactivity of QTc 
or TWA. A next step would be to investigate such reactivity measures (e.g. active 
standing or a stress task) for QTc and TWA in relation to depression and anxiety.  
Medication use and its derived daily dose were determined by inspection 
of medication containers that participants were asked to bring to the assessment 
session and self-report. Since psychiatric patients have shown low adherence to 
treatment,65 we cannot establish for certain that the reported (amount of) 
medication was taken by the participants, which might have influenced the results. 
In addition, the NESDA study only contains outpatient participants, who likely use 
lower dosage of antidepressants than inpatient persons. The current study did not 
include many participants who used antidepressants in a high dosage (DDD was 
equal or less than 1.5 for 99.3% persons who used TCA, 99.5% persons who used 
SNRI, and 97.4% persons who used SSRI). Therefore, we cannot rule out an effect 
of antidepressant overuse on cardiac repolarization. Indeed, studies have shown 
that especially TCA overdose was associated with ventricular tachycardia and 
abnormalities in TWA and QTc.66–68 However, here we aimed to investigate the 
effects of therapeutic use of antidepressants on cardiac repolarization, and did not 
find evidence for a significant relationship. Another limitation is that we only had 
data of TWA and QTc at one wave of data collection, which confined us to a cross-
sectional design where we could only compare antidepressant users to non-users. 
Longitudinal data would have allowed investigation of within-subject effects of 
antidepressant use (e.g. the effects of chronically using, starting, or stopping the 
use of medication) and might have rendered more conclusive results. 
These limitations are balanced by several strengths. This is one of few 
studies to investigate the relationship between depressive and anxiety disorders 
with TWA and QTc. This study was conducted within a large sample of participants 
recruited from community, primary care, and mental health care. Compared to 
healthy controls, persons with poor mental health often have poorer lifestyle (e.g. 
less physically active, more often smokers, higher BMI) and physical health (e.g. 
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more chronic diseases and use of medication).69,70 Previous research has shown 
that these factors are also drivers of autonomic change over time.60,71 Our large 
sample size allowed the correction for these important confounders. 
Conclusions 
In summary, in our large cohort study we did not find evidence that either 
depressive/anxiety disorder or antidepressant use is associated with abnormalities 
in TWA or QTc. Earlier findings of the sympathomimetic effects of TCAs and SNRIs 
on HR and pre-ejection period are not evident in these measures of cardiac 
repolarization.   
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ABSTRACT 
 
Background: Gene-by-exposure interactions could be affecting the association of 
depression and anxiety with cardiac autonomic dysregulation, causing the 
ambiguous findings in this field. We tested the presence of genetic moderation by 
the polygenic risk scores (PRS) for high heart rate (HR) and low heart rate variability 
(HRV) on the relationship between cardiac autonomic activity and psychopathology 
across a nine-year follow-up period. In parallel, we tested a potential 
pharmacogenetic moderation of the effects of antidepressant use on cardiac 
autonomic activity by HR and HRV PRS.  
Methods: Summary statistics from meta-analyses of genome wide association 
studies were used to derive PRS of HR and HRV in data (no. observations=6994, 
65% female) obtained from the longitudinal cohort from the Netherlands Study of 
Depression and Anxiety, with repeated waves of data collection of HR, HRV, and 
psychopathology.  
Results: Generalized estimating equations analyses showed that cardiac 
autonomic dysregulation was not associated with psychopathology across the 
nine-year follow-up.  We found no moderation by HR or HRV PRS on the 
relationship between cardiac autonomic activity and psychopathology. In 
contrast, a robust association was found between antidepressant use and cardiac 
autonomic activity across all waves. This association was not moderated by a 
genetic risk for high HR or low HRV.  
Conclusions: Our results confirm that there is no direct association between cardiac 
autonomic dysregulation and psychopathology, even when taking possible genetic 
moderation into account. Our findings suggest that previously observed 
associations between cardiac autonomic dysregulation and psychopathology are 
likely caused by confounding factors, in particular antidepressant use.  
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INTRODUCTION 
 
Persons with depressive and anxiety disorders, hereafter referred to as 
psychopathology, are known to have an increased risk of developing cardiovascular 
disease.1,2 It has been hypothesized that the autonomic nervous system is one of the 
underlying mechanisms that explains this relationship.3 Indeed, psychopathology 
has been associated with cardiac autonomic dysregulation, generally reflected by 
higher heart rate (HR) and lower heart rate variability (HRV).4–10 However, current 
literature in this area shows conflicting results.  
The most important debate revolves around findings from several 
studies, including our own, indicating that the relationship between cardiac 
autonomic activity and mental health might be attributable to antidepressant 
use.11–17 These claims were contradicted by studies that found lowered HRV in 
unmedicated patients with psychiatric disorders.18–20 However, even within the 
studies that suggested an independent effect of psychopathology on autonomic 
dysregulation, the results remain ambiguous. Striking examples are the studies 
conducted by Kemp and colleagues, who in 2010 conducted a meta-analysis 
concluding that HRV was reduced in patients with depression,21 while in 2012 they 
conducted a case-control study showing that the greatest reduction in HRV was 
displayed in depressed participants with comorbid generalized anxiety disorder 
(GAD),19 and in 2014 concluded from a large cohort study that only GAD with small 
effect sizes and not depression nor comorbid depression and anxiety disorder 
were associated with decreased HRV.22 The authors attributed these inconsistent 
findings to possible disorder heterogeneity and discrepant control of confounding 
factors.  
Another possibility for the ambiguous findings is the existence of an as yet 
unaccounted for factor that moderates the relationship between psychopathology 
and cardiac autonomic dysregulation, such as a genetic vulnerability. Previous 
studies have demonstrated a significant genetic contribution to depression,23–25 
resting HR,26,27 and HRV.28 One example of a gene-by-exposure (GxE) interaction 
regarding cardiac autonomic activity was demonstrated in twin studies.29–31 These 
studies found that the genetic contributions to cardiac autonomic traits at rest are 
larger in stress conditions. GxE interactions could also be at play in the association 
between psychopathology, generally associated with heightened stress levels, and 
cardiac autonomic dysregulation. For instance, poor mental health might primarily 
affect cardiac autonomic activity in persons with higher genetic vulnerability for 
high HR or low HRV, leaving the persons with lower genetic vulnerability less 
affected. Such genetic moderation may explain ambiguous findings in this field 
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through differences in sample selection across studies. For instance, selection criteria 
for some studies have resulted in the exclusion of people with health issues, such as 
cardiovascular disease.21 By doing so, these studies may have inadvertently selected 
samples with differential genetic risk for cardiac autonomic dysregulation, which 
may have led to inconsistent results.  
In contrast to psychopathology, evidence is more conclusive for 
antidepressant use to impact on HR and HRV. However, ambiguity also remains in 
this area, as studies found different results and effect sizes for different types of 
antidepressants. Most studies found large and robust associations between the 
use of tricyclic antidepressants and cardiac autonomic dysregulation.16,20,21,32,33 
However, findings concerning other antidepressants are less consistent. For 
instance, selective serotonin reuptake inhibitors are sometimes found to have no 
impact on HRV,16,21 a negative impact on HRV,11,13,34 or a beneficial effect on HRV32 
or HR.11,32 Differences in genetic vulnerability for cardiac autonomic dysregulation 
may also in part explain the discrepancies among these studies. A genetic 
predisposition for high HR or low HRV may enhance the effect of antidepressant 
use on cardiac autonomic dysregulation. If pharmacogenetic moderation is indeed 
in play, these findings would be clinically relevant as they contain important 
information for personalized treatment strategies.  
Given these consideration, the aim of this study was twofold. Our first 
aim was to investigate whether the relationship between psychopathology and 
cardiac autonomic activity across a nine-year follow-up period was moderated by 
a genetic risk for high HR or low HRV. Our second aim was to investigate whether 
the relationship between antidepressant use and cardiac autonomic activity across 
the nine-year follow-up was moderated by a genetic risk for high HR or low HRV. 
For the current study, the results of large genome wide association studies (GWAS) 
were used to derive polygenic risk scores (PRS) of resting HR,35 and the root mean 
square of differences between successive interbeat intervals (RMSSD),36 a 
frequently used measure of HRV. Genotype and phenotype data were obtained 
from the large longitudinal cohort of the Netherlands Study of Depression and 
Anxiety (NESDA, no. observations=6994). As far as we know, this is the first study 
to investigate the relationships of psychopathology and antidepressant use with 
cardiac autonomic activity across such a long time span, and the first to establish 
the role of genetic moderation in these relationships. 
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METHODS AND MATERIALS 
 
Subjects 
Subjects were participants in NESDA, a longitudinal cohort study examining the 
long-term course of depression and anxiety, including 2981 participants aged 18-
65 years recruited from community, primary care, and mental health care in the 
Netherlands. The NESDA sample consists of persons with a current diagnosis of 
depression and/or anxiety disorder, a prior history of these disorders, and healthy 
controls. A four-hour baseline measurement was conducted between September 
2004 and February 2007, and follow-up assessments took place after two, four, six, 
and nine years. A detailed description of the rationale, objectives, and methods of 
the NESDA study can be found elsewhere.37 The study protocol was approved by 
the Ethical Review Board of each participating center and written informed 
consent was provided by all participants. The study was performed in compliance 
with the declaration of Helsinki. 
Data for the present study were drawn from baseline (n=2981), 2-year 
(n=2596), 6-year (n=2256), and 9-year (n=2069) follow-up. Subjects were included 
if they had genetic and cardiac autonomic data. This resulted in a total of 2319 
subjects at baseline, 1870 subjects at 2-year follow-up, 1543 subjects at 6-year 
follow-up, and 1262 subjects at 9-year follow-up. Missing genetic data were mostly 
due to refusal to partake in DNA sampling, with a smaller part lost to genotyping 
errors. Missing physiological data was due to telephone or at-home interviews 
without ANS recording, equipment failure during assessment, or poor 
electrocardiogram quality (Figure 1).   
 
Depressive/anxiety disorder 
Participants were considered to have current psychopathology when they had in 
the 6-months preceding the assessment a diagnosis of major depressive disorder 
and/or anxiety disorder (panic disorder, social phobia and/or generalized anxiety 
disorder) according to the DSM-IV-based Composite International Diagnostic 
Interview, version 2.1.38 Participants were considered to be controls when they did 
not have current psychopathology. In addition to diagnosis, the severity of 
depression was measured using the 30-item Inventory of Depressive 
Symptomatology, Self-Report (IDS-SR).39 
 
Antidepressant use 
Participants were requested to bring their medication containers to the assessments 
so that medication use could be determined. Persons were considered to be using 
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antidepressants when they reported to have used medication frequently (daily or 
more than 50% of the time) in the past month. We established the use of tricyclic 
antidepressants (TCAs: ATC code N06AA), selective serotonin and noradrenalin 
reuptake inhibitors (SNRIs: ATC code N06AX), and selective serotonin reuptake 
inhibitors (SSRIs: ATC code N06AB).  
Figure 1. NESDA wave flow diagram
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72
Physiological measurements 
Physiological data was recorded with the ‘Vrije Universiteit Ambulatory Monitoring 
System’ (VU-AMS), an unobtrusive portable device. This device contains a six-
electrode configuration that measures electrocardiograms (ECG) and changes in 
thorax impedance (ICG).40 Data cleaning was performed with VU-AMS software 
(version 4.0, VU University Amsterdam, www.vu-ams.nl). Movement registration 
through vertical accelerometry was used to remove periods where the subjects 
were not stationary. Bad ECG signal fragments (artifacts) were automatically 
detected, after which a modified version of the algorithm by Christov41 was used 
to detect R-wave peaks. Visual data cleaning assured that suspicious IBIs and 
breathing cycles were corrected or discarded when displaying irregularities.  
HR and RMSSD were directly derived from the interbeat interval (IBI) 
time series from the ECG signal.40 Respiratory sinus arrhythmia (RSA), another 
frequently used measure of HRV, combined ECG with the respiration signal 
obtained from ICG, and was obtained by subtracting the shortest IBI during HR 
acceleration at inhalation from the longest IBI during HR deceleration at exhalation 
for all breaths.42 An event marker was used to divide the assessment into different 
conditions. At each wave, an average score of HR, RMSSD, and RSA was made by 
combining the conditions that were present at all waves: a supine rest condition 
with blood pressure measurement (±11 min) and three sitting conditions: a 
psychiatric interview (±42 min), a general interview (±36 min) and a computer task 
(±12 min), resulting in an average total recording duration of ± 107 minutes. 
GWAS data 
GWAS data for HR and RMSSD were derived from Den Hoed et al.35 (n=85,787) and 
Nolte et al.36 (n=26,785), respectively. GWAS data for major depressive disorder was 
derived from the GWAS summary statistics publicly released by the Psychiatric 
GWAS Consortium, excluding the dataset from 23andME (n=173,005).43 No large 
GWAS studies were available for anxiety.  
Polygenic risk scores 
Genotyping (95% of the samples on Affymetrix 6.0 Human SNP array and the 
remaining on Perlegen-Affymetrix 5.0 array), quality control steps and imputation 
were previously described in detail.44 Briefly, after platform-specific QC, in order to 
combine the SNPs genotyped in each platform, the two datasets were imputed 
using the GoNL (Genome of the Netherlands) reference panel45 and then merged. 
From the imputed dataset only the SNPs genotyped in the original platforms were 
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retained, creating a unique cross-platform imputed dataset. After more stringent 
QC, the cross-platform imputed dataset included ~1.2M SNPs. 
Polygenic risk scores (PRS) for depression, HR, and RMSSD were based 
on the GWAS summary statistics described in the previous paragraph. Since NESDA 
data was part of the RMSSD GWAS, the meta-analysis was corrected for the NESDA 
sample using MetaSubtract (cran.r-project.org/web/packages/MetaSubtract/index.html). 
Summary statistics of the discovery were lifted to human genome build hg19 and 
filtered by removing strand ambiguous variants and SNPs with MAF < 0.01. 
Overlapping SNPs (~1M) between the cross-platform GoNL were imputed and 
those retained from the discovery summary statistics were carried forward. PRS 
were calculated as the number of risk alleles weighted by effect sizes from the 
discovery statistics. Selection of SNPs and effect sizes was based on two methods. 
Firstly, clumping + P-thresholding method using PLINK was applied. SNPs were 
selected using p-value-informed LD clumping (250kb window, r2=0.25) using 1000 
unrelated individuals randomly selected from NESDA for LD for reference. Nine 
sets of score alleles and related effect size were selected based on different 
significance thresholds (P<10x-8, P<10x-7, P<10x-6, P<10x-5, P<10x-4, P<10x-3, P<0.05, 
P<0.5, P<1) of the discovery samples associations. Additionally, PRS’ were built 
using the LDpred method46 which has shown improved predictive performance 
compared with the previous method by modeling a Bayes prior on effect sizes and 
including LD information. The fraction of causal SNPs was set as infinitesimal, 
assuming the entire genome as causal, and at 3% consistent with the best 
performing fraction for cardiovascular disorders previously reported.46  
 
Statistical analyses 
Data were analyzed using SPSS, version 22.0. RMSSD and RSA values were highly 
skewed and therefore ln-transformed for analyses. HR-PRS and RMSSD-PRS were 
standardized (mean of 0 and standard deviation (SD) of 1) to aid interpretability of 
the results.  
Generalized estimating equations (GEE) analyses were performed with an 
independent correlation structure to take into account within-person correlations 
due to multiple observations per participant. GEE analyses were used to test the 
validity of HR-PRS and RMSSD-PRS in predicting cardiac autonomic variables 
within the NESDA sample. GEE analyses were also used to investigate whether 
current psychopathology and the use of antidepressants were associated with 
cardiac autonomic activity across all waves within the NESDA sample. To investigate 
the consistency of these relationships across waves, wave-interaction terms were added 
to the model. In the case of a consistent relationship, the interaction terms equal zero. 
GxE interaction effects were examined by adding HR/RMSSD-PRS-by- 
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psychopathology and HR/RMSSD-PRS-by-antidepressant interaction terms 
to the model. To investigate the effect of depression severity, we reran all analyses 
including Inventory of Depressive Symptomatology-Self Report (IDS-SR) scores 
instead of current psychopathology. All analyses were adjusted for sex, age, and 
wave. Analyses with PRS were also adjusted for ancestry-informative principal 
components. Interaction analyses were additionally adjusted for covariate-by-
gene and covariate-by-exposure interaction terms, as suggested by Keller.47   
In addition, we used PRS and GWAS summary level data to establish 
whether there was a genetic correlation of psychopathology with cardiac 
autonomic activity. Two types of analyses were performed: 1) regression analyses 
established whether HR/RMSSD-PRS were associated with depression and anxiety, 
and whether depression-PRS was associated with cardiac autonomic variables, and 
2) LD score regression (LDreg) analyses were performed on GWAS summary level 
data of depression and cardiac autonomic activity. LDreg is a newly developed 
method that can determine the genetic correlation of traits by using summary 
statistics from GWAS, while ensuring that confounding does not inflate the 
number of false positives.48 These analyses were conducted for two reasons: to 
provide more evidence on (the lack of) a shared etiology between the traits, and 
to examine the presence of a gene-exposure correlation, as this might cause 
spurious gene-by-exposure interactions. 
Given our sample, power simulations, carried out in R ‘MASS’ package, 
showed that we had sufficient power (80%) to detect an interaction effect of 
R2=0.09 for psychopathology and R2=0.12 for antidepressant use at alpha=.01. 
Correction for multiple testing was based on Matrix Spectral Decomposition 
suggested by Nyholt et al.,49 which corrects the alpha level, taking into account the 
correlations among the predictors (HR-PRS, RMSSD-PRS, current psychopathology, 
TCA use, SNRI use, SSRI use). Accordingly, the criterion for statistical significance 
was set at alpha=.0084.  
 
RESULTS 
 
Table 1 shows the characteristics of our sample at baseline (n=2319), 2-year FU 
(n=1870), 6-year FU (n=1543), and 9-year FU (n=1262). For instance, at baseline, 
our sample had a mean age of 42.4 years (SD=13.0) and included 66.1% females. 
 
The phenotypic association of depression/anxiety with cardiac autonomic activity 
GEE analyses showed no significant associations of cardiac autonomic variables 
with current psychopathology or IDS-SR across waves (Table 2). In addition, no 
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significant wave-interaction effects were found, suggesting that the associations 
did not differ across waves (not tabulated). 
The genetic association of depression/anxiety with cardiac autonomic activity 
First, we tested the validity of HR/RMSSD-PRS in predicting cardiac autonomic 
variables within NESDA. Supplementary figure 1 shows the explained variance in 
cardiac autonomic traits by HR-PRS and RMSSD-PRS per wave. These findings 
support the consistency of the contribution of polygenetic risk factors to variance 
in cardiac autonomic activity across 9-year FU data. We pursued the analyses with 
the best performing score for HR and RMSSD (i.e. LDpred (0.03), which assumes 
that 3% of all variants are causal for the trait of interest). As expected, GEE analyses 
showed that HR-PRS was positively associated with HR (B=1.810; p<.001), and 
negatively associated with RMSSD (B= -0.067; p<.001) and RSA (B= -0.046; p<.001) 
across all waves in NESDA (Table 2). Also in line with expectations, RMSSD-PRS was 
negatively associated with HR (B= -0.755; p<.001), and positively associated with 
RMSSD (B=0.061; p<.001) and RSA (B=0.049; p<.001) across all waves.  
After confirming the validity of HR/RMSSD-PRS, we investigated the 
genetic correlation between psychopathology and cardiac autonomic activity. We 
found no associations of HR-PRS (B=0.017; p=.53) and RMSSD-PRS (B=0.005; p=.84) 
with psychopathology (Supplementary figure 2), or of HR-PRS (B=0.113; p=.64) 
and RMSSD-PRS (B=0.288; p=.27) with IDS-SR (Supplementary figure 3). 
Congruently, we found depression-PRS not to be associated with HR (B=0.301; 
p=.092), RMSSD (B=-0.015; p=.14), or RSA (B=-0.014; p=.094). Additional LDreg 
analyses yielded no significant genetic correlation of depression with HR (rg=0.03; 
p=.97) or RMSSD (rg= -0.0027; p=.96), providing more evidence that these traits 
have no shared etiology. These analyses also excluded the presence of a gene-
exposure correlation, and thus the possibility of spurious gene-by-exposure 
interactions. 
The phenotypic association of antidepressants with cardiac autonomic activity 
Table 2 shows that TCA (B=10.292; p<.001) and SNRI (B=3.171; p<.001) use were 
associated with a significantly higher HR, while SSRI use was associated with a 
slightly lower HR (B= -1.134; p=.006) across waves. Use of all antidepressants was 
associated with lower RMSSD and RSA, with the largest effect of TCA (RMSSD: B= -
0.651; p<.001, RSA: B= -0.652; p<.001), followed by SNRI (RMSSD: B= -0.312; p<.001, 
RSA: B= -0.307; p<.001) and SSRI (RMSSD: B= -0.134; p<.001, RSA: B= -0.150; 
p<.001). No significant wave-interaction effects were found, suggesting that the 
associations were consistent across waves (not tabulated).  
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Table 2. Main and interaction effects of PRS and current psychopathology/antidepressant use on 
cardiac autonomic trait (no. observations = 6994) 
 Cardiac autonomic trait 
 HR  lnRMSSD  lnRSA 
Main effects B p  B p  B p 
HR-PRS 1.810 <.001  -0.067 <.001  -0.046 <.001 
RMSSD-PRS -0.755 <.001  0.061 <.001  0.049 <.001 
Current 
psychopathology 
-0.593 .070  0.010 .58  0.007 .67 
IDS-SRa -0.002 .86  -0.001 .36  -0.001 .24 
TCA use 10.292 <.001  -0.651 <.001  -0.652 <.001 
SNRI use 3.171 <.001  -0.312 <.001  -0.307 <.001 
SSRI use -1.134 .006  -0.134 <.001  -0.150 <.001 
Interaction effects         
HR-PRS*current 
psychopathology 
-0.481 .15  0.006 .71  0.018 .24 
HR-PRS*IDS-SRa -0.024 .086  4.7E-4 .50  0.001 .041 
HR-PRS*TCA use 1.086 .31  -0.104 .070  -0.085 .10 
HR-PRS*SNRI use 0.809 .17  0.008 .84  0.033 .34 
HR-PRS*SSRI use 0.310 .40  -0.011 .61  -0.013 .50 
RMSSD-PRS*current 
psychopathology 
-0.320 .40  0.012 .56  0.012 .51 
RMSSD-PRS*IDS-SRa -0.011 .44  3.2E-4 .68  2.8E-4 .70 
RMSSD-PRS*TCA use 2.281 .029  0.070 .20  0.045 .37 
RMSSD-PRS*SNRI use 0.176 .81  -0.048 .17  -0.063 .054 
RMSSD-PRS*SSRI use 0.488 .26  -0.005 .83  -0.003 .87 
Note: PRS = polygenic risk scores. HR = heart rate. RMSSD = root mean square of differences between 
successive interbeat intervals. RSA = respiratory sinus arrhythmia. IDS-SR = Inventory of Depressive 
Symptomatology-Self Report. TCA = tricyclic antidepressant. SNRI = selective serotonergic and 
noradrenergic reuptake inhibitors. SSRI = selective serotonin reuptake inhibitors. GEE analyses were 
performed separately for dependent variables HR, lnRMSSD, and lnRSA. Psychopathology and 
antidepressant use were added as independent variables in the same model. All analyses were 
adjusted for sex, age, and wave. Analyses with PRS were also adjusted for ancestry-informative 
principal components. Analyses with PRS-interaction terms were additionally adjusted for covariate-
by-gene and covariate-by-exposure interaction terms. aIDS-SR was not included in the same model 
as current psychopathology, but replaced psychopathology in a different model. Boldface indicates 
statistical significance (p<.0084). 
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Genetic moderation  
When investigating the effect of genetic moderation on the relationship between 
psychopathology and cardiac autonomic activity, no significant results were found 
for HR/RMSSD-PRS-by-psychopathology interaction terms on HR, RMSSD, or RSA. 
In addition, we did not find any significant interaction effects of antidepressant use 
with HR/RMSSD-PRS on cardiac autonomic variables (Table 2).  
 
Posthoc analyses using IBI-adjusted HRV variables 
Because the ability of RMSSD and RSA to index cardiac autonomic activity may be 
associated with the prevailing HR,50 we reran the GEE analyses with IBI, and HRV 
variables corrected for the mean IBI (the reciprocal of HR) as described by Van Roon 
and colleagues51 (Supplementary table 1). Overall, these results were similar to 
the original GEE analyses, suggesting that the present findings were not merely 
due to individual differences in HR. 
 
DISCUSSION 
 
Ambiguous findings on the relationship of cardiac autonomic activity with 
psychopathology and antidepressant use call for studies to resolve this. This study 
used a genetic perspective to investigate these relationships. Regarding cardiac 
autonomic dysregulation and psychopathology, our study found no phenotypic or 
genetic association across four waves in a nine-year longitudinal design. In 
addition, we found no evidence for a moderating effect of genetic risk for cardiac 
autonomic dysregulation that could partly explain discrepant findings in the 
literature. In sharp contrast, a significant association between antidepressant use 
and cardiac autonomic activity was found consistently across the nine year follow-
up. Genetic risk for cardiac autonomic dysregulation did not moderate this 
association. 
Previous NESDA studies indicated that there was little evidence for a 
direct association of psychopathology with cardiac autonomic dysregulation.11,14 
This was confirmed by the current nine-year follow-up study. In addition, the lack 
of a genetic correlation under a Mendelian randomization framework52 further 
confirmed the absence of a shared etiology between psychopathology and cardiac 
autonomic dysregulation.   
As studies in this field have used different selection criteria (e.g., 
excluding people with cardiovascular disease21), samples may differ in genetic risk 
for cardiac autonomic dysregulation. We hypothesized that this may partially 
cause the conflicting findings in this research area, and investigated possible 
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moderating effects of genetic risk for high HR and low HRV on the relationship 
between psychopathology and cardiac autonomic dysregulation. Evidence for the 
plausibility of such an interaction comes from twin studies that showed increased 
genetic variance of autonomic activity under stress compared to resting levels.29–31 
Because psychopathology is associated with high levels of stress, we expected a 
similar moderation here. However, the current study did not find evidence for 
genetic moderation of a PRS for resting HR or HRV on the association between 
psychopathology and cardiac autonomic activity across four waves.  
The absence of a phenotypic or genetic association and genetic 
moderation in the current study, calls for an explanation of the previous findings 
of a significant relationship between cardiac autonomic dysregulation and 
psychopathology. One explanation may lie in use of antidepressants. In contrast to 
psychopathology, antidepressant use was consistently associated with cardiac 
autonomic activity across nine-year longitudinal data. In line with our previous 
studies across shorter time spans,11,12,14 we found a detrimental effect on cardiac 
autonomic activity of TCA use, followed by SNRI use, and SSRI use. SSRI use might 
even have a slightly beneficial effect on HR. According to our study, these 
relationships were not moderated by a genetic risk for high HR or low HRV, 
meaning that the effects of antidepressant use were not exacerbated by genetic 
vulnerability, or ameliorated by genetic resilience. There are many other factors 
that might explain the different findings in the literature regarding the effects of 
antidepressant use on cardiac autonomic activity. For instance, it has been 
suggested that the contradictory findings for SSRIs are caused by differential 
effects of specific antidepressants within an antidepressant class.53 Other obvious 
influential factors may be the dosage and duration of use. In addition to the 
general confounding effect of antidepressant use, the heterogeneous effects of 
different types and treatment of antidepressants might be an additional factor that 
contributes to the confusion in the literature regarding mental health and cardiac 
autonomic activity, as studies might find associations to be significant in particular 
in samples where more detrimental types of antidepressants were used. 
Speculations aside, this study adds to the increasing evidence that almost all 
antidepressants affect cardiac autonomic activity,13,22 with the strongest 
detrimental effects associated with TCAs, and the mildest effects with SSRIs. These 
results are also in correspondence with recent findings in a very large general 
population sample (n=149,205), where similar effects on HRV were found for TCAs, 
SNRIs, and SSRIs.33 Although the relevant mechanisms are not entirely understood, 
it is thought that antidepressants influence relay nuclei of the parasympathetic 
nervous system in the brain stem,54 inhibit cardiac vagal tone by exerting 
anticholinergic activity,55 and/or inhibit the reuptake of norepinephrine in the heart.56  
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The major strength of this study is that it is one of the largest studies 
with the longest follow-up to investigate the relationship of psychopathology and 
antidepressant use with cardiac autonomic activity, and the first to address the role 
of genetics. However, several limitations need to be taken into account. As in most 
genetic studies, there is the question of whether there was adequate power to find 
the relationships of interest. Our sample (no. observations = 6994) had sufficient 
power (80%) to detect an interaction effect of R2=0.09 for psychopathology and 
R2=0.12 for antidepressant use at alpha=.01. Therefore, our analyses cannot 
exclude interaction effects smaller than these. However, an effect of smaller size 
might not be of clinical relevance, and probably could not explain the discrepant 
findings in this research area. Another limitation concerns the suggestion that 
heterogeneity in psychopathology may cause the discrepant findings regarding 
cardiac autonomic dysregulation.22 This was illustrated by Kemp and 
colleagues,19,21,22 but also by one of our own studies that attempted to replicate 
NESDA findings in the Adult Health and Behavior registries, a general population 
study.10 For this study, we only found the Beck Depression Inventory-II – but not 
the Center for Epidemiological Studies Depression Scale – to be significantly 
associated with HRV. This led to the conclusion that these depression scales may 
capture different symptom profiles,57 and stresses the possibility that disorder 
heterogeneity may contribute to the ambiguous findings on the association 
between psychopathology and cardiac autonomic activity. If this is the case, a 
GWAS of depression in general may not tease out the genetic risk for a disorder 
profile that is specifically associated with cardiac autonomic dysregulation. Future 
studies are needed to explore the effects of different depressive and anxious 
symptom dimensions. Future replication studies should also attempt to verify or 
falsify the current findings in a different (and larger) sample.      
To conclude, in this large longitudinal dataset, we found no evidence for 
a phenotypic relationship between psychopathology and cardiac autonomic 
activity, nor did we find evidence for a shared etiology through genetic correlation. 
We found no moderating effects of genetic risk that could explain discrepant 
findings in the literature. Our results confirm the robust effects of all classes of 
antidepressants on cardiac autonomic dysregulation. These relationships do not 
appear to be moderated by genetic risk. Our findings suggest that previously 
reported associations between psychopathology and cardiac autonomic 
dysregulation are likely caused by confounding factors, in particular antidepressant 
use. The increasing evidence of detrimental effects of antidepressant use on the 
autonomic nervous system ought to be taken into account by clinicians, especially 
when treating patients with poor cardiovascular health.  
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Supplementary table 1. Main and interaction effects of PRS and current psychopathology/ antidepressant 
use on cardiac autonomic trait (no. observations = 6994) 
Cardiac autonomic trait 
IBI Ln(RMSSD/IBI) Ln(RSA/IBI) 
Main effects B p B p B p 
HR-PRS -21.799 <.001 -0.041 <.001 -0.019 .012 
RMSSD-PRS 10.692 <.001 0.056 <.001 0.044 <.001 
Current psychopathology 6.225 .015 0.005 .71 0.008 .45 
IDS-SRa -0.064 .59 -1.2E-4 .81 -1.6E-4 .72 
TCA use -95.067 <.001 -0.463 <.001 -0.464 <.001 
SNRI use -42.116 <.001 -0.247 <.001 -0.233 <.001 
SSRI use 21.202 <.001 -0.119 <.001 -0.143 <.001 
Interaction effects 
HR-PRS*current 
psychopathology 
-1.849 .49 0.004 .73 0.005 .66 
HR-PRS*IDS-SRa 0.112 .38 7.2E-5 .89 0.001 .19 
HR-PRS*TCA use 2.469 .77 -0.073 .10 -0.058 .15 
HR-PRS*SNRI use 4.824 .42 0.014 .60 0.014 .63 
HR-PRS*SSRI use -1.329 .74 -0.003 .85 0.001 .93 
RMSSD-PRS*current 
psychopathology 
2.458 .40 0.016 .27 0.019 .10 
RMSSD-PRS*IDS-SRa -0.009 .94 0.001 .29 0.001 .30 
RMSSD-PRS*TCA use -9.581 .28 0.084 .072 0.048 .25 
RMSSD-PRS*SNRI use -3.734 .52 -0.039 .15 -0.056 .029 
RMSSD-PRS*SSRI use -2.076 .61 -0.002 .90 -0.010 .56 
Note: PRS = polygenic risk scores. IBI = interbeat interval. RMSSD = root mean square of differences 
between successive interbeat intervals. RSA = respiratory sinus arrhythmia. IDS-SR = Inventory of 
Depressive Symptomatology-Self Report. TCA = tricyclic antidepressant. SNRI = selective serotonergic 
and noradrenergic reuptake inhibitors. SSRI = selective serotonin reuptake inhibitors. GEE analyses 
were performed separately for dependent variables IBI, ln(RMSSD/IBI), and ln(RSA/IBI). 
Psychopathology and antidepressant use were added as independent variables in the same model. All 
analyses were adjusted for sex, age, and wave. Analyses with PRS were also adjusted for ancestry-
informative principal components. Analyses with PRS-interaction terms were additionally adjusted for 
covariate-by-gene and covariate-by-exposure interaction terms. aIDS-SR was not included in the same 
model as current psychopathology, but replaced psychopathology in a different model. Boldface 
indicates statistical significance (p<.0084). 
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ABSTRACT 
Physical activity, alcohol use and smoking might affect cardiovascular disease 
through modifying autonomic nervous system (ANS) activity. We investigated: 1) 
whether there are consistent relationships between lifestyle factors and cardiac 
ANS activity over time, and 2) whether 2-year changes in lifestyle factors relate to 
2-year changes in cardiac activity. Baseline (n=2618) and 2-year follow-up (n=2010) 
data of the Netherlands Study of Depression and Anxiety was combined. Baseline
data was collected in the Netherlands from 2004-2007. Lifestyle factors were
habitual physical activity, frequency of sport activities, alcohol use, and smoking.
Indicators of cardiac activity were heart rate (HR), respiratory sinus arrhythmia
(RSA) and pre-ejection period (PEP) (100 minutes of registration). The results
showed that high physical activity (-1.8beats/min compared to low activity), high
frequency of sport activities (‘couple of times/week’:-2.5beats/min compared to
‘almost never’) and mild/moderate alcohol use (-1.2beats/min compared to non-
drinking) were related to low HR. Heavy smoking was related to high HR 
(>30cigarettes/day:+5.1beats/min compared to non-smoking). High frequency of
sport activities was associated with high RSA (‘couple of times/week’:+1.7ms
compared to ‘almost never’) and moderate smoking with longer PEP (11-
20cigarettes/day:+2.8ms compared to non-smoking). Associations were
consistent across waves. Furthermore, 2-year change in frequency of sport 
activities and number of smoked cigarettes/day was accompanied by 2-year
change in HR (β=-.076 and β=.101, respectively) and RSA (β=.046 and β=-.040, 
respectively). Our findings support consistent effects of lifestyle on HR and
parasympathetic activity in the expected direction. Cardiac autonomic
dysregulation may be partly mediating the relationship between lifestyle and
subsequent cardiovascular health.
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INTRODUCTION 
Autonomic nervous system (ANS) dysfunction has been found to be prognostic for 
unfavorable health outcomes, such as the metabolic syndrome (MetS)1–4 and 
cardiovascular disease (CVD).5,6 Several lifestyle factors that are known risk factors 
for MetS and CVD have been hypothesized to affect these adverse health outcomes 
through modifying ANS activity. For instance, physical activity is suggested to be 
beneficial for cardiac ANS activity.7–12 Indeed, exercise was found to be associated 
with a favorable shift from sympathetic to parasympathetic cardiac activity.13–22 In 
contrast, alcohol use has been associated with unfavorable effects on cardiac ANS 
activity, illustrated by studies showing increased sympathetic and/or decreased 
parasympathetic activity with increased alcohol intake.23–29 Similarly, data suggests 
that smoking has a detrimental effect on cardiac ANS activity.30–32 This effect has 
been found after chronic33–36 and acute36–40 exposure to tobacco smoke. 
Studies on alcohol use and smoking have either investigated acute effects 
of these substances or effects of habitual drinking or smoking at one time point 
and studies on physical activity have often looked at effects of short-term exercise 
interventions on cardiac ANS activity. To our knowledge, only one study 
investigated the association between habitual physical activity and 
parasympathetic activity over a longer time period,16 and found that physical 
activity predicted positive changes in heart rate variability (HRV), an often-used 
measure of cardiac parasympathetic activity. Otherwise, not much is known about 
the longitudinal relationships between habitual lifestyle factors and both 
sympathetic and parasympathetic activity, leaving important questions 
unanswered, such as how changes in lifestyle affect cardiac ANS activity. Finally, 
the relationship between habitual lifestyle factors and cardiac ANS activity may not 
be linear and it is important to understand at which threshold a certain behavior is 
likely to be detrimental or beneficial. Some studies have found decreased HR and 
increased HRV with increased amounts of regular exercise behavior.17,41 In contrast, 
one study found that the effect of taking up regular exercise leveled off at a 
moderate dose, such that more prolonged and intense exercise training did not 
lead to more improvements in cardiac ANS activity.42 Regarding alcohol use, one 
study demonstrated that increasing doses of habitual drinking were associated 
with increasing sympathetic activity,24 while another study found that only heavy 
drinkers had significantly elevated sympathetic activity.23 As for smoking, one 
study implied that heavy smoking, but not moderate smoking, caused reduction 
in parasympathetic activity.36 Most of these studies have used small, diverse 
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samples and different methodology, which may have caused the discrepancies in 
results. 
The aim of the current study was to investigate: 1) whether there are 
consistent relationships between physical activity, alcohol use and smoking with – 
both sympathetic and parasympathetic – cardiac activity over a 2-year follow-up, 
and 2) whether changes in these lifestyle factors are related to changes in cardiac 
ANS activity over 2 years. Indicators of cardiac ANS activity were heart rate (HR), 
controlled by both branches of the ANS,43 respiratory sinus arrhythmia (RSA) as an 
index of parasympathetic control,44,45 and pre-ejection period (PEP) as an index of 
sympathetic activity.43,46 Our large sample size allowed for the inclusion of many 
important confounding factors.  
 
METHODS 
 
Subjects 
Participants belonged to the Netherlands Study of Depression and Anxiety (NESDA), 
an ongoing longitudinal cohort including 2981 respondents aged 18-65 years 
consisting of persons with depressive/anxiety disorders and healthy controls. 
Respondents were recruited from the community, primary care and mental health care 
in the Netherlands. A four-hour baseline measurement, including demographic, 
psychiatric and physical assessments, was conducted between September 2004 
and February 2007, and follow-up assessments took place after two, four and six 
years. Questions about lifestyle factors were incorporated in a self-report 
questionnaire filled out by the participants before every assessment. A detailed 
description of the rationale, objectives and methods of the NESDA study can be 
found elsewhere.47 The research protocol was approved by the Ethical Review 
Board of each participating center, and written informed consent was provided by 
all participants. 
Data for the present study were drawn from the baseline (n=2981) and 2-
year follow-up (n=2596) assessment. Of the total baseline sample, 225 individuals 
were excluded because of missing questionnaire data on lifestyle factors, and an 
additional 138 individuals because of missing physiological data due to equipment 
failure or poor electrocardiogram quality. At 2-year follow-up 331 individuals were 
excluded because of missing data on lifestyle factors, and 255 individuals because 
of missing physiological data. Consequently, the analyses were conducted with 
2618 participants at baseline and 2010 participants at 2-year follow-up. 
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Lifestyle factors 
We investigated four self-reported lifestyle factors: physical activity, sport 
activities, alcohol use and smoking.  
Physical activity was measured by the short IPAQ,48 a 7-item instrument 
assessing the amount of habitual vigorous activity, moderate and walking 
activities over the last 7 days. The continuous score is calculated in Metabolic 
Equivalent Total (MET)-minutes per week: MET level*minutes of activity*events per 
week.48 The categorical score indicates three levels of physical activity: low, 
moderate and high. Detailed information about the methodological 
development of the IPAQ can be found at the IPAQ website www.ipaq.ski.se.  
Sport activities was determined by the question: ‘How often do you 
engage in sport activities, such as swimming, cycling, playing soccer or other 
sports?’ Participants were required to choose from the categories: 1) almost never, 
2) a couple of times/year, 3) every month, 4) a couple of times/month, 5) every
week, or 6) a couple of times/week.
Alcohol use was assessed by the Alcohol Use Disorder Identification Test 
questionnaire49 from which we derived the number of alcoholic drinks per week. A 
drink was defined as follows: 1) a single small (8 ounces) glass of beer, 2) a single 
shot/measure of liquor/spirits, 3) a single glass of wine. For the categorical score, 
this number was divided into three categories: non-drinker (<1 drink/week), 
mild/moderate drinker (men: 1-21 drinks/week, women: 1-14 drinks/week), and 
heavy drinker (men: > 21 drinks/week, women: >14 drinks/week). 
Smoking was indicated by the current number of cigarettes/day. For the 
categorical score, this number was divided into the following categories: 0 
cigarettes, 1-10 cigarettes, 11-20 cigarettes, 21-30 cigarettes, and >30 cigarettes 
per day.50 
Physiological measurements 
Cardiac ANS measures were recorded with the ‘Vrije Universiteit Ambulatory 
Monitoring System’ (VU-AMS). The VU-AMS records electrocardiograms (ECG) and 
changes in thorax impedance (ICG) from a six-electrode configuration.43 During the 
recording, an event marker was used to indicate the start and end of the different 
assessment conditions. Movement registration through vertical accelerometry 
indicated periods where the subjects were not stationary. These non-stationary 
periods were removed from the analyses, resulting in four conditions: a supine rest 
condition with blood pressure measurement, a psychiatric interview, a general 
interview and an Implicit Association (computer) Task. The recording of these four 
conditions lasted approximately 100 minutes and data from these conditions were 
averaged to create a single value of HR and RSA per individual. Since postural 
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changes are the main source of change in preload,51 the supine condition was 
excluded when averaging PEP. HR, controlled by both branches of the ANS, was 
derived from the interbeat interval (IBI) time series from the ECG signal.44 The HRV 
measure of RSA was used as an index of cardiac parasympathetic activity, 
combined the ECG with the respiration signal obtained from ICG, and was 
obtained by subtracting the shortest IBI during HR acceleration at inhalation from 
the longest IBI during HR deceleration at exhalation for all breaths.44,45 PEP, an 
index of sympathetic activity, was ensemble averaged across one-minute periods 
time-locked to the R-waves in the ECG. PEP was defined as the interval between 
the Q-onset in the ECG, indicating onset of left ventricular electrical activity, and 
the upstroke (B-point) of the ICG signal, indicating the beginning of left ventricular 
ejection.43,46 Automated scoring of HR, RSA and PEP was checked by visual 
inspection and, where necessary, corrected or discarded.  
Covariates 
Analyses were adjusted for sociodemographic characteristics, including age, sex 
and years of education. In addition, adjustments were made for health indicators, 
including body mass index (BMI), number of chronic diseases for which people 
were under treatment (cardiovascular disease, epilepsy, diabetes, osteoarthritis, 
stroke, cancer, chronic lung disease, thyroid disease, liver disease, intestinal 
disorders and ulcer), current depression and/or anxiety disorder (according to the 
DSM-IV based Composite International Diagnostic Interview), and former smoking 
(for analyses of smoking). We also adjusted for use of heart medication (ATC codes 
C01, C02, C03, C04, C05, C07 and C08), and use of tricyclic antidepressants (TCAs, 
ATC code N06AA), selective serotonin reuptake inhibitors (SSRIs, ATC code N06AB), 
and selective serotonin and noradrenalin reuptake inhibitors (SNRIs, ATC code 
N06AX). Since it has been linked to RSA,52 respiration rate was included as a 
covariate when analyzing RSA.  
Statistical analyses 
RSA values were highly skewed and therefore ln-transformed for analyses. We used 
generalized estimated equations (GEE) analyses with an exchangeable correlation 
structure to examine the consistency of the association between the lifestyle 
factors and HR/RSA/PEP over time. GEE allowed us to conduct a combined cross-
sectional analyses on the relationship between lifestyle factors and HR/RSA/PEP for 
both baseline and follow-up. We first entered the predictors as continuous 
variables, and then as categorical variables to illustrate the dose-response effects 
and possible critical thresholds in non-linear relationships. To test for U-curve type 
effects we added quadratic effects of physical activity, alcohol use and smoking to 
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the GEE (since sport activities was a categorical variable we did not add a quadratic 
term for this variable). For these analyses we mean-centered the predictors to 
avoid multicollinearity of the linear and quadratic variables. To investigate whether 
the effects of lifestyle factors on cardiac ANS activity differed between the two 
assessments, the above analyses were repeated with the inclusion of an interaction 
term between lifestyle factors and time. Analyses were adjusted for sociodemographic 
and health characteristics. Covariates age, sex, years of education and former smoking 
were held at baseline, other covariates could vary over time. 
Change-variables of lifestyle factors, cardiac ANS activity and covariates 
were calculated by subtraction of the variables at baseline from the variables at 2-
year follow-up. We then conducted multiple linear regression analyses to examine 
whether 2-year changes in lifestyle factors were associated with 2-year changes in 
cardiac ANS activity. These analyses were adjusted for the corresponding lifestyle 
and ANS values at baseline, as well as for baseline age, sex, education and former 
smoking. Additional adjustments were made for 2-year change-scores of BMI, 
number of chronic diseases, use of heart medication, current psychopathology, 
antidepressant use, and respiration rate. We then investigated with analyses of 
covariance whether certain patterns of behavioral changes (Table 4) were 
accompanied by different changes in autonomic activity over time.  
Since it has been suggested that parasympathetic activity is underestimated 
in people with low HR,18 we performed sensitivity analyses for which we excluded 
people with HR<55.44 We also performed sensitivity analyses for which we excluded 
cardiac ANS activity during the psychiatric interview, since this condition has been 
shown to evoke differential stress reactivity in people with psychopathology 
compared to controls.53 
Data was analyzed using SPSS, version 20.0. The criterion for statistical 
significance was p<.05. 
RESULTS 
At baseline, our sample (n=2618) had a mean age of 41.6 years (SD=13.0) and 
66.2% were female (Table 1).  
Consistent associations existed between several lifestyle factors and 
Cardiac ANS activity across waves (Table 2). Physical activity and sport activities 
were associated with lower HR (B=-.141; p=.001 and B=-.461; p<.001, respectively). 
Sport activities was also associated with higher RSA (ln(B)=.010; p=.001). Smoking 
was associated with higher HR (B=.075; p<.001) and, unexpectedly, with longer 
PEP (B=.098; p=.013). The addition of an interaction term between lifestyle factors 
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Table 1. Sample characteristics 
Participants, % 
Variables Baseline 
n=2618 
2-year follow-up
n=2010
Demographics  
     Age, mean (SD), years 41.6 (13.0) 44.1 (13.2) 
     Female sex  66.2 66.5 
     Education, mean (SD) years 12.2 (3.2) 12.6 (3.3) 
Health factors 
     Body Mass Index, mean (SD), kg/m2 25.5 (4.9) 25.7 (4.9) 
     Number of chronic diseases, median (IQR)  0.0 (0.0 – 1.0) 0.0 (0.0 – 1.0) 
     Use of heart medication  12.5 15.0 
     Current depression and/or anxiety  56.8 37.6 
     Antidepressant use  
          TCA 2.6 2.9 
          SSRI  16.8 14.2 
          SNRI 4.0 3.7 
Lifestyle factors 
     Physical activity, median (IQR), 1000 METmin/week  2.8 (1.4 – 5.0) 3.1 (1.6 – 5.5) 
          Low physical activity  23.1 19.6 
          Moderate physical activity  42.2 40.5 
          High physical activity  34.6 39.9 
     Sport activities  
          Almost never  26.2 24.6 
          Couple of times a year  12.3 12.3 
          Every month  6.1 5.6 
          Couple of times a month  8.1 9.0 
          Every week  22.7 23.5 
          Couple of times a week  24.7 25.1 
     Alcohol use, median (IQR), drinks/week 3.7 (0.2 – 8.7) 3.7 (0.2 – 8.7) 
          Non-drinker 32.3 31.7 
          Mild/moderate drinker 51.5 52.7 
          Heavy drinker 16.2 15.6 
     Smoking, median (IQR), no. cigarettes/day 0.0 (0.0 – 8.0) 0.0 (0.0 – 5.0)  
          Current smoker 37.9 30.2 
Autonomic variables  
     HR, mean (SD), beats/min 72.0 (9.6) 72.6 (9.5) 
     RSA, mean (SD), ms 44.6 (26.0) 41.8 (22.3) 
     PEP, mean (SD), ms 120.1 (17.7) 119.7 (17.2) 
     Respiration rate, breaths/min 17.1 (1.2) 17.3 (1.2) 
Note:  Metmin = multiple of resting metabolic rate times minutes of physical activity per week. IQR 
= interquartile range. HR = heart rate. RSA = respiratory sinus arrhythmia. PEP = pre-ejection period.  
Baseline data was collected in the Netherlands from 2004-2007. 
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and time showed that the associations were generally consistent across the waves, 
except for the association between smoking*time and PEP (B=-.106; p=.015).  
Figure 1 illustrates the associations between categories of lifestyle factors 
and cardiac ANS activity over time, showing that the association between physical 
activity and HR was mainly driven by high physical activity (-1.8 beats/min; p<.001 
compared to low physical activity). The association between sport activities and 
HR was mainly driven by engaging ‘every week’ or ‘a couple of times/week’ in sport 
activities (-1.4 beats/min; p<.001 and -2.5 beats/min; p<.001 compared to ‘almost 
never’, respectively). These two categories also drove the association between 
sport activities and RSA (+1.5ms; p=.013, and +1.7ms; p=.007 compared to ‘almost 
never’, respectively). Analyses of quadratic relationships (Table 2) indicated that 
there was a non-linear association between number of drinks and HR and RSA. 
When analyzing categories of alcohol use, it seemed like these relationships were 
U-shaped with mild/moderate drinking being significantly associated with lower
HR (-1.2beats/min; p<.001) and non-significantly with higher RSA than non-
drinking. Analyses of quadratic relationships (Table 2) also indicated that there
was a non-linear association between smoking and HR and PEP. Figure 1 suggests 
that the association between HR and smoking was J-shaped with minimal effects
of light smoking but substantial effects of heavy smoking on HR (21-
30cigarettes/day: +1.6 beats/min; p=.024 ; >30cigarettes/day: +5.1beats/min; 
p<.001 compared to non-smoking). In addition, the association between smoking
and PEP seemed U-shaped with the moderately smoking group (11-
20cigarettes/day) showing longer PEP (+2.8ms; p=.002 compared to non-
smoking).
Table 3 shows that a 2-year increase in sport activities was associated with 
a 2-year decrease in HR (β=-.076; p=.001) and a 2-year increase in RSA (β=.046; 
p=.026). In addition, a 2-year increase in number of smoked cigarettes/day was 
associated with a 2-year increase in HR (β=.101; p<.001) and a 2-year decrease in 
RSA (β=-.040; p=.040).  
We investigated the lifestyle variables further by distinguishing categories 
of consistency and change in behavior (Table 4). We performed analyses of 
covariance to see whether certain patterns of change in lifestyle were 
accompanied by differences in changes in HR,  RSA and PEP over time (Figure 2). 
Regarding physical activity, results indicated that the persistently active group 
(-1.0beats/min; p=.017) and the newly active group (-1.4beats/min; p=.001) 
increased less in HR over time than the persistently inactive group. For sport 
activities, results showed that persistent activity was accompanied with smaller 
increase in HR over time compared to persistent inactivity (-0.8 beats/min; p=.022). 
For alcohol use, an overall effect was found for HR (p=.044), but post-hoc tests did 
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Table 2. Association between lifestyle factors with ANS values over two time points (baseline: 
n=2618; 2-year follow-up: n=2010) 
HR (beats/min) RSA (ms) PEP (ms) 
B p B p B p 
Linear effects  
Physical activity -.141 .001 .001 .71 .078 .32 
Sport activities -.461 <.001 .010 .001 -.021 .87 
Alcohol use .021 .29 -.001 .39 -.002 .94 
Smoking .075 <.001 .001 .44 .098 .013 
Linear and Quadratic effects  
Mean-centered physical activity -.201 <.001 .002 .32 .109 .30 
Mean-centered physical activity2 .012 .14 -3.4E-4 .45 -.007 .65 
Mean-centered alcohol use  -.067 .008 .002 .11 .041 .36 
Mean-centered alcohol use2 .003 .001 -9.0E-5 .024 -.002 .17 
Mean-centered smoking .018 .57 .002 .19 .235 <.001 
Mean-centered smoking2 .003 .018 -6.0E-5 .30 -.007 .006 
Time interaction effects  
Physical activity*time .001 .98 -.003 .31 .033 .78 
Sport activities*time .022 .81 -.005 .29 .244 .19 
Alcohol use*time .041 .061 -1.03E-5 .99 -.008 .83 
Smoking*time .037 .11 -.001 .16 -.106 .015 
Note: HR = heart rate. RSA = respiratory sinus arrhythmia. PEP = pre-ejection period. RSA was ln-
transformed for analyses. For quadratic analyses the predictors were mean-centered to avoid 
multicollinearity of the linear and quadratic variables. Physical activity was measured in 
1000metmin/week, alcohol use was measured in number of glasses per week and smoking in 
number of cigarettes per day. GEE analyses were adjusted for age, sex, education, BMI, number of 
chronic diseases, use of heart medication, current psychopathology, antidepressant use and time. 
RSA was additionally adjusted for respiration rate and smoking for former smoking. Boldface 
indicates statistical significance (p<.05). Baseline data was collected in the Netherlands from 2004-
2007. 
Table 3. Association between change in lifestyle factors with change in ANS activity over time 
Δ HR, beats/min Δ RSA, ms Δ PEP, ms 
N β p β p β p 
Δ Physical activity  1824 -.043 .065 -.011 .91 .027 .22 
Δ Sport activities 2071 -.076 .001 .046 .026 .004 .85 
Δ Alcohol use 2075 .033 .14 .005 .80 .016 .43 
Δ Smoking 2118 .101 <.001 -.040 .040 -.033 .099 
Note: HR = heart rate. RSA = respiratory sinus arrhythmia. PEP = pre-ejection period. Change-
variables of lifestyle factors and ANS activity were calculated by subtraction of the continuous 
variables at baseline from the continuous variables at 2-year follow-up. Multiple linear regression 
analyses were adjusted for the corresponding lifestyle and ANS values at baseline, as well as for 
baseline age, sex, education and former smoking (for analyses of smoking). In addition, adjustments 
were made for 2-year change-scores of BMI, number of chronic diseases, use of heart medication, 
current psychopathology, antidepressant use and respiration rate (for analyses of RSA). Boldface 
indicates statistical significance (p<.05). Baseline data was collected in the Netherlands from 2004-
2007. 
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not show that any of the groups significantly differed from the non-drinking group. 
For smoking, persistently heavy smoking (+3.2 beats/min; p<.001) and starting 
heavy smoking (+5.2beats/min; p<.001) were associated with a larger increase in 
HR over time compared to non-smoking. In addition, starting heavy smoking was 
related to a larger decrease of RSA compared to non-smoking (-5.1ms; p=.027). 
Sensitivity analyses excluding people with HR<55 did not alter any of the 
lifestyle associations with (change in) RSA. Similarly, excluding the psychiatric 
interview from our averaged values of cardiac ANS activity did not change our 
results.    
DISCUSSION 
The current study showed that high physical activity, high frequency of sport 
activities and mild/moderate alcohol use were related to low HR, and heavy 
smoking was related to high HR. In addition, high frequency of sport activities was 
associated with high RSA and moderate smoking with longer PEP. These effects 
were consistent over a 2-year period. Longitudinal analyses showed that 2-year 
increase in the frequency of sport activities had beneficial effects on HR and RSA 
over time. In addition, 2-year increase in number of smoked cigarettes/day had a 
negative impact on HR and RSA over time.  
Our findings indicate a more robust effect of frequency of sport activities 
on cardiac ANS activity than of general habitual physical activity (which was only 
associated with HR), possibly due to lower error in recall of these salient activities 
and therefore better reliability of the former measure.54 Another possibility is that 
frequency of sport activities captures a more vigorous form of being active than 
physical activity, since the former comprises purely sports while the latter also 
reflects more moderate forms of exercise. Since it is likely that the ANS is mainly 
influenced by the more vigorous form of activity, this might explain the more 
robust effect of frequency of sport activities. The results on sport activities are in 
line with previous research finding associations between exercise and improved 
parasympathetic activity,13,15,19,22 and comparable to studies that found increasing 
improvement of HR and HRV with increasing exercise.17,41 In contrast to some 
studies,14,19,22 we did not find evidence for a relationship between physical activity 
or sport activities with sympathetic activity. However, most of those studies 
sampled people with obesity, hypertension or cardiovascular disease. Since these 
conditions are related to compromised cardiac ANS activity,5,6,55,56 there may have 
been more obvious effects of exercise on sympathetic activity than in our study 
with relatively young and physically healthy respondents. Longitudinally, Soares-
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Miranda and colleagues16 found a relationship between baseline moderate to 
vigorous physical activity and 3-year increase in HRV. The current study adds to 
these findings by investigating how change in physical activity affects change in 
cardiac ANS activity, and found evidence that increase in frequency of sport 
activities had a beneficial effect on HR and RSA over time. 
Interestingly, our results on alcohol use did not corroborate the 
suggestion that there is a linear relationship between alcohol use and cardiac 
ANS activity.24 Our results rather imply that there is a U-shape relationship, with 
mild/moderate drinking being more favorable for HR than either non-drinking or 
heavy drinking, comparable to the results of Boschloo and colleagues on baseline 
NESDA data.23 A U-shaped relationship has been found between alcohol use and 
other health outcomes,57,58 and likely reflects the association between non-
drinking and formerly heavy drinking, diseases and medication use (sick quitter 
hypothesis).59
This U-shaped relationship also seems applicable for smoking and 
sympathetic activity, since we found a positive relationship between moderate 
smoking and PEP. The mechanisms underlying this counterintuitive finding are 
unclear, since smoking has been suggested to lead to sympathetic activation and 
attenuated baroreflex suppression of sympathetic activation.30 A possible 
explanation is compensatory down-regulation of cardiac beta-adrenergic 
receptors by moderate smoking which would compensate for increased cardiac 
sympathetic activity. At heavier levels of smoking this downregulation may either 
level off or fail to compensate for  the stronger smoking-induced increase in 
cardiac sympathetic activity.60 Another possibility is that baroreflex sensitivity is 
only impaired by heavy smoking, but is still intact in moderate smokers, 
providing the necessary negative feedback to suppress activation of the 
sympathetic nervous system.61 In contrast to many studies reporting smoking to 
be associated with lower parasympathetic activity,34,36,62–65 our results did not 
show this association across waves. One could argue that our non-smoker group 
consists of a considerable group of former smokers who might already have 
compromised ANS activity at baseline. However, former smoking was added as a 
covariate to our analyses and additional analyses separating the former smokers from 
our non-smoking group, did not significantly change our results. It therefore remains 
to be elucidated why our study did not robustly replicate the previously established 
relationship between smoking and lower parasympathetic activity. The effect of 
smoking on HR, however, followed expectation and was worst for heavy smoking. In 
addition, increase in number of smoked cigarettes/day was accompanied by 
detoriation of HR and RSA over time, and subjects who started to smoke heavily 
showed worse deterioration than non-smokers, persistent light or heavy smokers 
Lifestyle and cardiac autonomic activity     105
and people who stopped smoking. These findings comply with the major impact 
of smoking on cardiovascular disease.66 
Limitations 
When interpreting these findings, some limitations have to be taken into account. 
For instance, questions might be raised about the generalizability of this study, 
since the majority of the NESDA sample consists of people with a (history of) 
depressive and/or anxiety disorder. However, our results remained robust after 
adjustments for psychopathology status and previous research has indicated that 
psychopathology was not associated with ANS activity.67,68 We are therefore 
confident that our results apply to the general population. In addition, the effects 
found for lifestyle on cardiac ANS activity were rather modest and whether these 
are clinically relevant remains to be determined. However, we stress that our aim 
was to examine a potential biological mechanism in the association between 
lifestyle and cardiovascular disease, as opposed to providing a clinically useful 
marker of ANS dysregulation at the level of individuals. Also, in general, we found 
little evidence that PEP was affected by lifestyle factors. The reason for this remains 
unclear, since several other studies have shown sympathetic activity to be 
associated with physical activity14,19, alcohol use23,24 and smoking.33,34 Our sample 
consisted of relatively healthy behaving individuals. Perhaps a more unhealthy 
lifestyle would have larger effects on sympathetic activity. Finally, our results are 
based on self-reported lifestyle factors and not on e.g. accelerometer data. Self-
reports of lifestyle is more prone to inaccuracy and bias than such objective 
measurements. However, we did have data on cotinine levels at baseline and these 
levels showed strong correlations with self-reported number of smoked 
cigarettes/day, confirming the reliability and validity of our used measures.  
Conclusion 
Our findings support consistent effects of habitual exercise behavior, smoking and 
alcohol use on HR and cardiac parasympathetic activity in the expected directions. 
Cross-sectionally and longitudinally, high frequency of sport activities and heavy 
smoking had the most robust effects. Our finding support the hypothesis that altered 
regulation of cardiac autonomic activity is one of the mechanisms mediating the 
relationship between lifestyle and subsequent cardiovascular disease. 
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ABSTRACT 
Objectives: This study determined temporal stability of ambulatory measured 
cardiac autonomic activity for different time periods and investigated potential 
drivers of changes in this activity. 
Methods: Data was drawn from baseline (n=2379), 2-year (n=2245), and 6-year 
(n=1876) follow-up from the Netherlands Study of Depression and Anxiety. Cardiac 
autonomic activity was measured with heart rate (HR), respiratory sinus arrhythmia 
(RSA) and pre-ejection period (PEP). Autonomic temporal stability was determined 
across 2, 4, and 6 year intervals. We subsequently examined the association 
between sociodemographics, lifestyle, mental health, cardiometabolic health, and 
the use of antidepressant and cardiac medication with change in cardiac 
autonomic activity.  
Results: Over 2 years, stability was good for HR (ICC=.703), excellent for RSA 
(ICC=.792) and moderate for PEP (ICC=.576). Stability decreased for a 4- (HR ICC= 
.688, RSA ICC= .652 and PEP ICC= .387) and 6-year interval (HR ICC= .633, RSA ICC= 
.654 and PEP ICC= .355). The most important determinants for increase in HR were 
(increase in) smoking, increase in body mass index (BMI) and (starting) the use of 
antidepressants. Beta-blocking/antiarrhythmic drug use led to a decrease in HR. 
Decrease in RSA was associated with age, smoking and (starting) antidepressant 
use. Decrease in PEP was associated with age and (increase in) BMI.  
Conclusions: Cardiac autonomic measures were rather stable over 2 years, but 
stability decreased with increasing time span. Determinants contributing to 
cardiac autonomic deterioration were older age, (increase in) smoking and BMI, 
and (starting) the use of antidepressants. (Starting) the use of cardiac medication 
improved autonomic function.  
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INTRODUCTION 
The autonomic nervous system (ANS) plays a key role in cardiovascular regulation, 
and is a major determinant of resting heart rate (HR) and blood pressure (BP), two 
independent risk factors for coronary artery disease.1,2 Indicators of cardiac 
sympathetic and parasympathetic activity can be non-invasively and unobtrusively 
measured by electrocardiography (ECG) and impedance cardiography (ICG).3,4 In 
order to draw conclusions from longitudinal studies on indices of cardiac 
autonomic activity, these indices are assumed to remain rather stable within 
individuals. Since there are many factors in a person’s life that may influence 
autonomic measures, it is impossible to achieve 100% agreement within a person 
over time. Therefore, it is useful to determine the temporal stability of cardiac 
autonomic activity when interpreting the results of longitudinal studies. In 
addition, it is necessary to investigate which factors contribute to cardiac 
autonomic change, so that these factors are accounted for in longitudinal studies.  
Temporal stability has been investigated for HR, stroke volume, cardiac 
output, pre-ejection period (PEP), total peripheral resistance, systolic BP, and heart 
rate variability (HRV). 5–13 These studies generally yielded moderate to high stability. 
However, found correlation coefficients showed variations among studies, likely 
caused by differences in methodology. For instance, studies differ in time span 
(ranging from a couple of days to a couple of years), sample size (ranging from tens 
of participants to over a hundred participants) and sample population (population 
versus clinical samples). While it would be intuitively appealing for temporal 
stability to decrease with increasing time span, this was not inferred from the 
literature. To our knowledge, Goedhart and colleagues conducted the longest 
study in this research field across 3.3 years and still found moderate to high stability 
for both cardiac sympathetic and parasympathetic activity.9,10 Regarding sample 
population, it has been suggested that HRV, for instance, has significantly worse 
stability in clinical populations than in healthy controls, as shown for populations 
with chronic heart failure 14 and cardiac transplant recipients.15 
ANS dysregulation has been associated with unfavorable health 
outcomes, such as the metabolic syndrome16,17 and cardiometabolic health.18–20 
This can partly reflect a causal role of ANS activity in the onset of these diseases, 
but it is possible that in parallel changes in cardiac ANS activity over time might 
themselves be affected by these health issues, for instance through the effects of 
cardiac medication.21,22 Many more factors have been suggested to influence the 
ANS. Sociodemographics such as age,23 sex,24 and social economic status25 have 
been linked to autonomic activity. In addition, several lifestyle factors have been 
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associated with ANS activity,26 including physical activity,27 alcohol use,28 smoking 
behavior,29 and unhealthy dietary patterns as indexed by e.g. body mass index 
(BMI).30 Patients with psychiatric disorders, such as depression and anxiety, have 
been suggested to have altered ANS (re)activity, with causal effects possible in 
both directions.31,32 Importantly, there is increasing evidence that the use of 
antidepressants might negatively impact autonomic balance.33–35 For many of 
these factors, studies mostly investigated cross-sectional relationships with ANS 
and occasionally short-term longitudinal relationships. Longitudinal studies over 
the course of years are scarce. 
The current study aims to establish the temporal stability of ambulatory 
measured cardiac autonomic activity during several laboratory conditions over a 
2-, 4- and 6-year time period in a large cohort of the Netherlands Study of 
Depression and Anxiety (NESDA). We used the following indicators of cardiac ANS 
activity: HR (controlled by both sympathetic and parasympathetic activity),4 
respiratory sinus arrhythmia (RSA: an indicator of parasympathetic activity)3 and 
PEP (indicative of sympathetic activity).4 We investigated whether sociodemographics or 
(changes in) lifestyle, mental health, cardiometabolic health, and the use of 
antidepressant or cardiac medication were significant drivers of changes in cardiac 
autonomic activity over time.    
METHODS 
Subjects 
Data was obtained from NESDA, an ongoing longitudinal cohort study to examine 
the long-term course of depression and anxiety. Participants were recruited 
from community, primary care and mental health care in the Netherlands. The 
NESDA sample includes 2981 participants aged 18-65 years with a current 
diagnosis of depression and/or anxiety disorder, a prior history of these 
disorders, and healthy controls. A four-hour baseline measurement was 
conducted between September 2004 and February 2007, and follow-up 
assessments took place after two, four and six years. A detailed description of the 
rationale, objectives and methods of the NESDA study can be found 
elsewhere.36 The study protocol was approved by the Ethical Review Board of 
each participating center, and all participants provided written informed 
consent. The study was performed conform the declaration of Helsinki. 
Data for the present study were drawn from baseline (n=2981), 2-year 
(n=2596) and 6-year (n=2256) follow-up assessments (cardiac autonomic activity 
was not measured during 4-year follow-up). Subjects were included when they had 
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measurement of either HR, RSA or PEP during at least two assessments, so that 
temporal stability could be determined. This resulted in a total of 2379 subjects at 
baseline, 2245 subjects at 2-year follow-up and 1876 subjects at 6-year follow-up. 
Missing physiological data was due to telephone or at-home interviews without 
ANS recording, equipment failure during assessment or poor electrocardiogram 
quality.  
PROCEDURES 
The clinic visits consisted of biological assessment including a supine blood 
pressure measurement, a psychiatric interview, a general interview and a computer 
task. The psychiatric interview included questions about various indicators of 
anxious and depressive symptoms, as well as suicide ideation, mood disorder 
symptoms and experience of adverse life events. The general interview contained 
questions about somatic health, smoking behavior, use of medication, daily 
functioning and health care utilization. The computer task was an implicit 
association task (IAT).37  
Determinants of change in autonomic activity 
Determinants of autonomic instability were measured at all three waves and 
described in detail below.  
Sociodemographics 
The following sociodemographic factors were investigated: age (years), sex 
(1=male, 2=female), and education (years) as a proxy for social economic status.  
Lifestyle factors 
Physical activity was measured by the short IPAQ,38 a 7-item instrument assessing 
the amount of habitual vigorous activity, moderate and walking activities over the 
last 7 days. A continuous score is calculated in Metabolic Equivalent Total (MET)-
minutes per week: MET level*minutes of activity*events per week. Alcohol use was 
assessed by the Alcohol Use Disorder Identification Test questionnaire39 from 
which the number of alcoholic drinks per week was derived. A drink was defined 
as follows: 1) a single small (8 ounces) glass of beer, 2) a single shot/measure of 
liquor/spirits, 3) a single glass of wine. Smoking was indicated by the current 
number of cigarettes/day. Body mass index (BMI) was measured in kg/m2. 
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Mental health 
Participants were considered to have a current psychopathology when they had a 
6-month diagnosis of major depressive disorder and/or anxiety disorder (panic 
disorder, social phobia and/or generalized anxiety disorder) according to the DSM-
IV-based Composite International Diagnostic Interview, version 2.1.
Antidepressant use 
Participants were requested to bring their medication containers to the 
assessments so that medication use could be determined. We investigated the use 
of tricyclic antidepressants (TCAs: ATC code N06AA), selective serotonin reuptake 
inhibitors (SSRIs: ATC code N06AB), and selective serotonin and noradrenalin 
reuptake inhibitors (SNRIs: ATC code N06AX). Previous research on NESDA data has 
indicated that TCAs and SNRIs have a different effect on ANS activity than SSRIs, 
with detrimental effects of TCAs and SNRIs on HR,RSA and PEP, while SSRIs had less 
pronounced detrimental effects on RSA and even a beneficial effect on HR and 
PEP.34,35 Therefore, we decided to divide antidepressant use into 1) TCA and/or SNRI 
use, and 2) SSRI use.  
Cardiometabolic health 
Cardiometabolic health consisted of self-reported presence of cardiovascular 
disease (CVD: coronary disease, cardiac arrhythmia, angina pectoris, heart failure, 
and/or myocardial infarction), hypertension and diabetes which received medical 
attention.  
Cardiac medication use 
We investigated the use of beta-blocking/antiarrhythmic drugs (C01B, C07), and 
use of other cardiac medication (C08CA, C01D, C02AC01, C02CA01, C02CA04, C04, 
C09). 
Physiological measurements 
During the assessments physiological data was recorded with the ‘Vrije Universiteit 
Ambulatory Monitoring System’ (VU-AMS), an unobtrusive lightweight portable 
device. The VU-AMS contains a six-electrode configuration that measures 
electrocardiograms (ECG) and changes in thorax impedance (ICG).4 An event 
marker was used to divide the assessment into different conditions. Movement 
registration through vertical accelerometry was used to remove periods where the 
subjects were not stationary.  
HR was directly derived from the interbeat interval (IBI) time series from 
the ECG signal.4 RSA combined ECG with the respiration signal obtained from ICG, 
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and was obtained by subtracting the shortest IBI during HR acceleration at 
inhalation from the longest IBI during HR deceleration at exhalation for all breaths.3 
Since it has been suggested that repeatability of HRV is affected by differences in 
HR,40 we decided to add a variable of RSA divided by average interbeat interval (IBI) 
to investigate whether this would impact our results. PEP was ensemble averaged 
across one-minute periods time-locked to the R-waves in the ECG. PEP was 
extracted from the interval between the Q-onset in the ECG, indicating onset of left 
ventricular electrical activity, and the upstroke (B-point) of the ICG signal, 
indicating the beginning of left ventricular ejection.4  
Automated and visual data cleaning assured that suspicious IBIs and 
breathing cycles were corrected or discarded when displaying irregularities. Crucial 
landmarks in the ICG were detected by an automated scoring algorithm, which 
were visually inspected and manually corrected.  
For baseline, 2- and 6-year assessment an average score of HR, RSA, 
RSA/IBI, and PEP was made by combining the conditions that were present at all 
waves: a supine rest condition with blood pressure measurement (±11 min) and 
three sitting conditions: a psychiatric interview (±41 min), a general interview (±33 
min) and a computer task (±13 min). Since postural changes are the main source of 
change in preload,41 the supine condition was excluded in the average score of PEP. 
We will refer to these combined conditions as ‘total assessment’. 
Statistical Analyses 
Cardiac autonomic temporal stability was determined by Two Way Random 
intraclass correlation coefficients (ICC),  which indicates the absolute agreement 
between autonomic variables measured at one time point with those measured at 
another time point within subjects 42. We compared ICC confidence intervals 
between the different sitting conditions with the total assessment to determine 
whether certain ‘demarcated’ conditions would have better temporal stability than 
an overall average. In addition, we compared ICC confidence intervals of temporal 
stability over 2 years (baseline and 2-year follow-up), 4 years (2- and 6-year follow-
up) and 6 years (baseline and 6-year follow-up). RSA values were highly skewed 
and therefore ln-transformed for analyses. 
Multiple linear regression analyses were used to examine whether 
sociodemographics or (changes in) lifestyle, mental health, cardiometabolic 
health, and the use of antidepressant or cardiac medication were significantly 
associated with absolute change in cardiac autonomic activity over each of the 
three time intervals (baseline to 2-year, 2- to 6-year, and baseline to 6-year). For all 
lifestyle factors, continuous absolute change scores were included beside their 
basal value. For mental health, cardiometabolic health and medication use, 
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categories were made based on patterns of change. Since we investigated two 
waves per analysis, the change scores and patterns were solely based on the values 
of the two waves within an analysis, disregarding a third wave (i.e. when analyzing 
6-year ANS change, chronic psychopathology is defined as having a diagnosis at
baseline and at 6-year follow-up, regardless of the diagnosis at 4-year follow-up).
For mental health, the groups were divided as follows: 1) a control group with no 
6-month diagnosis at the start and end of the interval, 2) a chronic
psychopathology group with a present 6-month diagnosis at the start and end of 
the interval, 3) a new onset psychopathology group with no 6-month diagnosis at 
the start of the interval but a 6-month diagnosis at the end of the interval, and 4) a 
remitted psychopathology group with a 6-month diagnosis at the start of the 
interval but no 6-month diagnosis at the end of the interval. Cardiometabolic
health patterns were categorized as: 1) a control group with no diagnosis at the 
start and end of the interval, 2) a chronic group with diagnosis already present at 
the start of the interval, and 3) a new onset group with no diagnosis at the start of
the interval but a present diagnosis at the end of the interval. Medication use 
patterns were defined as: 1) a control group with no current medication use at the 
start and end of the interval, 2) a chronic group using medication at the start and 
end of the interval, 3) a starting group who did not use medication at the start of
the interval but who did use medication at the end of the interval, and 4) a stopping 
group who used medication at the start of the interval but who did not use 
medication at the end of the interval. The analyses were adjusted for basal ANS
values at the start of the interval. Since it has been linked to RSA 43, change in 
respiration rate was included as a covariate when analyzing change in RSA.
Data was analyzed using SPSS, version 22.0. Correction for multiple testing 
was based on Matrix Spectral Decomposition suggested by Nyholt et al.,44 which 
estimated and corrected for the number of independent predictor variables. 
Accordingly, the criterion for statistical significance was set at p<.0016. In addition, 
we looked at the consistency of the results across the different time intervals and 
considered a finding to be more reliable when it was found significant across 
multiple intervals.  
RESULTS 
At baseline our sample (n=2379) had a mean age of 42.0 years (SD=13.1) and 65.9% 
were female (Table 1). Over time, there was a slight increase in BMI and a decrease 
in number of people with psychopathology, as well as a decrease in the use of 
SSRIs. The number of people with cardiometabolic diseases increased over time 
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(incidence of cardiovascular diseases at 2-year follow-up: 0.3% coronary disease, 
0.8% cardiac arrhythmia, 0.4% angina pectoris, and 0.4% heart failure; incidence at 
6-year follow-up: 0.4% coronary disease, 0.8% cardiac arrhythmia, 0.6% angina 
pectoris, and 0.5% heart failure). The use of cardiac medication also increased over
time.
Table 2 shows the ICC of cardiac autonomic variables for several 
conditions over different time periods. When comparing the ICC confidence 
intervals of the separate conditions and the total assessment, we concluded that 
these intervals showed great overlap. In addition, the ICC were very similar for RSA 
and RSA/IBI. We therefore decided to report the results only for HR, RSA and PEP of 
the total assessment, and to use these variables for further analyses. For the total 
assessment, 2-year temporal stability was good for HR (ICC=.703), excellent for RSA 
(ICC=.792) and moderate for PEP (ICC=.576). In addition, for almost all cardiac 
autonomic variables temporal stability decreased with increasing time span (for 
HR: .688, and .633; for RSA: .652, and .654; and for PEP: .387, and .355 for a 4-, and 
6-year interval respectively). When comparing confidence intervals, decrease in 
temporal stability was significant for HR over 6 years compared to 2 and 4 years.
For RSA and PEP, a significantly lower temporal stability was seen over 4 years 
compared to 2 years.
Table 3 shows the association between our determinants and change in 
HR over the different time periods. No significant associations were seen for 
sociodemographic variables. Considering lifestyle, an increase in BMI was 
associated with an increase in HR over all three time periods (β=.131, β=.127 and 
β=.145 for a 2-, 4- and 6-year interval respectively). Basal number of cigarettes/day 
was significantly associated with an increase in HR over two time periods (β=.092 
and β=.108 for a 4- and 6-year interval respectively), as was increase in number of 
cigarettes/day (β=.089 and β=.112 for a 2- and 6-year interval respectively). 
Regarding mental health, the most consistent associations were seen for use of 
TCA/SNRI: chronic use was associated with increase in HR over two time periods 
(β=.078 and β=.106 for a 2- and 6-year interval respectively), started using with an 
increase in HR over all three time periods (β=.137, β=.112 and β=.099 for a 2-, 4- 
and 6-year interval respectively), and stopped using with a decrease in HR over two 
time periods (β=-.127 and β=-.091 for a 4- and 6-year interval respectively). A 
significant association was also seen for the group that stopped using SSRIs with 
an increase in HR over 2 years (β=.093), while associations were marginally 
significant over the other time periods. When investigating cardiometabolic 
health, consistent associations were found for use of beta-blocking/antiarrhythmic 
drugs, with chronic use being significantly associated with a decrease in HR over 2 
years (β=-.102), started using with a decrease in HR over all three time periods (β=-
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Table 1. Sample Characteristics  
Characteristics 
Baseline 
n=2379a
2-y follow-up
n=2245b
6-y follow-up
n=1876c
Social demographics 
   Age, years  42.0±13.1 44.2±13.2 48.1±13.1 
   Female sex (%) 65.9 66.2 65.4 
   Education, years 12.3±3.3 12.5±3.3 12.9±3.3 
Lifestyle 
   Physical activity, median 1000METmin/week (IQR) 2.8(1.4-5.1) 3.1(1.6-5.5) 2.9(1.5-5.4) 
   Alcohol use, median drinks/week (IQR) 3.7(0.2-8.7) 3.7 (0.2-8.7) 3.7(0.2-8.2) 
   Smoking, median no. cigarettes/day (IQR) 0.0(0.0-7.0) 0.0(0.0-5.0) 0.0(0.0-0.3) 
   Body mass index, kg/m2 25.5±4.9 25.8±4.8 26.1±5.0 
Mental health 
   Psychopathology (%) 53.9 37.3 27.8 
   Use of TCAs (%) 2.6 2.9 3.1 
   Use of SNRIs (%) 4.0 4.1 3.8 
   Use of SSRIs (%) 17.2 14.1 11.9 
Cardiometabolic health 
   CVD (%) 4.2 5.6 6.6 
   Diabetes (%) 3.7 5.0 5.4 
   Hypertension (%) 13.9 17.2 21.8 
   Use of beta-blocking/antiarrhythmic drugs (%) 8.3 9.4 10.7 
   Use of other cardiac medication (%) 7.4 9.2 11.5 
Cardiac autonomic measures 
   HR, beats/min 72.0±9.7 72.7±9.7 71.6±9.4 
   RSA, ms 43.8±24.9 41.7±22.5 45.0±25.8 
   PEP, ms 119.9±17.9 119.4±17.3 111.6±21.7 
   Respiration rate, breaths/min 17.1±1.2 17.3±1.3 16.3±1.4 
Note: Values represent mean ± SD unless otherwise indicated. METhours = multiple of resting metabolic rate 
times hours of physical activity per week. IQR = interquartile range. CVD = cardiovascular disease. HR = heart 
rate. RSA = respiratory sinus arrhythmia. PEP = pre-ejection period. aValues were missing for physical activity 
(143), alcohol use (24), smoking (12), BMI (1) and PEP (21). bValues were missing for physical activity (221), 
alcohol use (49), smoking (10), BMI (4), CVD (5), diabetes (5), hypertension (4), use of beta-
blocking/antiarrhythmic drugs (5), use of other cardiac medication (5), HR (6), RSA (4), PEP (14) and respiration 
rate (4). cValues were missing for physical activity (125), alcohol use (59), smoking (2), BMI (3), diabetes (1), 
hypertension (1), use of beta-blocking/antiarrhythmic drugs (1), use of other cardiac medication (1), RSA (1), 
PEP (23) and respiration rate (1).  
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Table 3. Determinants of change in HR over time. 
∆HR, beats/minute 
Determinants 
0-2 years 
n=1820
2-6 years 
n=1411
0-6 years 
n=1571
β p β p β p 
Sociodemographics 
Age, years  -.025 .27 -.008 .76 -.023 .35 
Female sex .060 .005 .022 .37 .037 .10 
Education, years -.044 .041 -.018 .48 -.004 .87 
Lifestyle 
Physical activity, METmin/week  -.026 .25 -.017 .53 -.012 .63 
   ∆physical activity, METmin/week -.034 .14 -.040 .14 -.055 .027 
Alcohol use, drinks/week .047 .055 -.041 .17 .007 .81 
   ∆Alcohol use, drinks/week .002 .95 -.025 .37 .035 .18 
Smoking, cigarettes/day .060 .011 .092 .001 .108 <.001 
   ∆Smoking, cigarettes/day .089 <.001 .072 .006 .112 <.001 
Body mass index, kg/m2 .056 .014 -.009 .72 .012 .60 
   ∆Body mass index, kg/m2 .131 <.001 .127 <.001 .145 <.001 
Mental health 
No psychopathology Reference group 
   Chronic psychopathology -.081 .001 -.004 .87 -.039 .11 
   New onset psychopathology -.056 .008 -.004 .87 .006 .77 
   Remitted psychopathology -.048 .038 .003 .91 -.013 .59 
Not using TCA/SNRI Reference group 
   Chronic use  .078 <.001 .028 .25 .106 <.001 
   Started using  .137 <.001 .112 <.001 .099 <.001 
   Stopped using  -.044 .035 -.127 <.001 -.091 <.001 
Not using SSRI Reference group 
   Chronic use -.004 .84 .008 .72 .013 .55 
   Started using  -.053 .011 -.059 .013 -.055 .011 
   Stopped using  .093 <.001 .075 .002 .063 .005 
Cardiometabolic health 
No CVD Reference group 
   Chronic CVD .058 .014 -.039 .16 -.025 .30 
   New onset CVD .010 .63 -.029 .27 -.015 .51 
No diabetes Reference group 
   Chronic diabetes .042 .049 .009 .72 .024 .29 
   New onset diabetes .025 .23 .034 .15 .051 .020 
No hypertension Reference group 
   Chronic hypertension .041 .19 .049 .19 .013 .70 
   New onset hypertension .016 .47 -.014 .60 .047 .067 
Not using beta-
blocking/antiarrhythmic drugs  
Reference group 
   Chronic use -.102 .001 -.058 .061 -.032 .25 
   Started using -.174 <.001 -.200 <.001 -.178 <.001 
   Stopped using .097 <.001 .032 .20 .066 .004 
Not using other cardiac medication Reference group 
   Chronic use -.006 .81 .010 .74 -.007 .81 
   Started using 1.2E-4 >.99 .032 .25 .036 .16 
   Stopped using .039 .062 .003 .90 .003 .90 
Note: HR = Heart rate. Metmin = multiple of resting metabolic rate times minutes of physical activity per 
week. TCA = tricyclic antidepressants. SNRI = selective serotonergic and noradrenergic reuptake inhibitors. 
SSRI = selective serotonin reuptake inhibitors. CVD = cardiovascular disease. Multiple linear regression 
analyses were adjusted for basal HR. Boldface indicates statistical significance (p<.0016). 
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.174, β=-.200 and β=-.178 for a 2-, 4- and 6-year interval respectively), and stopped 
using significantly with an increase in HR over 2 years (β=.097) and marginally 
significantly over 6 years.  
Table 4 shows which determinants were associated with change in RSA 
over the different time periods. Of the sociodemographic variables, older age was 
significantly associated with a decrease in RSA over two time periods (β=-.227 and 
β=-.090 for a 2- and 6-year interval respectively). Regarding lifestyle, higher basal 
number of cigarettes/day was significantly associated with a decrease in RSA over 
4 years (β=-.092) and 6 years (β=-.110). Of the mental health factors, similar to 
findings for HR, use of TCA/SNRI had the greatest impact on change in RSA over 
time: chronic use was significantly associated with a decrease in RSA over 2 years 
(β=-.096) and marginally significantly over 6 years, started using with a decrease in 
RSA over all three time periods (β=-.137, β=-.101 and β=-.102 for a 2-, 4- and 6-year 
interval respectively), and stopped using marginally significantly over 2 and 4 
years. In addition, persons that started using SSRI showed a decrease in RSA over 2 
years (β=-.076) and 6 years (β=-.077). Considering cardiometabolic health, only 
chronic use of beta-blocking/antiarrhythmic drugs was significantly associated 
with a decrease in RSA over 2 years (β=-.102), and marginally significantly over 6 
years. 
Table 5 shows the determinants associated with change in PEP over the 
different time periods. Of the sociodemographic variables, older age was 
significantly associated with a decrease in PEP over 2 time periods (β=-.174 and β=-
.144 for a 4- and 6-year interval respectively). Female sex was significantly 
associated with an increase in PEP over 6 years (β=.079) and marginally 
significantly over 4 years. Considering lifestyle, higher basal BMI was associated 
with a decrease in PEP over 4 years (β=-.125) and 6 years (β=-.118), and increase in 
BMI with a decrease in PEP over all three time periods (β=-.109, β=-.110 and β=-
.141 for a 2-, 4-, and 6-year interval respectively). Of the mental health factors, a 
significant association was found between people that started using SSRI and an 
increase in PEP over 2 years (β=.081). This association was marginally significant 
over 6 years. Finally, regarding cardiometabolic health, chronic use of beta-
blocking/antiarrhythmic drugs was marginally significantly associated with an 
increase in PEP over all three time periods. 
Figure 1 illustrates the associations between change patterns of 
antidepressant use and beta-blocking/antiarrhythmic drug use with change in ANS 
variables over a 6-year interval. 
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Table 4. Determinants of change in RSA over time. 
∆RSA, ms 
Determinants 
0-2 years 
n=1820 
2-6 years 
n=1409 
0-6 years 
n=1570 
β p β p β p 
Sociodemographics 
Age, years  -.227 <.001 -.098 .002 -.090 .001 
Female sex .049 .015 -.069 .007 -.067 .003 
Education, years .067 .001 -.043 .10 -.026 .26 
Lifestyle 
Physical activity, METmin/week  -.022 .30 -.044 .12 -.032 .21 
   ∆physical activity, METmin/week -.013 .56 .001 .98 .033 .18 
Alcohol use, drinks/week -.026 .25 .070 .023 .010 .73 
   ∆Alcohol use, drinks/week -1.5E-4 .99 .081 .006 .010 .70 
Smoking, cigarettes/day .004 .84 -.092 .001 -.110 <.001 
   ∆Smoking, cigarettes/day -.031 .14 -.033 .22 -.060 .016 
Body mass index, kg/m2 -.054 .011 -.028 .29 -.055 .020 
   ∆Body mass index, kg/m2 -.061 .002 -.019 .45 -.035 .13 
Mental health 
No psychopathology Reference group 
   Chronic psychopathology .030 .19 -.007 .80 .049 .050 
   New onset psychopathology .032 .11 .018 .49 .034 .13 
   Remitted psychopathology .027 .21 -.017 .50 .025 .30 
Not using TCA/SNRI Reference group 
   Chronic use  -.096 <.001 -.040 .11 -.049 .027 
   Started using  -.137 <.001 -.101 <.001 -.102 <.001 
   Stopped using  .059 .002 .066 .008 .012 .58 
Not using SSRI Reference group 
   Chronic use  -.034 .081 -.062 .012 -.049 .027 
   Started using  -.076 <.001 -.049 .045 -.077 <.001 
   Stopped using  .008 .69 .069 .006 .047 .037 
Cardiometabolic health 
No CVD Reference group 
   Chronic CVD -.010 .66 .020 .48 .032 .19 
   New onset CVD -.012 .55 .015 .59 .024 .30 
No diabetes Reference group 
   Chronic diabetes -.022 .27 .032 .21 .022 .33 
   New onset diabetes -.021 .28 -.025 .31 -.024 .28 
No hypertension Reference group 
   Chronic hypertension -.029 .31 .037 .33 .006 .86 
   New onset hypertension -.040 .053 -.026 .35 -.003 .89 
Not using beta-
blocking/antiarrhythmic drugs  
Reference group 
   Chronic use .017 .49 -.102 .001 -.069 .012 
   Started using .030 .14 -.009 .75 -.015 .54 
   Stopped using -.021 .29 -.033 .20 .024 .28 
Not using other cardiac medication Reference group 
   Chronic use .030 .23 -.009 .78 .005 .86 
   Started using .019 .35 .011 .71 -.043 .095 
   Stopped using -.019 .33 -.008 .75 -.006 .79 
Note: RSA = respiratory sinus arrhythmia. Metmin = multiple of resting metabolic rate times minutes of physical activity 
per week. TCA = tricyclic antidepressants. SNRI = selective serotonergic and noradrenergic reuptake inhibitors. SSRI = 
selective serotonin reuptake inhibitors. CVD = cardiovascular disease. Multiple linear regression analyses were adjusted 
for basal RSA and change in respiration rate. Boldface indicates statistical significance (p<.0016). 
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Table 5. Determinants of change in PEP over time. 
ΔPEP, ms 
Determinants 
0-2 years 
n=1799
2-6 years 
n=1390
0-6 years 
n=1542
β p β p β p 
Sociodemographics 
Age, years  .011 .61 -.174 <.001 -.144 <.001 
Female sex -.012 .56 .066 .010 .079 .001 
Education, years .027 .20 -.019 .48 -.004 .87 
Lifestyle 
Physical activity, METmin/week  .021 .35 -.014 .63 .017 .51 
   Δphysical activity, METmin/week .021 .35 .013 .64 .009 .72 
Alcohol use, drinks/week -.020 .38 .015 .63 .008 .77 
   ΔAlcohol use, drinks/week .021 .35 .044 .13 -.010 .71 
Smoking, cigarettes/day -.001 .96 -.029 .31 -.042 .12 
   ΔSmoking, cigarettes/day -.019 .39 .024 .37 -.018 .49 
Body mass index, kg/m2 -.065 .004 -.125 <.001 -.118 <.001 
   ΔBody mass index, kg/m2 -.109 <.001 -.110 <.001 -.141 <.001 
Mental health 
No psychopathology Reference group 
   Chronic psychopathology -.003 .90 .022 .42 .027 .31 
   New onset psychopathology .036 .082 .007 .78 .003 .91 
   Remitted psychopathology .021 .34 .050 .053 .024 .34 
Not using TCA/SNRI Reference group 
   Chronic use  -.109 <.001 .005 .86 .002 .93 
   Started using  .094 <.001 .012 .63 -.003 .89 
   Stopped using  .062 .002 .078 .002 .032 .15 
Not using SSRI Reference group 
   Chronic use .039 .054 .016 .51 -.005 .83 
   Started using  .081 <.001 -4.1E-4 .99 .062 .007 
   Stopped using  -.157 <.001 -.028 .26 .004 .88 
Cardiometabolic health 
No CVD Reference group 
   Chronic CVD -.007 .77 .006 .83 .018 .48 
   New onset CVD -.024 .24 .036 .19 .021 .39 
No diabetes Reference group 
   Chronic diabetes .005 .81 .012 .64 -.030 .20 
   New onset diabetes -.021 .30 .026 .29 .059 .011 
No hypertension Reference group 
   Chronic hypertension -.016 .59 .015 .70 -.011 .75 
   New onset hypertension -.010 .63 .040 .14 .015 .58 
Not using beta-
blocking/antiarrhythmic drugs  
Reference group 
   Chronic use .073 .005 .098 .002 .091 .002 
   Started using .034 .10 .041 .15 .061 .020 
   Stopped using -.024 .24 .020 .44 .017 .46 
Not using other cardiac medication Reference group 
   Chronic use -.021 .41 -.010 .75 .030 .31 
   Started using -.030 .16 -.026 .38 -.066 .014 
   Stopped using -.015 .46 -2.6E-4 .99 -.006 .81 
Note: PEP = pre-ejection period. Metmin = multiple of resting metabolic rate times minutes of physical 
activity per week. TCA = tricyclic antidepressants. SNRI = selective serotonergic and noradrenergic reuptake 
inhibitors. SSRI = selective serotonin reuptake inhibitors. CVD = cardiovascular disease. Multiple linear 
regression analyses were adjusted for basal PEP. Boldface indicates statistical significance (p<.0016). 
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DISCUSSION 
The present study investigated temporal stability for cardiac autonomic activity 
measured during comparable laboratory conditions over a 2-, 4-, and 6-year time 
period. Over 2 years, temporal stability was good for HR, excellent for RSA and 
moderate for PEP. As expected, cardiac autonomic temporal stability decreased 
with increasing time span. Since temporal stability of autonomic measures is 
imperfect, we investigated which determinants were the most important drivers of 
change in cardiac autonomic activity over time. The most important determinants 
for an increase in HR were (increase in) smoking behavior, increase in BMI and 
(starting) the use of antidepressant drugs. In contrast, (starting) the use of beta-
blocking/antiarrhythmic drugs was associated with a decrease in HR. Decrease in 
RSA was strongly associated with age, smoking and (starting) antidepressant use. 
As for decrease in PEP, the most consistent associations were found with older age 
and (increase in) BMI.  
When comparing the different time periods, we found that temporal 
stability especially decreased for PEP over a 4- and 6-year interval compared to a 2-
year interval. Visual inspection of the ICG was used to determine the B-point 
(beginning of left ventricular ejection) for PEP. However, the scoring of this B-point 
is difficult since many subject present with a less than ideal ICG wave form, 
introducing ambiguity in the scoring.45 This ambiguity adds to measurement error 
in the PEP, particularly if different raters are used for visual scoring. Here, the 6-year 
follow-up scoring of PEP from the ECG/ICG traces was done by a different rater than 
at baseline and 2-year follow-up. These factors most likely contributed to the lower 
temporal stability for PEP compared to the other autonomic variables. In general, 
our found cardiac autonomic stability over 2 years was similar to studies 
investigating these measures from weeks to a year.5–7,11,13 Despite this rather high 
stability, we could still determine factors contributing to 2-year autonomic 
instability, which were more or less consistent to those found for the longer 
intervals.  
Regarding sociodemographic determinants of autonomic instability over 
time, previous studies have established an association with older age and decline 
in autonomic function.23,46 Our results imply that older age is also significantly 
associated with a greater decrease in RSA and PEP over time. Although ANS 
functioning has been associated with SES.25 we did not find evidence for an 
association between years of education (a proxy for SES) and change in ANS activity 
over time. Similarly, although we found a trend of a greater decrease in PEP for men 
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than for women, we did not find convincing evidence that gender influenced 
changes in autonomic activity over time.  
Considering lifestyle determinants, our results indicated that (change in) 
smoking and BMI had the most robust associations with change in ANS values. 
These findings comply with the bulk of literature suggesting that smoking29 and 
obesity47 have a detrimental effect on cardiac autonomic activity.  
Our results add to the increasing evidence that it is not psychopathology, 
but rather use of antidepressants that drive autonomic dysregulations.33–35 
Moreover, they were in line with findings of NESDA research conducted by Licht 
et al.,34 who found that use of all antidepressants was associated with a 2-
year decrease in cardiac vagal control. Our longer follow-up also confirmed 
that specifically TCAs and SNRIs increased HR and decreased cardiac vagal 
activity, while SSRIs reduced cardiac parasympathetic activity but had a beneficial 
effect on cardiac sympathetic activity and HR over time.  
We did not find the expected associations between (change in) 
cardiometabolic health and change in cardiac ANS measures, despite the given 
that the association between autonomic dysregulation with cardiometabolic 
dysregulation has been well established in the literature.18–20 It is possible that 
autonomic dysregulations occur long before full-blown cardiometabolic diseases 
emerge,48 explaining why disease onset was not associated with change in ANS 
activity. Use of beta-blocking/antiarrhythmic drugs was found to significantly 
decrease HR (and sympathetic activity), conform to their mechanism of action on 
cardiac function.49,50 Surprisingly, this was paired to a less favorable effect on 
cardiac parasympathetic activity as reflected in lowered RSA. However, this effect 
was only (inconsistently) found for chronic use of medication. 
This study has some limitations. For instance, lifestyle factors and 
cardiometabolic disease status were based on self-report, which is prone to 
inaccuracy and bias. However, cotinine levels at baseline showed good correlations 
with self-reported number of smoked cigarettes/day, enhancing our confidence in 
the reliability and validity of the used lifestyle measures. In addition, previous 
research has shown that self-reported CVD and general practitioners information 
are in good agreement.51 Another limitation concerns our relatively young and 
healthy sample. Over the course of 6 years only a small percentage of our 
participants had or developed CVD or diabetes, perhaps contributing to our null-
findings for cardiometabolic health. Finally, the potential for rater-bias in PEP 
scoring warrants caution for interpreting these findings.  
These limitations are balanced by several strengths. To our knowledge, 
this is the largest and the longest follow-up study investigating ANS temporal 
stability, and the first to compare different time periods within one study. 
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Furthermore, this study investigated many plausible determinants of autonomic 
instability in one model, so that each determinant was adjusted for effects of the 
other determinants. In addition, determinants were measured during all three time 
points, allowing us to critically look at the consistencies of associations over 
different time periods.  
In summary, cardiac autonomic measures were rather stable over 2 years, 
but stability decreased with increasing time span. Determinants contributing to 
cardiac autonomic instability were older age, (increase in) smoking and BMI, and 
(starting) the use of antidepressants and cardiac medication. These determinants 
should be taken into account when researching ANS activity in longitudinal 
designs. 
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ABSTRACT 
Context: Basal autonomic nervous system (ANS) functioning has been linked to 
the metabolic syndrome (MetS), but the role of ANS reactivity in response to stress 
remains unclear. 
Objective: To examine cross-sectionally and longitudinally to what extent ANS 
basal level and stress reactivity are related to MetS. 
Design: 2-year and 6-year data from a prospective cohort: the Netherlands Study 
of Depression and Anxiety.  
Setting: Participants were recruited from the general community, primary care, 
and mental health care organizations. 
Participants: 1922 respondents (mean age=43.7 years). 
Main outcome measures: Indicators of ANS functioning were heart rate (HR), 
respiratory sinus arrhythmia (RSA) and pre-ejection period (PEP). ANS stress 
reactivity was measured during a cognitively challenging stressor and a personal-
emotional stressor. MetS components included triglycerides, high-density 
lipoprotein cholesterol, blood pressure, glucose and waist circumference. 
Results: Cross-sectional analyses indicated that higher basal HR, lower basal values 
of RSA and PEP, and higher RSA reactivity during cognitive challenge were related 
to less favorable values of almost all individual MetS components. Longitudinal 
analyses showed that higher basal HR and shorter basal PEP predicted 4-year 
increase in many MetS abnormalities. Higher RSA stress reactivity during cognitive 
challenge predicted 4-year increase in number of MetS components. 
Conclusion: Higher basal sympathetic, lower basal parasympathetic activity, and 
increased parasympathetic withdrawal during stress are associated with multiple 
MetS components, and higher basal sympathetic activity predicts an increase in 
metabolic abnormalities over time. These findings support a role for ANS 
dysregulation in the risk for MetS and, consequently, the development of 
cardiovascular disease. 
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INTRODUCTION 
Cardiovascular disease (CVD) is the most important cause of disability-adjusted life 
years according to the World Health Organization.1 The autonomic nervous system 
(ANS) plays a central role in cardiovascular regulation2 but is also implicated in the 
etiology of CVD through its effects on the metabolic syndrome (MetS), a cluster of 
risk factors for CVD.3 According to current biological understanding, innervation of 
the ANS modulates glucose and fat metabolism,4,5 liver metabolism,6 and virtually 
all other components of daily energy expenditure.7,8 Indeed, many studies have 
linked basal ANS dysregulation to high waist circumference, blood pressure (BP), 
triglycerides, glucose, and/or low high-density lipoprotein (HDL) cholesterol.9–18 In 
a cross-sectional study with 1883 participants, Licht et al.13 found that increased 
sympathetic (SNS) and decreased parasympathetic nervous system (PNS) activity 
were associated with MetS. Furthermore, Vrijkotte and colleagues14 showed that 
the association between this ANS imbalance and an unfavorable metabolic profile 
is already present in children at the age of 5 to 6 years. Longitudinal studies in this 
research field suggested that basal plasma norepinephrine predicted 5-year 
increases in weight and blood pressure,19 and that dysregulated basal ANS level 
predicted 2-year increase in metabolic abnormalities.20 
In addition to chronic elevations of basal ANS level, there is reason to 
believe that ANS reactivity to psychological stressors is implicated in MetS. In 
response to a threat, a shift toward SNS dominance and PNS withdrawal is seen, 
and it is suggested that exaggeration of this response leads to metabolic 
alterations.5,21,22 Some studies have linked elevated cardiovascular responses to 
stress with increased central adiposity, increased BP, and elevated levels of 
cholesterol and/or triglycerides.23–29 However, these studies used increases in HR 
and BP as indicators of stress reactivity. The association between autonomic stress 
reactivity of both the SNS and the PNS with the entire cluster of MetS components 
remains underexposed in the literature, as do longitudinal studies to infer 
directionality. Some longitudinal studies have linked higher cardiovascular 
reactivity in response to stress to the development of hypertension.30–36 Again, in 
these studies stress reactivity was mainly assessed by increased BP. Flaa et al.37 
showed that sympathetic activity during mental arithmetic predicted 18 year 
increase in blood pressure. However, this was only the case for absolute values 
during the stress task and not for stress reactivity values. To our knowledge, only 
one previous study aimed to determine the predictive value of autonomic 
responses to psychological laboratory stress for development of metabolic 
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burden.38 The results indicated that parasympathetic withdrawal in response to 
stress was associated with an increased metabolic burden in men, but not women.  
Given the scarcity of empirical data on this important theoretical link, this 
large-scale study aimed to 1) examine cross-sectionally to what extent ANS basal 
level and stress reactivity are independently related to MetS, and 2) establish the 
predictive value of ANS basal level and stress reactivity in the 4-year increase of 
MetS components. Indicators of ANS activity were: 1) heart rate (HR), an index of 
both parasympathetic and sympathetic cardiac control,39 2) respiratory sinus 
arrhythmia (RSA), an index of cardiac vagal control,39–41 and 3) pre-ejection period 
(PEP), an index of left ventricular sympathetic control.39,42 Stress reactivity was 
evoked by two types of stressors: 1) a cognitively challenging stressor (an n-back 
task) and 2) a personal-emotional stressor in the form of a psychiatric interview 
(earlier described by Hu et al.43). We hypothesized that an unfavorable basal ANS 
profile, defined by high HR in the presence of low vagal control (low RSA) and high 
sympathetic control (short PEP), and ANS hyperreactivity to stress, characterized 
by a greater increase in HR and greater decrease in RSA and PEP, would be 
associated with unfavorable metabolic profiles and would predict an increase in 
metabolic abnormalities over time. 
METHODS 
Subjects 
Data was obtained from the Netherlands Study of Depression and Anxiety 
(NESDA), an ongoing longitudinal cohort including 2981 respondents aged 
18-65 years. Respondents were recruited from the community, primary care and
mental health care in the Netherlands. A four-hour baseline measurement was
conducted between September 2004 and February 2007, and follow-up
assessments took place after two, four and six years. Demographic,
psychiatric and physical assessments were included, as well as collection of
blood. The two-year follow-up also included a cognitively challenging
stressor (n-back task). A detailed description of the rationale, objectives and
methods of the NESDA study can be found elsewhere.44 The research protocol
was approved by the Ethical Review Board of each participating center, and all
respondents provided written informed consent.
For the cross-sectional part of the current study, data were drawn from the 
two-year follow-up assessment (in later sections referred to as baseline data), since 
the cognitively challenging stressor was not introduced until then. Of the total 
sample of 2596 respondents, 674 individuals were excluded because of missing 
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physiological data due to equipment failure during assessment, poor electrocardiogram 
quality or because they did not complete one of the stress conditions. The cross-
sectional study sample therefore consisted of 1922 participants. 
The longitudinal part of this study was conducted with the two-year 
follow-up data (baseline) and the six-year follow-up data (in later sections referred 
to as 4-year data). The longitudinal sample consisted of 2256 respondents of which 
581 people were excluded because of missing physiological data, and another 59 
individuals because of missing data on all MetS components. Consequently, the 
longitudinal analyses were conducted with 1616 participants.  
Physiological measurement 
During the assessments, the participants wore the ‘Vrije Universiteit Ambulatory 
Monitoring System’ (VU-AMS). The VU-AMS is an unobtrusive lightweight portable 
device that records electrocardiograms (ECG) and changes in thorax impedance 
(ICG) from a six-electrode configuration.39 During the recording the different 
assessment conditions were divided by an event marker. Movement registration 
through vertical accelerometry was used to remove periods where the subjects 
were not stationary.  
The interbeat interval (IBI) time series were extracted from the ECG signal 
to obtain HR.40 RSA combined the ECG with the respiration signal obtained from 
the thorax impedance, and was derived by subtracting the shortest IBI during HR 
acceleration at inhalation from the longest IBI during HR deceleration at exhalation 
for all breaths.39–41 PEP was defined as the interval between the Q-onset in the ECG, 
indicating onset of left ventricular electrical activity, and the upstroke (B-point) of 
the ICG signal, indicating the beginning of left ventricular ejection.39,42 
Suspicious IBIs and breathing cycles were corrected or discarded during 
automated and visual data cleaning. An automated scoring algorithm was also 
used to detect crucial landmarks in the ICG, which were then visually inspected and 
manually corrected. 
Stress conditions 
As described in more detail before,43 the participants were exposed to two 
different stress conditions.  The order of exposure was first a psychiatric interview, 
evoking personal-emotional stress, and second the n-back task, representing the 
‘classical’ cognitively challenging tasks often used in laboratory settings. 
Psychiatric interview stressor  
The psychiatric interview of approximately 45 minutes included questions regarding 
various indicators of anxious and depressive symptoms, as well as suicidal thoughts, 
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mood disorder symptoms and experience of adverse life events. The participants were 
asked to describe and recall these negative experiences extensively.   
N-back task stressor
A spatial variant of the n-back task was administered for which the participants 
were required to remember the location of a stimulus presented a certain number 
‘n’ of stimuli back. Three n-back conditions (1-back, 2-back and 3-back) were 
presented to the participants, each consisting of 20 trials. There were two 
components which made this task stress-evoking: task difficulty and performance 
pressure on the one hand, and on the other hand the provision of false feedback 
and negative comparison to other participants.  
Basal level 
For the psychiatric interview stressor, a general interview served as a basal level. 
The general interview lasted approximately 30 minutes and included topics such 
as somatic health, smoking behavior, use of medication, daily functioning and 
health care utilization.  
Prior to the n-back task, an n-back rest was administered during which 
participants were presented with a series of neutral pictures for 2 minutes. The n-
back rest was used as a basal level to compare against the n-back task stressor.  
Metabolic syndrome components 
MetS was defined according to the American Heart Association and National Heart, 
Lung and Blood Institute’s update of the U.S. National Cholesterol Education 
Program-Adult Treatment Panel III criteria.45 The number of components was 
determined by the presence of the following criteria: 1) waist circumference ≥102 
cm in men and ≥88 cm in women, 2) SBP ≥130 and/or DBP ≥85 mm Hg or 
antihypertensive medication; 3) triglycerides ≥1.7 mmol/L or medication for 
hypertriglyceridemia; 4) HDL cholesterol <1.03 mmol/L in men and <1.30 mmol/L 
in women or medication for reduced HDL cholesterol; 5) fasting plasma glucose 
≥5.6 mmol/L or antidiabetic medication. 
Waist circumference was measured with a measuring tape at the central 
point between the lowest front rib and the highest front point of the pelvis. SBP 
was measured twice on the right arm during supine rest with Omron M4-I, HEM 
752A, and averaged over the two measurements. Triglycerides, HDL cholesterol 
and glucose were determined by collecting blood samples in the morning after an 
overnight fast.  
The continuous MetS components were adjusted for medication use based 
on estimated average effects of the medication.46 For persons using antihypertensive 
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medication, 10 mm Hg was added to their SBP values.47–52 For persons using fibrates, 
0.67 mmol/L was added to triglycerides and 0.10 mmol/L was subtracted from HDL 
cholesterol. In addition, when using nicotinic acid 0.19 mmol/L was added to 
triglycerides and 0.15 mmol/L was subtracted from HDL cholesterol.46,53 Subjects 
using antidiabetic medication were assigned a value of 7.0 mmol/L when glucose 
level was less than 7.0 mmol/L.52 
 
Covariates 
Adjustments were made for sociodemographic characteristics, including age, sex 
and years of education. We additionally included smoking status (yes/no) as a 
health confounder. Since it has been linked to RSA,54,55 respiration rate was also 
included as a covariate.  
 
Statistical analyses 
ANS basal values were obtained by taking the average score of n-back rest and the 
general interview. Absolute stress reactivity values for n-back were calculated by 
subtraction of ANS values during the n-back rest from ANS values during the n-
back task. Similarly, absolute stress reactivity values for interview were calculated 
by subtraction of ANS values during the general interview from ANS values during 
the psychiatric interview.  
Adjusted multiple linear regression analyses were used to analyze the 
cross-sectional association of basal ANS levels and stress reactivity values with the 
number of MetS components and continuous individual MetS components. Since 
triglycerides and glucose levels were non-normally distributed, these components 
were ln-transformed before analyses. Multiple linear regression was also used to 
investigate the longitudinal relationship between ANS (re)activity and changes in 
number of MetS components and changes in continuous individual MetS 
components over time. For these longitudinal analyses, baseline metabolic values 
were taken into account in addition to the other covariates. Both cross-sectional 
and longitudinal analyses were conducted in two steps: a first model including 
only basal HR, RSA or PEP levels, and a second model adding stress reactivity 
values. Sensitivity analyses were performed with additional adjustment for current 
and remitted depressive and anxiety disorder, and for antidepressant use. Regular 
use of the following antidepressants were included: tricyclic antidepressants 
(TCAs, ATC code N06AA), selective serotonin reuptake inhibitors (SSRIs, ATC code 
N06AB), and selective serotonin and noradrenalin reuptake inhibitors (SNRIs, ATC 
code N06AX). We also investigated possible sex modification by adding a sex-by-
ANS value interaction to the analyses. The criterion for statistical significance was 
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p<.05. Data was analyzed using IBM SPSS Statistics for Windows, version 20.0 (IBM 
Corp).  
RESULTS 
Cross-sectional associations between ANS and MetS components 
Table 1 shows that our sample (n=1922) had a mean age of 43.7 years (±13.2 SD) 
and 66.5% were female. 
Table 2 shows that several ANS measures were significantly associated 
with MetS components. Of the basal ANS values (model 1), higher HR was 
associated with higher levels of triglycerides (β=.152), SBP (β=.118), glucose 
(β=.108), larger waist circumference (β=.106), and higher number of MetS 
components (β=.128), all p-values <.001. Lower basal RSA (indicative of decreased 
PNS activity) and shorter basal PEP (indicative of increased SNS activity) were 
associated with higher levels of triglycerides (β=-.059, p=.027 and β=-.090, p<.001, 
respectively), SBP (β=-.079, p=.001 and β=-.120, p<.001, respectively), larger waist 
circumference (β=-.054, p=.024 and β=-.141, p<.001, respectively), and higher 
number of MetS components (β=-.071, p=.005 and β=-.127, p<.001, respectively). 
In addition, shorter basal PEP was significantly related to lower HDL cholesterol 
(β=.055, p=.009). 
We graphically illustrated the association between basal RSA and PEP and 
the number of MetS components, categorized as 0 components, 1 or 2 
components, and 3 or more components. Figure 1 shows that a higher number of 
MetS components was associated with lower (normalized and adjusted) values of 
both basal RSA and PEP. 
The addition of ANS stress reactivity measures to the analyses (model 2) 
showed that mainly reactivity to the cognitively challenging stressor was 
associated with MetS components. Unexpectedly, higher HR reactivity to cognitive 
challenge was related to higher HDL cholesterol (β=.056, p=.012) and lower waist 
circumference (β=-.055, p=.008). However, RSA and PEP reactivity showed results 
in the expected direction. Higher RSA reactivity to cognitive challenge was 
associated with higher levels of triglycerides (β=-.091, p<.001), SBP (β=-.071, 
p=.002), higher waist circumference (β=-.089, p<.001), and higher number of MetS 
components (β=-.102, p<.001). Higher PEP reactivity to a cognitively challenging 
stressor was related to higher SBP (β=-.040, p=.039). Some associations with 
metabolic abnormalities were also found for ANS reactivity to the personal-
emotional stressor. For this stressor, higher RSA reactivity was related to higher 
glucose levels (β=-.051, p=.023) and higher waist circumference (β=-.051, p=.017), 
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Table 1. Sample characteristics at baseline (n=1922) 
Demographics  
     Age 43.7 ± 13.2 
     Female sex (%) 66.5 
     Education, years 12.7 ± 3.3 
Health factors 
     Smoking (%) 30.7 
     Alcohol use 
          Non-drinker (%) 31.4 
          Mild/moderate drinker (%) 57.7 
          Heavy drinker (%) 10.9 
     Physical activity, median 1000 METmin/week (IQR) 3.1 (1.6 – 5.5) 
     Cardiovascular disease (%) 4.0 
     Use of heart medication (%) 13.9 
     Antidepressant use (%) 22.9 
     Resting respiration rate, breaths/min 16.5 ± 1.3 
Autonomic variables  
     Basal level values 
          HR, beats/min 70.0 ± 9.6 
          RSA, ms 46.1 ± 24.7 
          PEP, ms 122.1 ± 17.8 
     Cognitive challenge stress reactivity values  
          HR reactivity, Δbeats/min  3.49 ± 3.66 
          RSA reactivity, Δms  -7.69 ± 16.18
          PEP reactivity, Δms -2.52 ± 5.29
     Personal-emotional stress reactivity values 
          HR reactivity, Δbeats/min  3.60 ± 3.37 
          RSA reactivity, Δms  -4.51 ± 7.95
          PEP reactivity, Δms  -2.41 ± 6.06
Metabolic syndrome components 
     Number of metabolic components, median (IQR)  1.00 (0.00 – 2.00) 
          0 metabolic components (%) 27.3 
1-2 metabolic components (%) 49.7 
≥3 metabolic components (%) 23.1 
     Triglycerides, mmol/L  1.30 ± 0.95 
     HDL cholesterol, mmol/L  1.56 ± 0.42 
     Systolic blood pressure, mm Hg  132.89 ± 18.35 
     Diastolic blood pressure, mm Hg  79.19 ± 10.78 
     Glucose, mmol/L   5.31 ± 0.97 
     Waist circumference, cm  89.00 ± 13.93 
Note: Values represent mean ± SD unless otherwise indicated. Metmin = multiple of resting 
metabolic rate times minutes of physical activity per week. IQR = interquartile range. HR = heart rate. 
RSA = respiratory sinus arrhythmia. PEP = pre-ejection period. HDL = high density lipoprotein.  
Basal ANS values were obtained by taking the average score of n-back rest and the general interview. 
Stress reactivity values represent ANS values during cognitive challenge (n-back task) or personal-
emotional stress (psychiatric interview) minus values during n-back rest or the general interview 
respectively. 
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Table 2. Adjusted associations between autonomic basal and stress reactivity values and individual components of the metabolic syndrome  
ANS variable 
ΔNo. of MetS components 
N=1796 
ΔTriglycerides, mmol/L 
N=1839 
HDL cholesterol, mmol/L 
N=1843 
β p R2 β p R2 β p R2 
Model 1 HR basal, bpm .128 <.001 .232 .152 <.001 .148 -.038 .081 .170 
Model 2 HR basal, bpm .125 <.001 .149 <.001 -.032 .14 
HR cognitive challenge 
reactivity, Δbpm 
-.033 .12 .233 -.026 .25 .149 .056 .012 .174 
HR personal-emotional 
reactivity, Δbpm 
-.016 .45 -.011 .61 .031 .16 
Model 1 RSA basal, ms -.071 .005 .229 -.059 .027 .134 .031 .23 .176 
Model 2 RSA basal, ms -.141 <.001 -.115 <.001 .047 .13 
RSA cognitive 
challenge reactivity, 
Δms 
-.102 <.001 .237 -.091 <.001 .140 .048 .055 .179 
RSA personal-
emotional reactivity, 
Δms 
-.032 .16 -.012 .62 -.025 .27 
Model 1 PEP basal, ms -.127 <.001 .232 -.090 <.001 .134 .055 .009 .172 
Model 2 PEP basal, ms -.134 <.001 -.094 <.001 .065 .003 
PEP cognitive 
challenge reactivity, 
Δms 
-.030 .15 .234 -.038 .085 .135 -.010 .64 .174 
PEP personal-
emotional reactivity, 
Δms 
-.019 .37 -.003 .90 .044 .046 
Note: β = standardized β-coefficient. R2 = unadjusted explained variance. HR = heart rate. RSA = respiratory sinus arrhythmia. PEP = pre-ejection  
Triglycerides and glucose values were ln-transformed for analyses. Significant results at p <.05 and significant changes in R2 are highlighted with bold 
Model 1 is based on linear regression analysis between basal ANS values and MetS components, adjusted for age, sex, education and 
In model 2 ANS stress reactivity values during a cognitively challenging stressor and during a personal-emotional stressor were added to model 1 as  
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SBP, mm Hg 
N=1917 
Glucose, mmol/L 
N=1855 
Waist circumference, cm 
N=1897 
β p R2 β p R2 β p R2
.118 <.001 .275 .108 <.001 .211 .106 <.001 .268 
.117 <.001 .106 <.001 .105 <.001 
.024 .25 .276 -.034 .11 .212 -.055 .008 .271 
-.021 .28 .003 .87 .017 .41 
-.079 .001 .268 -.046 .071 .205 -.054 .024 .270 
-.126 <.001 -.088 .004 -.125 <.001 
-.071 .002 .272 -.038 .12 .208 -.089 <.001 .277 
-.014 .50 -.051 .023 -.051 .017 
-.120 <.001 .276 -.015 .49 .200 -.141 <.001 .277 
-.126 <.001 -.019 .39 -.147 <.001 
-.040 .039 .278 -.027 .21 .201 -.013 .51 .278 
-.010 .61 -.009 .69 -.018 .38 
period. MetS = metabolic syndrome. HDL = high density lipoprotein. SBP = systolic blood pressure. 
formatting. 
smoking (RSA was additionally adjusted for respiration rate).  
predictors.  
Autonomic activity and the metabolic syndrome     147
Fi
gu
re
 1
. M
ea
n 
z-
sc
or
e 
an
d
 s
ta
nd
ar
d
 e
rr
or
 (r
ep
re
se
nt
ed
 b
y 
er
ro
r b
ar
s)
 fo
r R
SA
 a
nd
 P
EP
 a
ft
er
 a
d
ju
st
in
g 
fo
r 
ag
e,
 s
ex
, e
d
uc
at
io
n 
an
d
 
sm
ok
in
g 
(R
SA
 w
as
 a
d
d
iti
on
al
ly
 a
d
ju
st
ed
 fo
r r
es
pi
ra
tio
n 
ra
te
), 
d
ep
ic
te
d
 fo
r p
ar
tic
ip
an
ts
 w
it
h 
no
 M
et
S 
co
m
po
ne
nt
s 
("
0"
), 
in
te
rm
ed
ia
te
 
nu
m
b
er
 o
f M
et
S 
co
m
p
on
en
ts
 ("
1-
2"
) a
nd
 h
ig
h 
nu
m
be
r o
f M
et
S 
co
m
p
on
en
ts
 ("
>
=
3"
). 
-,2
0
-,1
5
-,1
0
-,0
5
,0
5
,1
0
,1
5
,2
0
-,4
0
-,3
0
-,2
0
-,1
0
,1
0
,2
0
,3
0
,4
0
PNS (ZRSA)
SN
S 
(Z
PE
P)
0 1-
2
>
=
3
N
o.
 o
f M
et
S 
co
m
po
ne
nt
s
148
whereas higher PEP reactivity was related to lower levels of HDL cholesterol 
(β=.044, p=.046).  
Longitudinal associations between ANS and changes in MetS components 
Table 3 shows that over the 4-year follow-up period, a mean increase was seen in 
triglycerides, HDL cholesterol, SBP, glucose, waist circumference and number of 
metabolic components.  
Longitudinal associations between ANS measures and changes in MetS 
components (Table 4) were less prominent than the cross-sectional relationships. 
However, basal ANS values (model 1) significantly predicted 4-year increases in 
metabolic abnormalities. Higher HR values predicted a decrease in HDL cholesterol 
(β=-.052, p=.038) and an increase in SBP (β=.059, p=.016) and number of MetS 
components (β=.062, p=.016). Lower basal RSA only predicted increased SBP (β=-
.070, p=.015). Shorter basal PEP predicted increased triglycerides (β=-.050, p=.028), 
SBP (β=-.051, p=.034), waist circumference (β=-.061, p=.015), and number of MetS 
components (β=-.068, p=.007). 
When adding ANS stress reactivity values to the analyses (model 2), only 
one significant association was found: higher RSA reactivity during cognitive 
challenge was associated with an increased number of MetS components (β=-.069, 
p=.020).  
Additional analyses 
We performed sensitivity analyses to additionally adjust for current and remitted 
depressive and anxiety disorder, as well as for the use of TCA, SSRI and SNRI. The 
results remained comparable after the adjustments, suggesting that neither 
psychopathology status or antidepressant use were driving our findings 
(Supplementary table 1 and 2).  
When testing for sex modification, the analyses generally yielded a 
stronger relationship between ANS basal level and stress reactivity with MetS 
components for women than for men. 
Table 3. Longitudinal Changes in Metabolic Syndrome Components (n=1616) 
Baseline 4-year follow-up Δ 
Number of metabolic components, median (IQR) 1.0 (0.00 – 2.00) 1.00 (0.00 – 3.00) 0.17 ± 1.00 
Triglycerides, mmol/L  1.28 ± 0.90 1.29 ± 0.86 0.01 ± 0.72 
HDL cholesterol, mmol/L  1.55 ± 0.42 1.56 ± 0.43 0.01 ± 0.26 
Systolic blood pressure, mm Hg  132.70 ± 18.04 134.30 ± 19.55 1.60 ± 12.69 
Diastolic blood pressure, mm Hg  78.98 ± 10.65 79.36 ± 10.74 0.38 ± 7.66 
Glucose, mmol/L   5.30 ± 0.90 5.52 ± 1.04 0.22 ± 0.72 
Waist circumference, cm  89.16 ± 13.92 92.00 ± 14.07 2.82 ± 7.63 
Note:  Values represent mean ± SD unless otherwise indicated. IQR = interquartile range. HDL = high density 
lipoprotein. 
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Table 4. Adjusted associations between autonomic basal and stress reactivity values and 4-year changes in individual components of the metabolic  
ANS variable 
ΔNo. of MetS components 
N=1400 
ΔTriglycerides, mmol/L 
N=1504 
ΔHDL cholesterol, mmol/L 
N=1508 
β p R2 β p R2 β p R2 
Model 1 HR basal, bpm .062 .016 .132 .009 .71 .222 -.052 .038 .087 
Model 2 HR basal, bpm .060 .021 .004 .87 -.050 .049 
HR cognitive challenge 
reactivity, bpm 
-.015 .57 .132 -.016 .50 .223 -.007 .80 .088 
HR personal-emotional 
reactivity, bpm 
-.010 .69 -.033 .16 .023 .36 
Model 1 RSA basal, ms  -.043 .16 .130 -.052 .060 .224 .033 .26 .086 
Model 2 RSA basal, ms -.096 .009 -.055 .098 .051 .16 
RSA cognitive challenge 
reactivity, ms 
-.069 .020 .134 -.012 .66 .225 .028 .32 .086 
RSA personal-emotional 
reactivity, Δms 
-.032 .24 .007 .77 .003 .90 
Model 1 PEP basal, ms -.068 .007 .132 -.050 .028 .224 .019 .44 .085 
Model 2 PEP basal, ms -.065 .013 -.045 .054 .023 .38 
PEP cognitive challenge 
reactivity, Δms 
.009 .73 .133 .024 .29 .225 -.002 .93 .085 
PEP personal-emotional 
reactivity, Δms 
.009 .72 .015 .54 .014 .59 
Note: β = standardized β-coefficient. R2 = unadjusted explained variance. HR = heart rate. RSA = respiratory sinus arrhythmia. PEP = pre-ejection  
Triglycerides and glucose values were ln-transformed for analyses. Significant results at p <.05 and significant changes in R2 are highlighted with bold 
Model 1 is based on linear regression analysis between basal ANS values and longitudinal changes in MetS components, adjusted for baseline MetS 
In model 2 ANS stress reactivity values during a cognitively challenging stressor and during a personal-emotional stressor were added to model 1 as  
150
syndrome 
ΔSBP, mm Hg 
N=1565 
ΔGlucose, mmol/L 
N=1495 
ΔWaist circumference, cm 
N=1541 
β p R2 β p R2 β p R2
.059 .016 .119 .009 .72 .046 .031 .22 .078 
.054 .028 .005 .85 .029 .25 
-.020 .42 .120 -.005 .85 .047 .010 .69 .078 
-.028 .25 -.033 .20 -.016 .52 
-.070 .015 .121 -.020 .51 .045 -.024 .42 .078 
-.074 .035 -.032 .39 -.030 .41 
-.001 .96 .121 -.022 .46 .045 -.025 .38 .079 
-.008 .77 .001 .97 -.021 .43 
-.051 .034 .118 -.047 .066 .048 -.061 .015 .081 
-.047 .059 -.048 .069 -.066 .010 
-.002 .93 .118 -.005 .86 .048 .012 .62 .081 
.018 .47 -.004 .89 -.027 .29 
period. MetS = metabolic syndrome. HDL = high density lipoprotein. SBP = systolic blood pressure. 
formatting. 
values, age, sex, education and smoking (RSA was additionally adjusted for respiration rate).  
predictors.  
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DISCUSSION 
This large study demonstrated that an unfavorable ANS profile, characterized by 
higher basal values of HR and lower values of RSA and PEP, was cross-sectionally 
associated with less favorable values of almost all individual MetS components. 
Longitudinal follow-up showed that higher basal values of HR and lower basal 
values of PEP predicted 4-year increase in many MetS abnormalities. Stress-
induced changes in ANS parameters, mainly decrease in RSA during cognitive 
challenge, were cross-sectionally associated with less favorable MetS profiles, and 
longitudinally predicted an increase in number of MetS components.  
Our cross-sectional results are largely in line with literature linking basal 
autonomic dysregulation to MetS9–11,14,15,17,18,56 and MetS components.12,16 
Furthermore, our cross-sectional findings in the 2-year follow-up data collection of 
the NESDA study are consistent with those in the baseline wave13 where 
associations between basal SNS and PNS values and MetS components of similar 
magnitude were found. In addition, our 4-year follow-up findings were congruent 
with those of the previously conducted 2-year follow-up study20 that also 
suggested an important role of the SNS in the development of metabolic 
abnormalities. Lower vagal control significantly predicted an increase in BP but 
only a trend was seen toward lower PNS activity predicting worsening of other 
metabolic values over time. The reason why the PNS had a robust association with 
MetS in the cross-sectional but not the longitudinal analysis remains unclear but 
could reflect lower power to detect effects on the change-scores in MetS 
components compared to effects on levels. Overall, our longer follow-up duration 
elicited stronger associations than the 2-year follow-up study of Licht and 
colleagues.20 This suggests that with longer follow-up duration more robust effects 
of the PNS on the development of MetS components are seen.  
In addition to a strong replication of the effects of ANS basal levels we 
tested the added value of ANS reactivity in response to stress in explaining 
variance in the MetS components. Our findings were partly comparable to the 
results of Gentile and colleagues38 who found that parasympathetic withdrawal in 
response to psychological stress predicted increased metabolic burden. 
Interestingly, the results of Gentile et al. were mostly evident in men. When looking 
solely at women, a blunted responsiveness of the PNS predicted increased 
metabolic burden. In contrast, our results implied that the relationship between a 
hyperactive ANS and MetS components was mostly evident in women. These 
conflicting findings illustrate the current state of research on the link between 
stress reactivity and metabolic abnormalities yielding mixed results. For instance, 
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one study found that HR acceleration during laboratory tasks was associated with 
higher serum lipids,23 another study indicated that blunted HR reactivity in 
response to a cognitive task was associated with more central adiposity,57 whereas 
our analyses did not yield convincing results for HR reactivity. Overall, our findings 
implicate a small added value of testing for exaggerated parasympathetic stress 
reactivity in addition to the basal levels when trying to explain individual 
differences in MetS. The value of stress reactivity might increase with larger 
absolute reactivity; the stressors used here evoked significant but rather modest 
ANS reactivity. More research is needed on SNS and PNS reactivity in response to 
different stressors to further our understanding of the relationship between ANS 
basal level, autonomic stress reactivity and MetS. 
When interpreting our findings, some limitations have to be considered. 
First, the majority of the NESDA sample consists of people with (a history of) 
depression and/or anxiety disorder, and both disorders have been linked to ANS 
dysregulation.28,58–61 Furthermore, a considerable number of our respondents were 
using antidepressants, and studies have shown that these might influence ANS 
activity.62–64 Therefore, our results may not be entirely generalizable to the general 
population. However, additional adjustments for both psychopathology status 
and antidepressant use did not change our findings, suggesting a genuine 
association between ANS activity and the MetS. Second, our personal-emotional 
stressor is not validated as a stress task in literature and this stressor is susceptible 
to interpersonal variability. However, previous research showed that this condition 
generally evoked an increased autonomic stress reactivity compared to basal ANS 
level.43 Another limitation is that, compared to daily life stress, our short-term 
stressors likely induced a mild stress reactivity. However, stress reactivity during 
the psychiatric interview was equal to the reactivity during the n-back task, which 
in turn is similar to the magnitude of reactivity found in literature.65 We note that 
our aim was to examine potential biological pathways contributing to the MetS, as 
opposed to providing a clinically useful marker of dysfunctional stress reactivity at 
the level of individual participants. Finally, we did not have data available yet to 
address the question of reverse causality, or to investigate how changes in ANS 
functioning are associated with changes in MetS components over time. These 
questions should be clarified by future research.  
Our study also had several strengths. We focused on both cross-sectional 
and longitudinal associations of ANS dysregulation with metabolic alterations, 
confirming previous findings in literature and contributing evidence to a causal 
pathway. Multiple measures of ANS were used, indicating both SNS and PNS 
activity, and continuous MetS components adjusted for medication use were 
analyzed individually in addition to a combined MetS count variable. Also, this is 
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one of few studies to investigate the effect of ANS stress reactivity on MetS. And, 
finally, our large sample size allowed us to adjust for several key confounding 
factors. 
In summary, this study suggests that higher basal sympathetic and lower 
basal parasympathetic activity are associated with MetS. Stress-induced decreases 
in PNS further contribute to MetS. In the longitudinal follow-up study, higher basal 
SNS activity proved to be the best predictor of the 4-year increase in metabolic 
abnormalities. These findings support a role for ANS dysregulation in the risk for 
MetS and they are congruent with our biological understanding of the autonomic 
stress response mobilizing the body for action, amongst others by recruiting 
available energy resources. When stress becomes chronic, this prolonged defense 
reaction can lead to a shift in metabolism and have detrimental effects on 
cardiovascular health. Interventions restoring ANS balance, such as stress-
reducing programs, might ameliorate metabolic abnormalities and thereby 
cardiovascular morbidity and mortality.
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Supplementary table 1. Associations between autonomic basal and stress reactivity values and individual components of the  
ANS variable 
No. of MetS components 
N=1796 
Triglycerides, mmol/L 
N=1839 
HDL cholesterol, mmol/L 
N=1843 
β p R2 β p R2 β p R2 
HR basal, bpm .121 <.001 .152 <.001 -.024 .28 
HR cognitive challenge 
reactivity, Δbpm 
-.030 .17 .239 -.020 .37 .155 .053 .016 .178 
HR personal-emotional 
reactivity, Δbpm 
-.021 .33 -.016 .47 .035 .11 
RSA basal, ms -.117 <.001 -.092 .005 .028 .38 
RSA cognitive challenge 
reactivity, Δms 
-.097 <.001 .241 -.088 .001 .145 .044 .076 .182 
RSA personal-emotional 
reactivity, Δms 
-.027 .24 -.007 .77 -.030 .20 
PEP basal, ms -.133 <.001 -.096 <.001 .058 .012 
PEP cognitive challenge 
reactivity, Δms 
-.031 .14 .239 -.038 .082 .142 -.010 .63 .177 
PEP personal-emotional 
reactivity, Δms 
-.020 .36 -.003 .88 .043 .048 
Note: β = standardized β-coefficient. R2 = unadjusted explained variance. HR = heart rate. RSA = respiratory sinus arrhythmia. PEP  
Triglycerides and glucose values were ln-transformed for analyses.  Results are based on linear regression analysis between basal  
antidepressant use (RSA was additionally adjusted for respiration rate).  Significant results at p <.05 are highlighted with bold  
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metabolic syndrome with additional adjustments for psychopathology status and antidepressant use 
SBP,  mm Hg 
N=1917 
Glucose, mmol/L 
N=1855 
Waist circumference, cm 
N=1897 
β p R2 β p R2 β p R2 
.106 <.001 .109 <.001 .096 <.001 
.019 .35 .279 -.030 .16 .214 -.049 .016 .284 
-.014 .47 .003 .88 .008 .70 
-.118 <.001 -.081 .010 -.086 .003 
-.065 .005 .277 -.038 .12 .210 -.082 <.001 .290 
-.019 .38 -.048 .034 -.042 .049 
-.123 <.001 -.014 .55 -.141 <.001 
-.039 .048 .282 -.027 .20 .203 -.013 .52 .290 
-.012 .56 -.008 .71 -.017 .40 
= pre-ejection period. MetS = metabolic syndrome. HDL = high density lipoprotein. SBP = systolic blood pressure.  
ANS and stress reactivity values and MetS components, adjusted for age, sex, education, smoking, psychopathology status and 
formatting. 
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Supplementary table 2. Associations between autonomic basal and stress reactivity values and 4-year changes in  
and antidepressant use 
ANS variable 
ΔNo. of MetS 
components 
N=1400 
ΔTriglycerides, 
mmol/L 
N=1504 
ΔHDL cholesterol, 
mmol/L 
N=1508 
β p R2 β p R2 β p R2 
HR basal, bpm .066 .014 -.004 .86 -.054 .038 
HR cognitive challenge reactivity, 
bpm 
-.011 .67 .135 -.015 .54 .226 -.007 .78 .089 
HR personal-emotional reactivity, 
bpm 
-.013 .62 -.037 .12 .022 .39 
RSA basal, ms -.095 .013 -.043 .22 .054 .15 
RSA cognitive challenge 
reactivity, ms 
-.070 .017 .137 -.009 .74 .227 .029 .32 .087 
RSA personal-emotional 
reactivity, Δms 
-.031 .26 -.010 .68 .005 .87 
PEP basal, ms -.074 .007 -.037 .14 .028 .30 
PEP cognitive challenge 
reactivity, Δms 
.010 .70 .136 .024 .30 .227 -.003 .92 .086 
PEP personal-emotional 
reactivity, Δms 
.007 .78 .016 .50 .015 .55 
Note: β = standardized β-coefficient. R2 = unadjusted explained variance. HR = heart rate. RSA = respiratory  
lipoprotein. SBP = systolic blood pressure. Triglycerides and glucose values were ln-transformed for analyses. Significant 
Results are based on linear regression analysis between basal ANS and stress reactivity values and longitudinal  
psychopathology status and antidepressant use (RSA was additionally adjusted for respiration rate). 
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individual components of the metabolic syndrome with additional adjustments for psychopathology status 
ΔSBP, 
mm Hg 
N=1565 
ΔGlucose, 
mmol/L 
N=1495 
ΔWaist circumference, 
cm 
N=1541 
β p R2 β p R2 β p R2 
.053 .036 -.001 .97 .032 .22 
-.021 .40 .121 -.005 .87 .051 .008 .75 .083 
-.027 .28 -.036 .17 -.014 .58 
-.078 .033 -.024 .53 -.052 .16 
-.002 .95 .123 -.021 .48 .049 -.029 .31 .085 
-.010 .71 -.002 .94 -.016 .55 
-.049 .059 -.045 .11 -.071 .009 
-.002 .93 .119 -.004 .87 .052 .013 .61 .086 
.016 .51 -.004 .89 -.027 .29 
sinus arrhythmia. PEP = pre-ejection period. MetS = metabolic syndrome. HDL = high density
results at p <.05 are highlighted with bold formatting. 
changes in MetS components, adjusted for baseline MetS values, age, sex, education, smoking, 
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ABSTRACT 
Objective: Autonomic nervous system (ANS) imbalance has been cross-sectionally 
associated with inflammatory processes. Longitudinal studies are needed to shed 
light on the nature of this relationship. We examined cross-sectional and 
bidirectional prospective associations between cardiac autonomic measures and 
inflammatory markers. 
Methods: Analyses were conducted with baseline (n=2823), 2-year (n=2099), and 
6-year (n=1774) data from the Netherlands Study of Depression and Anxiety 
(NESDA). To compare the pattern of results, prospective analyses with ANS (during 
sleep, leisure time and work) and inflammation were conducted in two datasets
from the Netherlands Twin Register (NTR) measured over 4.9 years (n=356) and 5.4
years (n=472). ANS measures were heart rate (HR) and respiratory sinus arrhythmia
(RSA). Inflammatory markers were C-reactive protein (CRP) and interleukin(IL)-6.
Results: NESDA results showed that higher HR and lower RSA were cross-
sectionally significantly associated with higher inflammatory levels. Higher HR
predicted higher levels of CRP (B=.065; p<.001) and IL-6 (B=.036; p=.014) at follow-
up. Higher CRP levels predicted lower RSA (B=-.024; p=.048) at follow-up. NTR 
results confirmed that higher HR was associated with higher CRP and IL-6 levels 4.9 
years later. Higher IL-6 levels predicted higher HR and lower RSA at follow-up.
Conclusions: Autonomic imbalance is associated with higher levels of 
inflammation. Independent data from two studies converge in evidence that
higher HR predicts subsequent higher levels of CRP and IL-6. Inflammatory markers
may also predict future ANS activity, but evidence for this was less consistent.
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INTRODUCTION 
Autonomic nervous system (ANS) imbalance, characterized by high sympathetic 
activity and low vagal activity, plays an important role in cardiovascular 
dysregulation and is a risk factor for coronary artery disease (CAD).1,2 Inflammatory 
processes are thought to cause vascular endothelial dysfunction3 and may provide 
a link between autonomic dysfunction and CAD.  
Indicators of cardiac sympathetic and vagal activity, such as heart rate (HR) 
and respiratory sinus arrhythmia (RSA), can be non-invasively and unobtrusively 
measured by electrocardiography (ECG) and impedance cardiography (ICG).4,5 
Both high HR and low RSA have been associated with CAD.1,6 Two of the most 
important and most studied markers of inflammation are C-reactive protein (CRP) 
and interleukin(IL)-6, both of which have been implicated in atherogenesis.7 Given 
these findings, researchers have sought to associate measures of cardiac vagal 
activity with inflammatory markers, and have indeed consistently found increased 
vagal activity to be cross-sectionally associated with decreased levels of CRP and 
IL-6.8–14 This association corresponds with the cholinergic anti-inflammatory 
pathway, stating that high vagal activity has an anti-inflammatory effect by 
inhibiting the production of pro-inflammatory markers.15,16 In addition, studies 
have shown that high heart rate, indicative of relative sympathetic dominance,4 is 
associated with increased levels of pro-inflammatory markers.17–20  
Studies investigating the relationship between ANS activity and 
inflammation have mostly been cross-sectional, whereas few studies have 
investigated this relationship longitudinally. A study by Jarczoc and colleagues21 
investigated this longitudinal association unidirectionally and found that higher 
high- frequency heart rate variability (HF-HRV), indicative of higher vagal activity, 
at baseline predicted lower levels of CRP 4 years later. Singh and colleagues22 
investigated the bidirectional longitudinal relationship between HF-HRV and CRP 
over 3 years and, surprisingly, found that higher CRP predicted subsequent 
increases in vagal activity. Thus it remains unclear whether there is a unidirectional 
causal effect of ANS activity on inflammation, a reverse effect of inflammation on 
ANS activity, a bidirectional effect, or an underlying mechanism causing parallel 
changes of autonomic functioning and inflammation levels over time. Additional 
longitudinal analyses are needed to investigate whether longer term exposure to 
deviant ANS functioning may lead to accumulative effects on inflammation or vice 
versa.  
The current study determined whether HR and RSA were cross-sectionally 
associated with IL-6 and CRP levels. In addition, we investigated bidirectional 
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prospective associations between cardiac autonomic activity and inflammatory 
markers. These analyses were conducted with baseline, 2-, and 6-year data from 
the Netherlands Study of Depression and Anxiety (NESDA). We additionally 
conducted prospective analyses with ANS and inflammation data of two studies 
from the Netherlands Twin Register (NTR) measured over five years in order to 
compare the pattern of results.     
METHODS 
Subjects 
NESDA 
Participants were recruited from community, primary care and mental health care 
in The Netherlands as part of the NESDA study, an ongoing longitudinal cohort 
study to examine the long-term course of depression and anxiety. The NESDA 
sample consists of 2981 participants aged 18-65 years with a current diagnosis of 
depression and/or anxiety disorder, a prior history of these disorders, and healthy 
controls. Exclusion criteria were a primary clinical diagnosis of other severe 
psychiatric disorders, and non-fluency in Dutch. The baseline assessment, 
conducted between 2004 and 2007, lasted approximately four hours, and follow-
up assessments took place after two, four and six years. A detailed description of 
the rationale, objectives and methods of the NESDA study can be found 
elsewhere.23 The study protocol was performed conform the declaration of Helsinki 
and approved by the Ethical Review Board of each participating center. All 
participants provided written informed consent.  
For the present study, data were drawn from baseline (n=2981), 2-year 
(n=2596) and 6-year (n=2256) follow-up assessments. Of the participants, 118, 334, 
and 375 people were excluded at baseline, 2-, and 6-year follow-up respectively, 
because of missing physiological data (due to telephone or at-home interviews 
without ANS recording, equipment failure during assessment or poor 
electrocardiogram quality). Another 40, 161, and 107 subjects were excluded at 
baseline, 2-, and 6-year follow-up respectively, because of missing data on 
inflammatory markers. This resulted in a total of 2823 subjects at baseline, 2099 
subjects at 2-year follow-up, and 1774 subjects at 6-year follow-up.  
NTR 
Study 1 (1998 – 2003) consisted of 816 participants of a large cardiac ambulatory 
monitoring study conducted in families registered with the NTR. Exclusion criteria 
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for this study were heart disease, diabetic neuropathy, and pregnancy. The number 
of participants with valid data on ANS activity was 741. Of these participants, we 
had valid data on inflammatory markers of 356 persons, because they had also 
participated in a large NTR biobank study (2004 – 2008),24 conducted on average 
4.9 (SD=1.7) years later.  
Study 2 comprised of 592 subjects who participated in the NTR biobank 
study and in the second part of the cardiac ambulatory monitoring study (2010 – 
2012), conducted on average 5.4 (SD=1.1) years later. The same exclusion criteria 
were applied as for study 1. Of the total sample, 472 participants had valid data on 
inflammatory markers and ANS activity. 
Physiological measurements 
For both NESDA and NTR, physiological data were recorded with the ‘Vrije 
Universiteit Ambulatory Monitoring System’ (VU-AMS), an unobtrusive lightweight 
portable device containing a six-electrode configuration. These electrodes 
measure electrocardiograms (ECG) and changes in thorax impedance (impedance 
cardiography: ICG).4 HR was directly derived from the ICG interbeat interval (IBI) 
time series.4 RSA combined ECG with ICG, and was obtained by subtracting the 
shortest IBI at inhalation from the longest IBI at exhalation for all breaths.5  
Movement registration through vertical accelerometry was used to 
remove non-stationary periods. Suspicious IBIs and breathing cycles were 
investigated with automated and visual data cleaning, and corrected or discarded 
when necessary.  
NESDA 
The participants wore the VU-AMS device during the assessments at baseline and 
follow-up. The assessments were divided into different conditions by an event 
marker. ANS data of four conditions were present at all waves: a supine rest 
condition with blood pressure measurement (±11 min) and three sitting 
conditions: a psychiatric interview (±41 min), a general interview (±33 min) and a 
computer task (±13 min). Cardiac autonomic variables during the separate 
conditions were highly correlated and previous research has shown that an 
average score of these conditions had higher temporal stability than the individual 
scores.25 Therefore, data during the four conditions were collapsed to create one 
single HR and RSA value per subject per wave.  
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NTR 
The participants wore the device an entire day and night, starting in the morning 
before their normal daily activities until awakening the next morning. In addition, 
they kept a diary in which they wrote down a chronological account of activity, 
posture, location, and social situation over the past time period. This was done 
every 30 minutes for study 1, and every 60 minutes for study 2. The activity diary 
entries were used in combination with visual inspection of the movement 
registration to divide the 24-hour recording into fixed periods. An average score of 
HR and RSA was calculated for three conditions: 1) sleep, 2) leisure: defined as the 
period with the lowest HR in the evening from 6 pm until bedtime during which 
the participant was sitting, and 3) work: all periods in which the participant was 
engaged in sitting activities at work between 9 am and 6 pm during a reported 
working day.  
Inflammatory markers 
NESDA 
At each wave, fasting blood samples were obtained in the morning between 8 and 
9 am and kept frozen at -80°C. CRP and IL-6 were assayed at the Clinical Chemistry 
department of the VU University Medical Center.  
At baseline, plasma levels of CRP were measured in duplicate by an in-
house high-sensitivity enzyme-linked immunosorbent assay (ELISA) based on 
purified protein and polyclonal anti-CRP antibodies (Dako, Glostrup, Denmark). 
The lower detection limit of CRP was 0.1 mg/L and the sensitivity was 0.05 mg/L. 
Intra- and inter-assay coefficients of variation were 5% and 10%, respectively. 
Plasma levels of CRP at 2- and 6-year follow-up were measured in duplicate by a 
high-sensitivity particle enhanced immunoturbidimetric assay (CRPHS, Roche 
Diagnostics, Indianapolis, IN, USA). In this kit, the lower detection limit of CRP was 
0.15mg/L and the sensitivity was 0.3 mg/L. Intra-assay coefficients of variation were 
5% for 2-year follow-up and 7% for 6-year follow-up. Inter-assay coefficients of 
variation were 4% for 2-year follow-up and 9% for 6-year follow-up. Individuals 
with CRP values > 10 mg/L were considered outliers and excluded from all analyses 
at that same wave. 
Plasma IL-6 levels at baseline were measured in duplicate by a high-
sensitivity ELISA (PeliKine CompactTM ELISA, Sanquin, Amsterdam, the 
Netherlands). The lower detection limit of IL-6 was 0.35 pg/ml and the sensitivity 
was 0.10 pg/ml. Intra- and inter-assay coefficients of variation were 8% and 12%, 
respectively. At the 2- and 6-year follow-up, IL-6 was measured in duplicate by a 
high-sensitivity solid phase ELISA (Human IL-6 Quantikine HS kit, R&D systems, 
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Minneapolis, MN, USA). In this kit, the lower detection limit of IL-6 was 0.08 pg/ml 
and the sensitivity range was 0.016-0.110 pg/ml. Intra- and inter-assay coefficients 
of variation were 8% and 7%, respectively.  
NTR 
After an overnight fast, blood samples were collected in EDTA, heparin and CTAD 
blood tubes and stored at -30˚C.24 CRP was measured in heparin plasma, using 
Immulite 1000 CRP assay (Diagnostic Product Corporation, USA). Inter-essay 
coefficients of variation was <5%. Again, individuals with CRP values > 10 mg/L 
were excluded for all inflammatory markers. IL-6 was measured in EDTA plasma, 
using an UltraSensitive ELISA (R&D systems, Minneapolis, USA, Quantikine HS 
HSTA00C) 26. Inter-essay coefficients of variation was <12%. 
Covariates  
NESDA 
Adjustments were made for sociodemographics: age, sex and years of education. 
We further adjusted for other covariates measured at all time points: physical 
activity measured by the International Physical Activity Questionnaire,27 number of 
smoked cigarettes/day, alcohol use (units per week), body mass index (BMI), 
number of treated chronic diseases (cardiovascular disease, epilepsy, diabetes, 
osteoarthritis, stroke, cancer, chronic lung disease, thyroid disease, liver disease, 
intestinal disorders and ulcer), current (6-month recency) depression and/or 
anxiety disorder (according to the DSM-IV based Composite International 
Diagnostic Interview), and use of antidepressants (tricyclic antidepressants, ATC 
code N06AA; selective serotonin reuptake inhibitors, ATC code N06AB; and 
selective serotonin and noradrenalin reuptake inhibitors, ATC code N06AX), heart 
medication (ATC codes C01, C02, C03, C04, C05, C07 and C08), anti-inflammatory 
agents (ATC codes M01A, M01B, A07EB, A07EC), and statins (ATC codes C10AA, 
C10B). Since it has been linked to RSA,28 respiration rate was included as a covariate 
when analyzing RSA.  
NTR 
NTR covariates were measured before the start of ANS activity recording and 
before blood collection. Comparable to NESDA, adjustments were made for age, 
sex, level of education, smoking (yes/no) and BMI. The number of participants 
using medication (antidepressants, heart medication and anti-inflammatory 
agents) was negligible and therefore this was not included as covariate. Number of 
chronic diseases or mental health status were not registered at the moment of ANS 
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 activity recording or blood collection. Respiration rate was included as a covariate 
when analyzing RSA.  
 
Statistical analyses 
Data were analysed using SPSS, version 22.0. All autonomic and inflammation 
variables were z-transformed in order to make comparisons between estimated 
effects. Since RSA, CRP and IL-6 values were skewed, these were first ln-transformed 
and then z-transformed when analysed as outcome (dependent) variables. 
NESDA 
We used generalized estimated equations (GEE) analyses with an exchangeable 
correlation structure to examine the consistency of the cross-sectional association 
between autonomic variables and inflammatory markers across waves. To 
investigate whether these associations differed between waves, the above 
analyses were repeated with the inclusion of an interaction term between ANS 
activity and categorical time. In addition, effects of gender were investigated by 
including a gender-interaction term in the analyses. Covariates age, sex and years 
of education were held at baseline. Other covariates could vary over time. 
Autoregression GEE models with an independent correlation structure 
were used to investigate whether autonomic activity at one time point (t) predicted 
levels of inflammatory markers at the next time point (t+1), while accounting for 
covariates and inflammatory markers at t. This analysis was repeated with 
inflammatory markers as predictors and autonomic activity as outcome. To 
investigate whether these prospective relationships differed over waves, we added 
an interaction term between the predictor and categorical time.  
Since BMI is suggested to be in the pathway between ANS activity and 
inflammatory markers, adjusting for it might be considered overcorrection.29 
Therefore, we first ran the above analyses adjusting for all covariates excluding BMI. 
In a second model, we included BMI. 
To investigate whether results were independent from disease status, 
sensitivity analyses were performed that excluded people with diabetes or 
cardiovascular disease.  
 
NTR 
Since blood samples for NTR were processed in different batches (NESDA used one 
batch), we used a residual score of the inflammatory markers correcting for batch 
and season effects.26 For study 1, GEE analyses with an exchangeable correlation 
structure were used to investigate the association between ANS activity at one 
time point and inflammatory markers 4.9 years later. These analyses were repeated 
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for study 2, with inflammatory markers at one time point and ANS activity 5.4 years 
later. Adjustments were made for covariates at baseline. Again, we first adjusted 
for all covariates excluding BMI, and included BMI in a second model. Family was 
included as variable random factor to account for the familial clustering of the data.  
Since RSA is prone to a ceiling effect during sleep due to low HR,30 we 
performed additional sensitivity analyses by excluding participants (study 1: n=47; 
study 2: n=20) who showed a quadratic relationship between RSA and HR. In 
addition, effects of gender were investigated by including a gender-interaction 
term in the analyses. 
RESULTS 
NESDA 
At baseline, the NESDA sample (n=2823) had a mean age of 41.8 years (SD=13.1) 
and 66.5% were female (Table 1). Table 2 shows the cross-sectional associations 
between cardiac autonomic activity with inflammatory markers across waves. In 
the models without adjustments for BMI, a higher HR was significantly associated 
with higher levels of CRP (B=.179;p<.001) and IL-6 (B=.141;p<.001). A higher RSA 
was associated with lower levels of CRP (B=-.041;p=.013) and IL-6 (B=-.073;p<.001). 
When additionally adjusting for BMI, the strength of associations slightly decreased 
but remained significant between HR with CRP (B=.141;p<.001) and IL-6 
(B=.141;p<.001). RSA and Il-6 also remained significantly associated (B=-
.063;p<.001), but the association between a higher RSA and a lower CRP level 
rendered non-significant. The fully-adjusted cross-sectional relationships between 
ANS values and inflammatory markers are illustrated in Figure 1.  
When repeating the analyses with an interaction term between ANS 
variables and time, we found that time significantly modulated the relationship 
between HR and CRP, and between RSA and IL-6. We therefore stratified these 
analyses per wave and found that the strength of associations differed somewhat 
between waves but were all significant in the fully adjusted models (for HR and 
CRP:B=.151;B=.155;B=.126, for RSA and IL-6:B=-.046;B=-.100;B=-.060, for baseline, 
2-, and 6-year follow-up, respectively). 
Table 3 shows that, in the models without adjustments for BMI, a higher 
HR at one time point significantly predicted higher inflammatory markers at the 
next time point (for CRP:B=.076;p<.001, for IL-6:B=.056;p<.001). Again, the strength 
of associations slightly decreased but remained significant after additional 
adjustment for BMI (for CRP:B=.065;p<.001, for IL-6:B=.036;p=.014). A higher RSA at  
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Table 1. Sample Characteristics NESDA 
Characteristics 
Baseline 
n=2823
2-y follow-up
n=2099
6-y follow-up
n=1774
Social demographics 
   Age, mean years ± SD    41.8 ± 13.1 44.3 ± 13.2 48.3 ± 13.1  
   Female sex, % 66.5 65.4 65.2 
   Education, mean years ± SD 12.2 ± 3.3 12.6 ± 3.3 12.9 ± 3.3 
Lifestyle 
   Physical activity, median 
1000METmin/week (IQR) 
2.8 (1.4–5.0) 3.1 (1.5–5.4) 2.9 (1.5–5.4) 
   Alcohol use, median drinks/week (IQR) 3.7 (0.2–8.7) 3.7 (0.2–8.7) 3.7 (0.2–8.2) 
   Smokers, %  35.7 30.6 25.8 
      Median no. cigarettes/day (IQR) 14.0 (7.0–20.0) 12.0 (7.0–
20.0) 
12.0 (5.7–
20.0) 
Health factors  
   Body mass index, kg/m2 25.6 ± 5.0 25.7 ± 4.8 26.1 ± 5.0 
   No. chronic diseases  
      0 chronic diseases, % 58.3 61.3 57.3 
      1 chronic disease, % 27.9 27.1 29.3 
>2 chronic diseases, % 13.8 11.6 13.4 
   Use of cardiac medication, % 12.2 14.9 17.0 
   Use of anti-inflammatory agents, % 18.6 17.6 18.2 
   Use of statins, % 6.8 7.1 10.0 
   Current psychopathology, % 57.0 37.3 26.9 
   Use of TCA, % 2.7 3.1 3.2 
   Use of SNRI, % 4.1 4.0 3.9 
   Use of SSRI, % 17.0 14.1 12.0 
Cardiac autonomic measures 
   HR, mean beats/min ± SD 72.0 ± 9.6 72.7 ± 9.7 71.7 ± 9.5 
   RSA, median ms (IQR) 38.8 (27.2–
55.5) 
37.2 (25.1–
52.9)  
39.4 (26.9–
55.5) 
   Respiration rate, mean breaths/min ± SD 17.1 ± 1.2 17.3 ± 1.3 16.3 ± 1.4 
Inflammatory markers 
   CRP, median mg/l (IQR) 1.1 (0.5–2.6) 1.0 (0.4–2.3) 1.1 (0.5–2.4) 
   IL-6, median pg/ml (IQR) 0.8 (0.5–1.3) 1.0 (0.7–1.7) 0.9 (0.6–1.6) 
Note: METmin = multiple of resting metabolic rate times minutes of physical activity per week. IQR 
= interquartile range. TCA = tricyclic antidepressant. SNRI = selective serotonin and noradrenalin 
reuptake inhibitors. SSRI = selective serotonin reuptake inhibitors. HR = heart rate. RSA = respiratory 
sinus arrhythmia. CRP = C-reactive protein. IL-6 = interleukin-6. 
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Table 2. Adjusted association between ANS values with inflammatory markers across waves in NESDA 
CRP  IL-6  
No. of 
observations 
B SE p No. of 
observations 
B SE p 
HRa  6398 .179 .014 <.001 6688 .162 .013 <.001 
HRb .141 .013 <.001 .141 .013 <.001 
RSAa  6398 -.041 .016 .013 6689 -.073 .016 <.001 
RSAb -.024 .015 .10 -.063 .015 <.001 
Note: HR = heart rate. RSA = respiratory sinus arrhythmia. CRP = C-reactive protein. IL-6 = interleukin-6. Boldface 
indicates significant results.  aGEE analyses were adjusted for age, sex, education, physical activity, alcohol use, 
smoking, number of chronic diseases, current psychopathology, use of antidepressants, heart medication, anti-
inflammatory agents, and statins, and time. RSA was additionally adjusted for respiration rate. bAdjustmenta + 
additionally adjusted for body mass index.  
Table 3. Prospective adjusted association between predictor values at one time point (t) with outcome values at 
the next time point (t+1) in NESDA 
Outcome 
CRP  IL-6 
Predictor No. of 
observations 
B SE p No. of 
observations 
B SE p 
HRa  3538 .076 .017 <.001 3819 .056 .015 <.001 
HRb .065 .017 <.001 .036 .015 .014 
RSAa  3539 -.021 .022 .34 3821 -.033 .017 .044 
RSAb -.018 .022 .42 -.024 .017 .15 
Outcome 
HR RSA 
Predictor No. of 
observations 
B SE p No. of 
observations 
B SE p 
CRPa 3534 -.015 .013 .24 3533 -.036 .012 .002 
CRPb  -.021 .013 .12 -.024 .012 .048 
IL-6a 3696 -.020 .012 .10 3696 .98 
IL-6b -.021 .012 .081 
-4.3E-4 .016 
.004 .015 .77 
Note: HR = heart rate. RSA = respiratory sinus arrhythmia. CRP = C-reactive protein. IL-6 = interleukin-6. Boldface 
indicates significant results. aGEE analyses were adjusted for basal values of the outcome, age, sex, education, 
physical activity, alcohol use, smoking, number of chronic diseases, current psychopathology, use of 
antidepressants, heart medication, anti-inflammatory agents, and statins, and time. RSA was additionally adjusted 
for respiration rate.bAdjustmenta + additionally adjusted for body mass index. 
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one time point predicted lower levels of Il-6 only in the model without adjustment 
for BMI (B=-.033;p=.044).  
The addition of an interaction-term between ANS variables and time, 
showed that time modulated the relationship between HR at one time point and 
CRP at the next time point. Stratified analyses showed that the association was 
stronger for a higher HR at baseline predicting higher CRP level at 2-year follow-up 
(B=.092;p<.001) than for HR at 2-year follow-up predicting CRP at 6-year follow-up 
(B=.027;p=.27). 
When testing the reverse relationship (Table 3), analyses showed that 
higher levels of CRP significantly predicted a lower RSA at the next time point, 
without (B=-.036;p=.002) and with adjustment for BMI (B=-.024;p=.048).  
To investigate whether these results were independent from disease 
status, sensitivity analyses were performed that excluded persons with diabetes or 
cardiovascular disease. These results showed that only the prospective association 
between CRP and RSA rendered non-significant after exclusion. However, in 
general, there was little change in strength of associations after exclusion, 
suggesting that our results were not driven by diabetes or cardiovascular disease.  
Additional information on the underlying data structure is presented in 
Supplementary table 1, showing that changes in ANS are correlated with changes 
in inflammation over time. 
NTR 
Compared to NESDA, the NTR sample was smaller (study 1: n=344; study 2: n= 454) 
and younger at baseline (study 1: 31.7 (SD=10.5) years; study 2: 31.8 (SD=5.4) years. 
Study 1 consisted of 58.4% females and study 2 of 61.2% females (Supplementary 
table 2).  
Prospective analyses between ANS values and inflammatory markers in study 
1 (Table 4) showed that a higher HR during sleep was significantly associated with 
higher levels of CRP (B=.132;p=.013) and IL-6 (B=.158;p=.012) 4.9 years later in the 
models without adjustment for BMI. When additionally adjusting for BMI, the strength 
of associations decreased but remained significant (for CRP:B=.127;p=.013, for IL-
6:B=.146;p=.017). Higher HR during leisure time was also significantly associated with 
higher CRP, without (B=.126;p=.017) and with adjustment for BMI (B=.112;p=.027). 
Higher HR during work was associated with higher IL-6 levels in the model without 
adjustment for BMI (B=.171;p=.048). No significant associations were found between 
RSA and inflammatory markers at follow-up.  
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Table 5. Prospective association between inflammatory markers at baseline with ANS values 5.4 years later in NTR 
Outcome 
HR sleep HR leisure HR work 
Predictor N B SE P N B SE P N B SE P 
CRPa 435 .067 .045 .14 406 .066 .049 .18 247 .107 .061 .081 
CRPb .063 .048 .19 .070 .054 .19 .103 .065 .11 
IL-6a 446 .125 .044 .004 416 .102 .046 .026 251 .133 .056 .017 
IL-6b .122 .046 .007 .103 .048 .030 .128 .058 .027 
Note: CRP = C-reactive protein. IL-6 = interleukin-6. HR = heart rate. RSA = respiratory sinus arrhythmia. Boldface 
additionally adjusted for respiration rate. bAdjustmenta + additionally adjusted for body mass index. 
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Table 4. Prospective association between ANS values at baseline with inflammatory markers 4.9 
years later in NTR study 1 
Outcome 
CRP  IL-6  
Predictor N B SE p N B SE p 
HR sleepa 322 .132 .053 .013 330 .158 .063 .012 
HR sleepb .127 .051 .013 .146 .061 .017 
HR leisurea  320 .126 .053 .017 327 .100 .063 .11 
HR leisureb .112 .051 .027 .087 .063 .17 
HR worka  175 .048 .072 .50 175 .171 .087 .048 
HR workb .035 .071 .61 .157 .088 .073 
RSA sleepa  322 .028 .060 .64 330 -.008 .070 .97 
RSA sleepb  -.012 .058 .83 -.042 .069 .55 
RSA leisurea  320 -.030 .063 .64 327 .028 .067 .67 
RSA leisureb  .002 .061 .97 .056 .064 .38 
RSA worka  175 -.046 .083 .58 175 -.137 .098 .16 
RSA workb  -.031 .084 .71 -.120 .100 .23 
Note: HR = heart rate. RSA = respiratory sinus arrhythmia. CRP = C-reactive protein. IL-6 = interleukin-6. 
Boldface indicates significant results. aGEE analyses were adjusted for age, sex, level of education, 
and smoking. RSA was additionally adjusted for respiration rate. bAdjustmenta + additionally 
adjusted for body mass index. 
study 2 
Outcome 
RSA sleep RSA leisure RSA work 
N B SE P N B SE P N B SE p 
435 .051 .047 .28 406 -.020 .050 .69 247 -.054 .055 .32 
.008 .050 .88 -.030 .056 .59 -.034 .056 .55 
446 -.037 .041 .37 416 -.097 .042 .022 251 -.037 .050 .47 
-.066 .045 .14 -.107 .045 .016 -.016 .051 .75 
indicates significant results. aGEE analyses were adjusted for age, sex, level of education and smoking. RSA was 
Cardiac autonomic activity and inflammation     177
When investigating the reverse associations in study 2 (Table 5), analyses 
showed that higher IL-6 was associated with higher levels of HR during sleep 
(B=.125;p=.044 and B=.122;p=.007, without and with adjustment for BMI, 
respectively), leisure time (B=.102;p=.026 and B=.103;p=.030, without and with 
adjustment for BMI, respectively), and work (B=.133;p=.017 and B=.128; p=.027, 
without and with adjustment for BMI, respectively) 5.4 years later. Higher IL-6 was 
also associated with lower RSA during leisure time (B=-.097;p=.022 and B=-
.107;p=.016, without and with adjustment for BMI, respectively).  
Sensitivity analyses excluding people who showed a ceiling effect for RSA 
during sleep did not change our results.  
We additionally checked for gender-interactions in both NESDA and NTR 
analyses. Within NTR, no significant gender-interactions were found. Within 
NESDA, a higher HR and lower RSA were stronger associated with a higher CRP 
level in women than in men. However, since no consistent gender-interactions 
were found, these findings might have been due to chance. 
DISCUSSION 
The current study showed that both higher HR and lower RSA were cross-
sectionally associated with higher inflammation levels, as measured by CRP and IL-
6. We aimed to unravel directionality by testing associations in both directions in 
two independent cohorts: NESDA and NTR. In both studies, higher HR at baseline 
was associated with higher levels of CRP and IL-6 at follow-up. Inflammatory
markers at baseline were also associated with ANS activity at follow-up. However,
evidence for these reverse associations was less consistent.
The current results contribute to existing evidence that vagal activity is 
coupled with the inflammatory system.8–16 Longitudinal studies focusing on the 
relationship between these two biological systems are scarce. One study found 
that higher CRP predicted increase in vagal activity at follow-up,22 and another 
suggested that higher vagal activity predicted lower levels of CRP.21 Both studies 
were rather small in sample size (< 200 participants). Our study found consistent 
evidence for HR predicting subsequent levels of inflammatory markers. Since 
resting HR has been suggested to be predominantly governed by cardiac vagal 
control,31 and because RSA, a direct measure of cardiac vagal activity,5 also showed 
evidence of association, we suggest that vagal changes precede inflammatory 
changes. This hypothesis is further supported by the NTR data showing a stronger 
relationship between HR and inflammatory markers during sleep, when vagal 
activity predominates, than during work, when sympathetic activity prevails.32 
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Effects of vagal activity on IL-6 and CRP over time might reflect the cholinergic anti-
inflammatory pathway: the neural mechanism that inhibits the inflammatory 
response by vagal acetylcholine secretion.33 Alternatively, low cardiac vagal activity 
may increase the risk for atherosclerosis, e.g. by effects on blood pressure,2,34,35 and 
atherosclerosis may in turn drive inflammatory responses.36 
Besides the effect of cardiac autonomic activity on future inflammation, 
we also found reverse associations. The NESDA data showed an association 
between CRP at baseline and subsequent RSA. The NTR data, in contrast, showed 
associations between IL-6 at baseline and HR and RSA at follow-up. Although this 
pattern of results is less consistent than the effect of HR on future pro-inflammatory 
state, we cannot rule out reverse effects of CRP or IL-6 on cardiac autonomic 
regulation. A bidirectional effect of the two systems on each other is biologically 
plausible, since activation of the inflammatory response has been suggested to 
stimulate the hypothalamus, which in turn influences autonomic activity.37   
Prospective studies provide a better stab at causality than cross-sectional 
studies but are still imperfect. Many unmeasured confounders can influence both 
autonomic activity and inflammation. If they do so at different time points in life, 
this can create the false impression of causality. Furthermore, repeatedly 
measuring two systems that show substantial tracking can lead to erroneous 
conclusions about causality. It has indeed been shown that HR and RSA show 
substantial tracking over time.25 The found prospective association between IL-6 
and RSA/HR, for instance, could therefore have arisen from earlier effects of vagal 
activity on baseline inflammation levels. A promising next step to further unravel 
causality is to establish whether genetic variances of one biological system predicts 
the other, suggesting that shared genetics is in play as a third underlying factor.  
The current research is one of few that investigates the relationship 
between cardiac autonomic activity and inflammatory markers longitudinally, and 
does so within two independent prospective studies. However, some limitations 
need to be considered. First, although we suspect vagal activity to predict 
subsequent inflammatory markers, we only found a cross-sectional association 
between low RSA and high levels of CRP and IL-6. The lack of predictive power of 
RSA might be due to a higher standard deviation for this measure than for HR, 
rendering HR as the more powerful measure to discern associations. However, 
although resting HR is mostly determined by the strongly age-dependent intrinsic 
heart rate5 and, particularly during sleep, vagal activity, it is also partly controlled 
by the sympathetic nervous system. Processes related to intrinsic heart regulation 
and sympathetic influences may have further contributed to the inflammatory 
state. Second, there were multiple methodological differences between the NESDA 
and the NTR sample. For instance, the majority of the NESDA sample consists of 
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people with (a history of) depression and/or anxiety. Although we adjusted for 
psychopathology within NESDA, the sample differences complicate a one-on-one 
comparison between the two studies. In contrast to NESDA, the NTR study only 
measured ANS and inflammatory data at one time point. Therefore, we were 
unable to correct for these measures at baseline. Also, there were differences 
between sensitivity of assays of the inflammatory markers and between measured 
covariates. Furthermore, the conditions of ANS data collection were not uniform 
between the two studies, as data for NTR was collected during 24-hours of a regular 
day and data for NESDA was collected in a laboratory setting. One could argue that 
the NTR data is more ecologically valid but also more prone to interpersonal 
variability than the NESDA data. These methodological differences compromise 
comparability between the studies. However, the combined data of the two 
studies allowed us to confirm that the pattern of results in the relationship between 
cardiac autonomic activity and inflammatory markers holds across such diverse 
settings. 
In conclusion, lower cardiac vagal activity is associated with higher levels 
of inflammation. Coupling between these two biological systems is most evident 
in cross-sectional data but clearly reflects a prolonged coupling across the time 
course as shown by longitudinal analyses. Our analyses provide stronger evidence 
for an effect of cardiac autonomic regulation on inflammatory markers than the other 
way around. Future studies should further investigate the causal mechanisms 
underlying this relationship. 
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Supplementary table 1. Associations between change in ANS activity and change in inflammatory 
markers 
2-y DCRP 6-y DCRP 2-y DIL-6 6-y DIL-6
r p r p r p r p 
2-y DHR .177 <.001 - .132 <.001 - 
6-y DHR - .201 <.001 - .064 .008 
2-y DRSA -.102 <.001 - -.108 <.001 - 
6-y DRSA - -.081 .002 - -.051 .038 
Note: HR = heart rate. RSA = respiratory sinus arrhythmia. CRP = C-reactive protein. IL-6 = interleukin-
6. Change-scores of ANS and inflammatory markers were corrected for values at baseline.
Supplementary table 2. Sample characteristics NTR 
N Study 1 N Study 2 
Social demographics 
  Age, mean years ± SD   344 31.7 ± 10.5 454 31.8 ± 5.4 
   Female sex, % 344 58.4 454 61.2 
   Level of education 344 454 
      Low, % 0.9 0.4 
      Moderate, % 52 53.1 
      High, % 47.1 46.5 
Health factors 
      Smoker, % 344 20.6 454 24.4 
      BMI, mean ± SD    344 23.6 ± 3.9 454 23.5 ± 3.4 
Cardiac autonomic measures 
   HR sleep, mean beats/min ± SD  333 62.7 ± 8.2 448 61.7 ± 7.8 
   HR leisure, mean beats/min ± SD 330 70.7 ± 9.7 418 68.0 ± 9.6 
   HR work, mean beats/min ± SD 175 79.6 ± 11.4 252 75.9 ± 9.9 
   RSA sleep, median ms (IQR) 333 50.9 (37.3–70.4) 448 50.2 (38.2–66.0) 
   RSA leisure, median ms (IQR) 330 48.9 (33.2–66.6) 418 46.3 (34.1–60.9) 
   RSA work, median ms (IQR) 175 41.4 (31.1–53.6) 252 43.1 (32.5–54.7) 
   Respiration rate sleep, mean breaths/min ± SD 333 15.8 ± 2.0 448 15.7 ± 2.2 
   Respiration rate leisure, mean breaths/min ± SD 330 17.7 ± 1.8 418 17.8 ± 2.1 
   Respiration rate work, mean breaths/min ± SD 175 16.9 ± 1.4 252 17.3 ± 1.4 
Inflammatory markers 
   CRP, median mg/l (IQR) 333 1.2 (0.5–2.6) 440 1.0 (0.5–2.3) 
   IL-6, median pg/ml (IQR) 341 1.0 (0.7–1.5) 452 0.9 (0.6–1.4) 
Note: IQR = interquartile range. HR = heart rate. RSA = respiratory sinus arrhythmia. CRP = C-reactive protein. 
IL-6 = interleukin-6. 
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ABSTRACT 
Objectives: This study examined 1) the cross-sectional relationships between 
symptoms of depression/anxiety and immunometabolic risk factors, and 2) 
whether these relationships might be explained in part by cardiac vagal activity.  
Methods: Data were drawn from the Adult Health and Behavior registries 
(n=1785), comprised of community dwelling adults (52.8% women, aged 30-54). 
Depressive symptoms were measured with the Center for Epidemiological Studies 
Depression Scale (CES-D) and the Beck Depression Inventory-II (BDI-II), and anxious 
symptoms with the Trait Anxiety scale of the State-Trait Anxiety Inventory (STAI-T). 
Immunometabolic risk factors included fasting levels of triglycerides, high-density 
lipoproteins, glucose, and insulin, as well as blood pressure, waist circumference, 
body mass index, C-reactive protein, and interleukin-6. Measures of cardiac 
autonomic activity were high- and low-frequency indicators of heart rate variability 
(HRV), standard deviation of normal-to-normal R-R intervals, and the mean of 
absolute and successive differences in R-R intervals.  
Results: Higher BDI-II scores, in contrast to CES-D and STAI-T scores, were 
associated with increased immunometabolic risk and decreased HRV, especially 
HRV likely reflecting cardiac vagal activity. Decreased HRV was also associated with 
increased immunometabolic risk. Structural equation models indicated that BDI-II 
scores may relate to immunometabolic risk via cardiac vagal activity (indirect 
effect: β=.012, p=.046) or to vagal activity via immunometabolic risk (indirect 
effect: β=-.015, p=.021). 
Conclusions: Depressive symptoms, as measured by the BDI-II, but not anxious 
symptoms, were related to elevated levels of immunometabolic risk factors and 
low cardiac vagal activity. The latter may exhibit bidirectional influences on one 
another in a mediational framework. Future longitudinal, intervention, an 
nonhuman animal work is needed to elucidate the precise and mechanistic 
pathways linking depressive symptoms to immune, metabolic, and autonomic 
parameters of physiology that predispose to cardiovascular disease risk.  
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INTRODUCTION 
Mood disorders have long been suggested to confer risk for cardiovascular disease 
(CVD).1–3 Several physiological mechanisms are thought to contribute to this risk, 
particularly those involving the autonomic nervous system and immunometabolic 
dysfunction.4,5 Understanding the pathways that might link symptoms of 
depression and anxiety to CVD risk remains an important and open issue, as 
depression and anxiety disorders and CVD are often highly comorbid and are 
among the leading causes of disability and disease burden worldwide.6–8 
Work in clinical and community samples suggests that depressed mood 
may precede immunometabolic dysregulations. For example, major depressive 
disorder has been associated with risk for the metabolic syndrome (MetS), a cluster 
of CVD risk factors – insulin resistance, dyslipidemia, central adiposity, and elevated 
blood pressure – that increase risk for CVD events and mortality.9,10 In community 
samples, depressive symptoms also predict risk for future MetS.11 According to 
recent studies, markers of systemic inflammation, such as C-reactive protein (CRP) 
and interleukin (IL)-6, might be plausibly included as features of the MetS and may 
play a role in the pathogenic aggregation of its multiple components.12,13 
Congruently, studies have related depression to increased levels of inflammatory 
markers.14–17 Regarding anxiety and immunometabolic dysregulation, existing 
evidence is inconclusive. Although anxious symptoms have been associated with 
the MetS18–20 and systemic inflammation,21–23 many studies show contrary results24–
27 for reasons that have yet to be clarified.  
Depressive and anxiety disorders and related mood symptom profiles 
have also been linked to autonomic dysregulation, although the nature of this 
relationship remains debated. Among the most commonly investigated indices of 
autonomic activity are measures of heart rate variability (HRV), especially 
presumptive indicators of cardiac vagal activity, such as high-frequency HRV (HF-
HRV) and respiratory sinus arrhythmia (RSA).28 Generally, negative mood states – 
such as depression and anxiety – are thought to decrease cardiac vagal activity.29–
34 However, findings from several studies that distinguished medicated from un-
medicated individuals observed that the relationship between depressed mood 
and suppressed cardiac vagal activity might be attributable to antidepressant use, 
as drug-naïve affected persons did not uniformly differ from healthy controls.35–40 
The relationship of suppressed cardiac vagal activity to depression and anxiety is 
of interest because vagal dysregulation is often reported to accompany 
immunometabolic risk. For example, many studies have linked decreased HRV to 
increased levels of metabolic risk factors41–48 and inflammatory markers.49–57 
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Evidence from longitudinal studies further suggests that autonomic or vagal 
dysfunction, as revealed by low HRV, may in fact precede metabolic abnormalities58,59 
and increased levels of systemic inflammation.60  
Given the above findings, it is plausible that symptoms of depression and 
anxiety might associate with cardiac vagal activity and immunometabolic risk 
factors. Moreover, existing evidence suggests that cardiac vagal dysregulation may 
partly account for the association between mood related symptoms and 
immunometabolic risk. The few studies that have formally tested the latter 
explanatory pathway have chiefly focused on cardiovascular mortality as a late-
stage endpoint, and they have yielded contradictory conclusions. Carney and 
colleagues,61 for example, reported a partial mediation effect of low cardiac vagal 
activity on the relationship between depression and mortality, whereas Kamphuis 
and colleagues62 did not find such an effect. As far as we know, no study has tested 
whether patterns of cardiac vagal activity reflected by metrics of HRV partly explain 
the relationship of depressive and anxious symptoms to immunometabolic risk 
factors in a preclinical context or non-clinical sample of adults. Moreover, we know 
of no studies that have tested alternative associational possibilities. For instance, 
immunometabolic risk may well account for the association of mood related 
symptoms with cardiac vagal activity, as cardiac autonomic activity may plausibly 
be disrupted by a greater risk burden that is consequent to depressive behaviors 
(e.g., from vascular, inflammatory, or metabolic sources). 
Accordingly, the current study used a relatively large community sample 
of midlife people from the Adult Health and Behavior registries (AHAB-1 and 
AHAB-2)63,64 to test: 1) the relationships between symptoms of depression and 
anxiety and immunometabolic risk factors, and 2) whether observable 
relationships between depressive/anxious symptoms and immunometabolic risk 
might be partly explained (statistically mediated) by cardiac vagal activity using 
structural equation modeling (SEM). To permit more comprehensive testing, 
multiple indicators of HRV, including HF-HRV, low-frequency(LF)-HRV, standard 
deviation of normal-to-normal R-R intervals (SDNN), and the mean of absolute and 
successive differences in R-R intervals (MSD) were assessed in the present study. In 
this regard, LF-HRV and SDNN, although suggested to predominantly reflect 
cardiac vagal activity, are also influenced by sympathetic activity.28,65 Accordingly, 
such metrics might aid in more completely understanding the relationship 
between cardiac autonomic function with depressive and anxious symptoms and 
immunometabolic risk in a preclinical context. Finally, ancillary analyses were 
conducted to test for the moderating influence of sex, as well as alternative 
statistical mediation pathways. 
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METHODS 
Subjects 
Data were derived from the University of Pittsburgh Adult Health and Behavior 
(AHAB) project phases 1 (AHAB-1) and 2 (AHAB-2), including behavioral and 
biological measurements of participants aged between 30-54.63,64  
AHAB-1 consisted of 1295 participants who were recruited in 2001-2005 via mass-
mail solicitation from communities of Southwestern Pennsylvania in the United 
States (principally Allegheny County). Participants were excluded if they had a 
reported history of atherosclerotic CVD, chronic kidney or liver disease, past-year 
cancer treatment, major neurologic disorders, schizophrenia or other psychotic 
illness. Other exclusions included pregnancy and the use of insulin, glucocorticoid, 
antiarrhythmic, psychotropic, or prescription weight-loss medications.  
AHAB-2 consisted of 490 participants who were recruited in 2008-2011, 
also via mass-mail solicitation and from the same geographic region. Exclusion 
criteria were the same as for AHAB-1, with the following additional exclusions: 
unemployment, occupational shift work, or working less than 25 hours per week 
outside the home (this restriction was due to a sub-study focusing on occupational 
stress), stage 2 hypertension (systolic diastolic BP ≥160/100 mm Hg), high alcohol 
consumption (≥five portions at one occasion on three to four occasions per week), 
use of fish oil supplements (because of the requirements of another sub-study), 
and lipid-lowering or antihypertensive medications. Informed consent was 
obtained in accordance with approved guidelines of the University of Pittsburgh 
Institutional Review Board.  
Depressive/anxious symptoms 
Depressive symptoms were measured using the Center for Epidemiological 
Studies Depression Scale (CES-D)66 and the Beck Depression Inventory-II (BDI-II).67 
The CES-D is a 20-item self-report questionnaire to assess how frequently subjects 
experienced symptoms of depression during the past week. The BDI-II is a 21-item 
measure of depression severity during the past week. Anxious symptoms were 
measured by the Trait Anxiety scale of the State-Trait Anxiety Inventory (STAI-T), a 
20-item self-report scale to measure the general propensity to experience states of 
anxiety in response to perceived threats.68 In our sample, these questionnaires 
demonstrated high internal consistency (Cronbach’s α = .90, .85, and .92, for CES-
D, BDI-II, and STAI-T, respectively). In addition, these questionnaires have shown 
adequate psychometric properties supporting their reliability and validity.69–71 The 
combined data of AHAB-1 and -2 yielded 1769 participants who completed the 
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CES-D, 1775 participants who completed the BDI-II, and 1754 participants who 
completed the STAI-T. 
Current diagnosis of a mood or anxiety disorder (including major 
depressive disorder, dysthymia, generalized anxiety disorder, panic disorder, 
simple phobia, social phobia, obsessive compulsive disorder, and post-traumatic 
stress disorder) was assessed with the Structured Clinical Interview for DSM-IV Axis 
1 Disorder (SCID)72 nonpatient edition (AHAB-1) and the Mini International 
Neuropsychiatric Interview (MINI),73 Version 6.0 (AHAB-2). 
Immunometabolic risk 
The components of immunometabolic risk were assessed in the morning after an 
overnight fast. At this visit, a medical history and medication use interview was 
administered, and measurement of body mass index (BMI; kg/m2) and waist 
circumference was obtained. Systolic and diastolic blood pressure (SBP and DBP, 
respectively) were computed as the average of 2 readings measured by a 
sphygmomanometer after at least 5 minutes of rest in a seated position. Fasting 
serum triglycerides, HDL cholesterol and glucose were determined by the Heinz 
Nutrition Laboratory, University of Pittsburgh Graduate School of Public Health. 
Fasting serum insulin concentration was measured in duplicate with a 
radioimmunoassay (Code-a-count; Diagnostic Products, Inc, Los Angeles, CA). Of 
the total sample, 30 participants were excluded because of missing data on one or 
more metabolic components, rendering 1755 participants for analyses.  
IL-6 was determined by a high-sensitivity quantitative sandwich enzyme 
immunoassay kit (R&D Systems, Minneapolis, MN). The assay standard range is 
from 0.156 to 10 pg/mL. IL-6 levels were extrapolated from a standard curve with 
linear regression from a log-linear curve. All samples were run in duplicate and the 
average coefficient of variation (CV) between samples was 5%. CRP was measured 
with the BNII nephelometer from Dade Behring (Newark, DE) using a particle-
enhanced immunonephelometric assay. The assay range is 0.175-1100 mg/L. Intra-
assay CVs ranged from 2.3-4.4% and inter-assay CVs ranged from 2.1-5.7%. 
Participants were excluded from analyses of inflammatory markers if they had chronic 
inflammatory disease or used medications known to impact immune function (cold 
medications, antihistamines, inhaled corticosteroids, immunosuppressants, or 
allergy shot in the previous 2 weeks). In addition, data on inflammatory markers 
were excluded when CRP concentrations were greater than 10 mg/L, due to the 
possibility of underlying inflammatory disease 74. In AHAB-2, the blood draw was 
rescheduled if participants reported symptoms of acute infection, receiving a 
vaccination, or use of antibiotics or antivirals in the previous 2 weeks. Possibly as a 
consequence, all levels of IL-6 fell below the maximum levels of detection of the 
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assay (10 pg/ml). In contrast, common acute illnesses were not considered in the 
timing of the blood draw in AHAB-1. For this reason, we excluded individuals with 
levels of IL-6 >10pg/mL, but only when BMI was < 30 kg/m2, due to evidence that 
individuals with high levels of adiposity have elevated levels of IL-6 in the absence 
of acute illness. This resulted in 1546 participants with a valid measure for CRP and 
1455 participants with a valid measure for IL-6.      
Assessment of HRV and cardiac vagal activity 
HRV measures were derived from a modified lead II electrocardiogram (ECG) 
recording protocol. Participants were seated in a temperature and sound-
controlled chamber for a 10-min rest period, after which 5-min resting ECG 
recordings were obtained. Automated algorithms and visual inspection were used 
to correct artifacts in the ECG and the derived inter-beat interval (IBI) time series. 
Recording periods were divided into three 90-s epochs and were excluded based 
on percent artifact (>20%) and length (>10% missing). By these criteria, there were 
missing HRV data for 61 participants. The following variables were averaged across 
retained epochs: high-frequency heart rate variability (HF-HRV), low-frequency 
heart rate variability (LF-HRV), the standard deviation of normal to normal R-R 
interval (SDNN), and the mean of successive and absolute differences in IBIs (MSD). 
The MSD is highly correlated to the more conventionally used RMSSD,75 which is 
also putative indicator of cardiac vagal activity.76 SDNN, while often used as an 
index of total variability, covaries strongly with more specific measures of cardiac 
vagal control obtained during brief recording periods (r=0.8 in this study).75 To 
obtain HF-HRV and LF-HRV, the band-limited variance within the frequency range 
of 0.12-0.40 Hz and 0.04-0.12 Hz (Allen et al., 2007), respectively, was extracted 
using PhysioScripts.77 HRV variables were available for 1724 participants. Raw and 
de-identified data used to generate HRV metrics are available on request. 
Covariates 
Covariate adjustments were made for age, sex, years of education, race (non-
Hispanic Caucasian or other), and study (AHAB-1 or AHAB-2). We also accounted 
for lifestyle factors: physical activity (estimated kilocalories expended per week by 
the Paffenbarger Physicial Activity Questionnaire78), alcohol use (drinks/week), and 
smoking (cigarettes/day). From a medical history interview, we determined self-
reported medical conditions and current medications, and included the following 
covariates: presence/absence of any non-excluded medical conditions and use of 
antihypertensive or lipid-lowering medications. Because it is linked to HRV metrics, 
respiration rate was included as a covariate.75,79,80 Respiration rate was computed 
from strain-gauge respiratory recordings obtained concurrently during EKG 
Psychopathology and immunometabolic risk: the role of cardiac vagal activity     191
monitoring. The number of participants taking antidepressants was negligible 
(n=1) and therefore antidepressant use was not included as a covariate.  
Statistical analyses 
Triglycerides, glucose, insulin, CRP, IL-6, HF-HRV, LF-HRV, SDNN and MSD exhibited 
skewed distributions and these variables were natural log transformed prior to 
analyses. Multiple linear regression analyses were first performed with IBM SPSS 
Statistics version 24 (IBM corp) to test the associations between depressive and 
anxious symptoms, HRV metrics, and immunometabolic risk factors. Covariates in 
the base models included age, sex, education, and study (and respiration rate 
when analyzing HRV). In subsequent models, additional covariate adjustments 
were made for physical activity, alcohol use, smoking, presence/absence of 
medical conditions, and use of antihypertensive or lipid-lowering medications. We 
added interaction terms to the models to test for study- and sex-dependent 
effects. 
Following regression analysis, SEM was performed with Mplus (version 
7).81 Covariance matrices of models were analyzed using the maximum likelihood 
(ML) method. Confirmatory factor analyses (CFA) established cardiac vagal activity
and immunometabolic risk latent variables. These latent variables were used to 
investigate possible mediating effects of cardiac vagal activity in the relationship
between depressive/anxious symptoms and immunometabolic risk, as well as
alternative mediation pathways. Model fit indices were compared across
alternative models. Because the c2-test is sensitive to negligible sources of ill fit in 
large samples using real-world data, we also used multiple alternative fit indices to 
evaluate model fit. Adequate fit corresponds with the root mean square error of
approximation (RMSEA) and its 90% confidence interval (CI) with values less than
.05, the comparative fit index (CFI) close to .95 or greater, and the standardized root
mean residual (SRMR) of less than .08.82 Analyses controlled for all a priori
covariates (age, sex, education, study, physical activity, alcohol use, smoking, 
presence/absence of medical conditions, use of antihypertensive or lipid-lowering
medications, and respiration rate).
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RESULTS 
Table 1 shows that participants in AHAB-1 (n=1295) had a mean age of 44.6 years 
(±6.7 SD), and were 52.7% female and 83.5% non-Hispanic Caucasian. Participants 
in AHAB-2 (n=490) had a mean age of 42.8 years (±7.3 SD), with 52.9% females and 
81.8% non-Hispanic Caucasians.  
Regression analyses 
Table 2 shows associations of depressive and anxious symptoms with 
immunometabolic risk factors. In the first adjusted model, higher CES-D scores 
were associated with higher IL-6 (β=.055; p=.029), and higher STAI-T scores were 
associated with higher triglyceride levels (β=.050; p=.030). In addition, higher BDI-
II scores were associated with higher triglycerides (β=.064; p=.005), glucose 
(β=.064; p=.006), waist circumference (β=.058; p=.007), BMI (β=.056; p=.018), CRP 
(β=.063; p=.013) and IL-6 (β=.066; p=.008) levels. After full covariate adjustments, 
the associations between BDI-II scores and triglyceride (β=.055; p=.016), glucose 
(β=.051; p=.028), waist circumference (β=.059; p=.005), BMI (β=.064; p=.006), and 
IL-6 levels (β=.049; p=.049) remained significant.  
Table 3 shows that, of the depressive/anxious symptom scales, only a 
higher BDI-II score was statistically associated with a lower HF-HRV (model 1: β=-
.066; p=.003, and model 2: β=-.062; p=.006), LF-HRV (model 1: β=-.049; p=.031, and 
model 2: β=-.046; p=.046), SDNN (model 1: β=-.050; p=.031, and model 2: β=-.046; 
p=.049), and MSD (model 1: β=-.077; p=.001, and model 2: β=-.073; p=.002).  
Table 4 shows that all HRV variables were associated with almost all 
immunometabolic components in both the first and second adjusted models. 
After full adjustment, lower HF-HRV was associated with higher triglyceride (β=-
.060; p=.011) and glucose (β=-.055; p=.022) levels. Lower LF-HRV was associated 
with higher triglycerides (β=-.070; p=.002), glucose (β=-.063; p=.008), waist 
circumference (β=-.055; p=.011), and BMI (β=-.061; p=.010). Lower SDNN and 
lower MSD were associated with higher triglycerides (SDNN: β=-.108; p<.001, and 
MSD: β=-.113; p<.001), SBP (SDNN: β=-.062; p=.009, and MSD: β=-.061; p=.011), 
glucose (SDNN: β=-.096; p<.001, and MSD: β=-.099; p<.001), insulin (SDNN: β=-
.091; p<.001, and MSD: β=-.128; p<.001), waist circumference (SDNN: β=-.082; 
p<.001, and MSD: β=-.087; p<.001), BMI (SDNN: β=-.084; p=.001, and MSD: β=-.075; 
p=.002), and CRP (SDNN: β=-.066; p=.014, and MSD: β=-.089; p=.001). Lower MSD 
was also associated with lower HDL cholesterol (β=.059; p=.008). 
Psychopathology and immunometabolic risk: the role of cardiac vagal activity     193
Table 1. Sample characteristics 
Variables n AHAB 1 n AHAB 2 
Sociodemographics 
Age, years (mean±SD) 1295 44.6±6.7 490 42.8±7.3 
Female (%) 1295 52.7 490 52.9 
Education, years (mean±SD) 1295 15.7±2.8 490 16.9±2.9 
 Non-Hispanic Caucasion (%) 1295 83.5 490 81.8 
Lifestyle & Health 
Physical activity, 1000kcal/week 
(mean±SD) 
1295 2.4±1.8 490 2.8±2.1 
Alcohol use, drinks/week (median(IQR)) 1295 2.0 (1.0 – 4.0) 490 1.0 (0.0 – 4.0) 
Smokers (%) 1295 14.5 490 12.4 
 Number of smoked cigarettes/day 
(median(IQR)) 
1295 13.0 (6.0 – 20.0) 490 6.4 (1.7 – 10.0) 
Presence of medical conditions (%) 1295 40.3 490 30.4 
Use of antihypertensive/lipid-lowering 
medication (%) 
1295 9.8 490 0.4 
Physiological measures 
Heart rate, beats/min (mean±SD) 1246 65.0±9.3 478 69.0±10.9 
HF-HRV (median(IQR)) 1246 316.1 (149.8 – 619.9) 478 262.9 (108.7 – 615.9) 
LF-HRV (median(IQR)) 1246 228.8 (115.2 – 415.4) 478 183.0 (101.9 – 415.8) 
SDNN (median(IQR)) 1246 41.8 (31.5 – 54.3) 478 38.5 (28.3 – 53.3) 
MSD (median(IQR)) 1246 24.8 (16.9 – 35.0) 478 21.8 (12.9 – 34.1) 
Respiration rate, breaths/min (mean±SD) 1246 15.9±2.2 478 16.0±2.5 
Mental health 
CES-D (median(IQR)) 1285 6.0 (2.0 – 11.0) 484 6.0 (3.0 – 12.0) 
BDI-II (median(IQR)) 1285 3.0 (0.5 – 6.0) 490 3.0 (1.0 – 7.0) 
STAI-T (median(IQR)) 1270 30.0 (25.0 – 37.0) 484 31.0 (26.0 – 38.0) 
Presence of current mood/anxiety 
disorder (%) 
1295 13.1 490 2.0 
Immunometabolic risk factors 
   Triglycerides, mg/dl (median(IQR)) 1270 98.0 (71.8 – 145.0) 485 91.0 (65.0 – 131.0) 
   HDL cholesterol, mg/dl (mean±SD) 1270 53.5±14.6 485 55.9±15.0 
   SBP, mm Hg (mean±SD) 1270 116.4±13.5 485 115.1±11.2 
   DBP, mm Hg (mean±SD) 1270 78.3±9.4 485 72.3±8.2 
   Glucose, mg/dl (median(IQR)) 1270 94.0 (88.0 – 101.0) 485 97.0 (91.0 – 104.0) 
   Insulin, µU/ml (median (IQR)) 1270 11.6 (8.6 – 15.8) 485 10.9 (9.0 – 13.7) 
   Waist circumference, cm (mean±SD) 1270 91.9±15.9 485 90.4±14.1 
   BMI, kg/m2 (mean±SD) 1270 27.4±5.7 485 26.9±5.2 
   CRP, ng/ml (median(IQR)) 1110 0.9 (0.5 – 2.1) 436 0.8 (0.4 – 1.7) 
   IL-6, pg/ml (median(IQR)) 1021 1.2 (0.8 – 2.0) 434 0.9 (0.6 – 1.3) 
Note: IQR = interquartile range. Kcal=kilocalories.  BMI= body mass index. HF-HRV = high-frequency heart rate 
variability. LF-HRV = low-frequency heart rate variability. SDNN = standard deviation of normal to normal R-R 
intervals. MSD = the mean of absolute and successive differences in inter-beat intervals. CES-D = Center for 
Epidemiologic Studies Depression Scale. BDI-II = Beck Depression Inventory-II. STAI-T = Trait Anxiety scale of 
the State-Trait Anxiety Inventory. HDL = high density lipoprotein. SBP = systolic blood pressure. DBP = diastolic 
blood pressure. BMI = body mass index. CRP = C-reactive protein. IL-6 = interleukin-6. 
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Table 2. The relationship between depressive/anxious symptoms with immunometabolic risk factors 
Immunometabolic risk factors 
Triglycerides HDL cholesterol SBP Glucose 
Depression/anxietyscale n β p β p β p β p 
CES-Da 1739 .036 .12 -.008 .71 -.009 .71 .043 .064 
CES-Db .026 .25 -.020 .34 -.015 .50 .025 .28 
BDI-IIa 1745 .064 .005 -.012 .57 -.005 .83 .064 .006 
BDI-IIb .055 .016 -.020 .35 -.008 .74 .051 .028 
STAI-Ta 1727 .050 .030 -.025 .24 -.028 .21 .025 .29 
STAI-Tb .032 .15 -.027 .20 -.037 .10 .005 .82 
Note: HDL = high density lipoprotein. SBP = systolic blood pressure. BMI = body mass index. CRP = C-reactive protein.  
II. STAI-T = Trait Anxiety scale of the State-Trait Anxiety Inventory. aRegression analyses were adjusted for age, sex
presence/absence of medical conditions, and use of antihypertensive or lipid-lowering medications.
Table 4. The relationship between HRV and immunometabolic risk factors 
Immunometabolic risk factors 
Triglycerides HDL cholesterol SBP Glucose 
HRV n β p β p β p β p 
HF-HRVa  1696 -.069 .005 .031 .17 -.027 .26 -.060 .015 
HF-HRVb -.060 .011 .024 .27 -.024 .31 -.055 .022 
LF-HRVa 1696 -.079 .001 .021 .33 -.014 .55 -.064 .008 
LF-HRVb -.070 .002 .007 .73 -.014 .55 -.063 .008 
SDNNa 1696 -.124 <.001 .047 .036 -.068 .004 -.104 <.001 
SDNNb -.108 <.001 .033 .14 -.062 .009 -.096 <.001 
MSDa 1696 -.130 <.001 .071 .002 -.066 .006 -.107 <.001 
MSDb -.113 <.001 .059 .008 -.061 .011 -.099 <.001 
Note: HDL = high density lipoprotein. SBP = systolic blood pressure. BMI = body mass index. CRP = C-reactive protein. IL-6 =  
variability. SDNN = standard deviation of normal to normal R-R intervals. MSD = the mean of absolute and successive differences  
+ additionally adjusted for smoking, alcohol use, physical activity, presence/absence of medical conditions, and use of 
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Immunometabolic risk factors 
Insulin Waist BMI CRP IL-6
β p β p β p n β p n β p 
.014 .55 .034 .11 .031 .19 1534 .044 .084 1443 .055 .029 
.020 .40 .030 .16 .032 .17 .027 .29 .038 .13 
.023 .34 .058 .007 .056 .018 1539 .063 .013 1448 .066 .008 
.032 .17 .059 .005 .064 .006 .049 .057 .049 .049 
.008 .73 .015 .48 .008 .75 1522 .039 .13 1431 .044 .080 
.009 .69 .004 .86 .002 .92 .024 .36 .024 .34 
IL-6 = interleukin-6. CES-D = Center for Epidemiologic Studies Depression Scale. BDI-II = Beck Depression Inventory 
education, race and study. bAdjustmenta + additionally adjusted for smoking, alcohol use, physical activity,  
Immunometabolic risk factors 
Insulin Waist BMI CRP IL-6 
β p β p β p n β p n β p 
.052 .039 .045 .050 .052 .040 1491 -.036 .19 1403 -.010 .71 
.048 .051 .038 .088 .046 .060 -.033 .22 -.004 .87 
.051 .038 .063 .005 .067 .006 1491 -.048 .069 1403 .024 .36 
.045 .065 .055 .011 .061 .010 -.046 .080 .027 .30 
.102 <.001 .097 <.001 .097 <.001 1491 -.072 .008 1403 .002 .95 
.091 <.001 .082 <.001 .084 .001 -.066 .014 .010 .69 
.138 <.001 .104 <.001 .089 <.001 1491 -.094 .001 1403 -.057 .033 
.128 <.001 .087 <.001 .075 .002 -.089 .001 -.047 .077 
interleukin-6. HRV = heart rate variability. HF-HRV = high-frequency heart rate variability.  LF-HRV = low-frequency heart rate  
in inter-beat intervals. aRegression analyses were adjusted for age, sex, education, race, study, and respiration rate. bAdjustmenta 
antihypertensive or lipid-lowering medications.  
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Structural equation modeling 
BDI-II was the only scale associated with immunometabolic risk factors and HRV. 
Accordingly, mediation analysis by SEM was restricted to this scale. We established 
a latent variable putatively reflecting cardiac vagal activity including HF-HRV, LF-
HRV, SDNN, and MSD. Within this model, we allowed LF-HRV and SDNN to covary 
in order to account for the putative and additional sympathetic nervous system 
contributions to these variables relative to the other variables of presumptive 
cardiac vagal control comprising the latent factor.28,65 By this latter approach, we 
thus interpret the remaining (residual) contributions of the indicators to the 
derived latent factor as predominantly vagal in origin hereafter. We also add here 
that additional SEMs were executed without LF-HRV as a facet of the cardiac vagal 
latent variable. The results of the latter models were compatible with those 
presented here (results available on request). A latent factor for immunometabolic 
risk was established by a second-order factor model with five first-order factors 
having two indicators each: dyslipidemia (triglycerides and HDL), blood pressure 
(SBP and DBP), insulin resistance (glucose and insulin), adiposity (waist 
circumference and BMI), and inflammation (CRP and IL-6). After adjusting for all 
covariates, the model fit the data well (c2(82)=251.83, p<.001; RMSEA=.039, 90% CI 
[.033, .044]; CFI=.99; SRMR=.016). The mediation analysis showed a total (β=.074, 
p=.018, 95% CI [.012, .135]) and direct (β=.062, p=.047, 95% CI [.001, .123]) 
association between BDI-II and immunometabolic risk. In addition, a relationship 
was found between a higher BDI-II and lower cardiac vagal activity (β=-.056, 
p=.036), and between lower cardiac vagal activity and higher immunometabolic 
risk (β=-.207, p<.001). Congruently, there was an indirect effect of cardiac vagal 
activity on the association between BDI-II and immunometabolic risk (β=.012, 
p=.046, 95% CI [.000, .023]), providing cross-sectional evidence for statistical 
mediation. A graphical depiction of this model is shown in Figure 1.  
In alternative SEMs, we tested for several other indirect pathways. Model 
fit was comparatively poorer (for RMSEA, CFI, and SRMR) for pathways where BDI-
II was treated as the mediator (vagal activity→BDI-II→immunometabolic risk: 
c2(126)=1172.72, p<.001; RMSEA=.077, 90% CI [.073, .081]; CFI=.93; SRMR=.050; 
immunometabolic risk→BDI-II→ vagal activity: c2(192)=2390.51 p<.001; 
RMSEA=.091, 90% CI [.088, .094]; CFI=.86; SRMR=.073), as well as where BDI-II was 
treated as an outcome variable (vagal activity →immunometabolic risk→BDI-II: 
c2(126)=1172.72, p<.001; RMSEA=.077, 90% CI [.073, .081]; CFI=.93; SRMR=.050; 
immunometabolic risk→ vagal activity →BDI-II: c2(192)=2390.51 p<.001; 
RMSEA=.091, 90% CI [.088, .094]; CFI=.86; SRMR=.073). 
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Finally, there was equivocal evidence that immunometabolic risk vs. vagal 
activity were most appropriately modeled as outcome or mediator variables when 
BDI-II scores were modeled as the predictor. Hence, model fit indices were 
essentially equivalent between our hypothesized a priori model tested above 
(cardiac vagal activity as mediator) and an alternative model wherein 
immunometabolic risk was modeled as a statistical mediator of the association 
between BDI-II scores and cardiac vagal activity (indirect effect: β=-.015, p=.021, 
95% CI [-.028, -.002]; model fit: c2(82)=251.83, p<.001; RMSEA=.039, 90% CI [.033, 
.044]; CFI=.99; SRMR=.016). 
In aggregate, these findings indicate that depressive symptoms (BDI-II 
scores) may be better modeled as predictors and not as mediators or outcome 
variables in association with immunometabolic risk and cardiac vagal activity. In 
addition, immunometabolic risk and cardiac vagal activity appeared to be 
equivalently modeled as mediators and outcome variables (see Discussion).   
Additional analyses 
Secondary analyses tested whether the patterns of association differed between 
AHAB cohorts (1 and 2); however, interaction terms coding for cohort did not reach 
statistical significance. 
We also tested for sex differences in the pattern of associations reported 
above. First, regression analyses with an interaction term for sex indicated that the 
relationships between some HRV metrics and immunometabolic components 
differed between men and women. Hence, stratified analyses (reported in 
Supplementary Tables 1 and 2) showed that the direction of the effects was 
similar for men and women, but some effect sizes were comparatively greater in 
men. We then used multi-group SEMs to examine whether our mediation models 
were significantly moderated by sex, but found no evidence that this was the case.  
Because the ability of HRV metrics to index cardiac autonomic or vagal 
activity may be associated with the prevailing heart rate,83 we re-executed the 
SEMs with HRV variables corrected for the mean IBI (the reciprocal of heart rate) as 
described by Van Roon and colleagues.84 The indirect effects in the models with 
cardiac vagal activity (β=.009, p=.051, 95% CI [.000, .017]) and immunometabolic 
risk (β=-.011, p=.030, 95% CI [-.021, -.001]) as mediators were not appreciably 
altered, suggesting that the present findings were not plausibly attributable to 
individual differences in basal heart rate (i.e., mean IBI).  
In addition, further analyses tested the possible influence of current 
diagnoses of a mood or anxiety disorder. After statistically controlling for or 
excluding people with current mood or anxiety disorder diagnoses (n=137), the 
total, direct, and indirect effects of the SEMs did not reach statistical significance.
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DISCUSSION 
The current study builds on prior work by providing evidence for cross-
sectional associations between depressive symptoms, as measured by the BDI-II, 
and greater immunometabolic dysregulation among otherwise healthy and 
largely un-medicated community dwelling adults. Additional novel findings 
suggest that lower cardiac vagal activity may partly explain the association 
between higher BDI-II scores and immunometabolic risk. However, alternate 
statistical mediation testing likewise suggested the possibility that higher BDI-
II scores may relate to lower cardiac vagal activity via an immunometabolic 
pathway. 
The finding of a relationship between depressive symptoms and reduced 
HRV in our predominantly antidepressant-naïve sample is notable, as previous 
studies have suggested that it is mainly antidepressant use that may drive 
this relationship.35–40 For instance, within the large cohort of the Netherlands Study of 
Depression and Anxiety, Licht and colleagues85 found antidepressant use to 
strongly attenuate the relationship between major depressive disorder and HRV. 
However, a small significant association remained after adjusting for antidepressants. 
Our results add to evidence that, although antidepressants have been shown to 
play an important part, depressive symptoms might also be independently 
associated with autonomic dysregulation apart from pharmacological influences 
among otherwise healthy individuals.86  
These results are partly in line with previous findings from AHAB-1 by Bleil 
et al.,33 showing that trait negative affect was inversely associated with HF-HRV. In 
contrast to our results, the authors found significant associations of both depressive 
and anxious symptoms with suppressed HF-HRV. An important difference with the 
current study is that Bleil and colleagues used latent factors composed of 
several depressive (CES-D, BDI-II, and the Depression facet scale of the NEO 
Personality Inventory-Revised) and anxious symptom scales (the STAI-T, the 
anxiety facet scale of the NEO Personality Inventory-Revised, and the Harm 
Avoidance scale of the Temperament and Character Inventory), obscuring the 
effects of the separate scales as identified here. Although there was a high 
correlation (.75) between the depression scales in the current study, our 
results indicate that there is a considerable difference between these scales, as we 
found significant effects for the BDI-II, but not for the CES-D. A high correlation does 
not necessarily imply that scales measure the same construct, as high convergent 
validity can be achieved between scales that capture very different symptom profiles 
that are only minimally related.87 Indeed, it has been shown that the mean 
overlap among seven common depression scales is low, with the CES-D standing 
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out in terms of idiosyncratic items (e.g. it captures items such as ‘people were 
unfriendly’ or ‘I felt that people disliked me’ that are not commonly understood to 
belong to symptoms of depression and do not appear in other scales) and lesser 
overlap (0.27 compared to a mean overlap of 0.36 among the other scales included 
in the study).87 Similarly, the null-findings in the relationship between anxious 
symptoms with HRV, in contrast to results of Bleil and colleagues, might be due to 
differences in used anxiety questionnaires, as discrepancies in items may impact 
the measured construct.88 Importantly, the Trait Anxiety scale of the STAI measures 
the general (dispositional) propensity to experience states of anxiety, as opposed 
to the BDI-II and the CES-D, which measure actual depressive symptoms 
experienced or reported over a recent period. The trait versus state issue might 
bear on explanations for why the STAI-T did not parallel the BDI-II findings. Finally, 
we examined a broader range of HRV metrics than Bleil and colleagues. These 
somewhat divergent results emphasize the need for careful attention to specific 
scale items and questionnaires and call attention to the need for a symptom-based 
approach to better understand which characteristics of depression and anxiety are 
truly associated with systemic physiology, particular autonomic metrics, and 
negative health outcomes.  
Ample research has established the relationship between depression and 
immunometabolic risk factors,9–11,14–17 while evidence for anxiety is less 
reproducible.18–27 We confirmed the association between higher BDI-II scores and 
metabolic factors and indicators of systemic inflammation. Again, we did not find 
significant associations between immunometabolic risk and the CES-D or the STAI-
T, possibly due to the measured constructs in these questionnaires, as discussed 
above. Accordingly, discrepancies in anxiety scales might contribute to the general 
lack of convergent evidence for a possible relationship between anxious 
symptoms and immunometabolic dysregulation. It might also be that comorbid 
depressive symptoms partly account for some previously observed associations 
with indicators of anxiety. 
In line with previous studies, HRV was associated with almost all 
immunometabolic risk factors.41–60 Interestingly, HF-HRV – a presumptive indicator of 
cardiac vagal control – showed less consistent associations with immunometabolic 
components than the other measures. A possible explanation is that these 
measures, especially SDNN and LF-HRV, although likely reflecting vagal 
contributions in resting humans, have been shown to be influenced by the 
sympathetic nervous system as well.28 Indeed, sympathetic activity has been 
suggested to track with immunometabolic components.59,89 However, we interpret 
the findings regarding LF-HRV with caution, as this measure is regarded as 
ambiguous with respect to precise influences from sympathetic, parasympathetic, 
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and other complex neurophysiological determinants.65 This caution is only 
warranted for the individual analyses with LF-HRV, because the latent variable 
derived from all HRV measures, as used in the SEM, would likely have extracted 
only their shared and presumptive cardiac vagal component. A future direction in 
this line of work would therefore be to test the relative specificity or consistency of 
different HRV metrics and non-HRV measures of autonomic function to associate 
with parameters of immune and metabolic physiology individually or in aggregate 
in longitudinal or related experimental designs.  
The mediation analysis implemented by SEM suggested that the 
association between depressive symptoms and immunometabolic risk may be 
partly explained by suppressed cardiac vagal activity. A potential mechanism of 
action for such a putative pathway is that psychological distress accompanying 
depressive mood states leads to neuroendocrine or central autonomic outflow 
alterations, affecting autonomic outflow in the periphery.90 In turn, such 
autonomic dysregulations across multiple organ and physiological systems could 
plausibly modulate glucose and fat metabolism,91,92 liver metabolism,93 and 
virtually all other components of daily energy expenditure.94 In addition, previous 
studies on the autonomic nervous system and inflammation suggest that higher 
vagal activity may exert an anti-inflammatory effect by inhibiting the production 
of pro-inflammatory cytokines, the so-called cholinergic anti-inflammatory 
pathway.95 When vagal activity is low, the lack of cholinergic inhibition may lead to 
increased systemic inflammation, which appears consistent with prior work 
indicating an inverse association between several metrics of HRV and 
inflammatory markers.96,97 Although autonomic pathways are plausible 
biologically, there may be other mechanisms that explain the link between 
depression and immunometabolic dysregulations or a bidirectional association 
between autonomic activity and immune or metabolic physiology.9 Indeed, the 
existence of other underlying mechanisms is supported by a significant direct 
pathway between depressive symptoms and immunometabolic risk in our study.  
In extension, when testing other candidate pathways, all but one 
mediation model had comparatively poorer fit than our a priori model where 
cardiac vagal activity was treated as a statistical mediator. This exception was a 
model where immunometabolic risk was treated as a mediator between 
depressive symptoms and vagal control, which had an essentially identical model 
fit. The plausibility of such a pathway is supported by research indicating that 
metabolic, preclinical vascular disease, and immune factors may influence 
autonomic function.98 In addition, it is possible that metrics of HRV and 
components of immunometabolic risk may be best conceptualized or considered 
as indicators of a broader, aggregate, and correlated (non-independent) clustering 
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of systemic risk factors that mutually influence one another through bidirectional 
or feedback pathways. Moreover, depressive symptomatology might exhibit 
parallel effects on autonomic and immunometabolic dysregulations that unfold 
simultaneously. The present cross-sectional findings provide an empirical basis for 
future longitudinal, mechanistic, or interventional work designed to adjudicate 
between the above possibilities.    
Additional findings merit consideration and inform the interpretation of 
the possible pathways linking depressive symptoms to suppressed cardiac vagal 
activity and immunometabolic risk. First, as the ability of HRV to index autonomic 
or vagal activity may be influenced by the prevailing heart rate,83 we performed 
additional analyses with HRV measures corrected for the reciprocal of heart rate 
(the mean of the inter-beat interval; IBI). These analyses suggested that the 
observed mediation pathways were not solely dependent on individual 
differences in mean heart rate (or IBI). This is the first such observation to our 
knowledge, and thus adds support for the use of HRV metrics in this area of 
research. Second, we examined possible interactive effects with sex using multi-
group SEM models. We found no statistical evidence for moderation by sex. Third, 
the observed indirect effect (mediation pathway) for both models did not reach 
statistical significance after controlling for/excluding individuals with current 
mood or anxiety disorder diagnoses. Indeed, BDI-II scores were higher among 
individuals with a current mood or anxiety disorder diagnosis (mean=8.1, SE=7.4; 
n=137) compared to those without evident psychopathology (mean=3.7, SE=4.1; 
N = 1251). The latter pattern of results may suggest the influence of a restricted 
range of variance or clinical threshold effects. 
Findings from the present study should be interpreted within the context 
of its strengths and limitations. Strengths include our relatively large sample of 
otherwise healthy community dwelling adults without confounding pathologies 
and the measurement of many relevant confounding biological, behavioral, and 
demographic factors. In addition, this is one of few studies to perform mediation 
analyses in this field. Notwithstanding, this is a cross-sectional study, and therefore 
we cannot draw causal inferences. As noted above, alternative mediation 
pathways are possible and longitudinal and interventional studies are needed to 
shed more light on questions of causality. In addition, although we adjusted for 
many potential confounders, we cannot rule out residual confounding by variables 
that have not been measured. Finally, participants comprising the AHAB registries 
may not reflect a generalizable sample. In aggregate, these participants exhibited 
comparatively less demographic, racial, and ethnic variability than other 
epidemiological, clinical, and community samples in this literature. Moreover, 
exclusionary criteria (e.g., use of psychotropic medications, unemployment, etc.) 
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may have restricted variability in mood-related symptoms. As a result, observed 
effect sizes may under- or mis-estimate the magnitude of associations at the 
population level or may vary depending on sample characteristics in future 
research.  
Overall, our study found a relationship between depressive symptoms as 
measured by the BDI-II and immunometabolic risk. Our results suggest that 
reduced cardiac vagal activity may be in the pathway between symptoms of 
depression and immunometabolic dysregulation. However, alternate statistical 
mediation testing also suggested that depressive symptoms may relate to low 
cardiac vagal activity via an immunometabolic pathway, as well as the possibility 
that cardiac autonomic or vagal activity and immunometabolic factors are not 
necessarily dissociable as clustered or inter-related risk factors. Research 
investigating pre-clinical pathways between mental health and cardiovascular 
outcomes are important for the development of intervention and prevention 
strategies. Future (longitudinal), interventional, and nonhuman mechanistic 
animal studies are warranted to confirm our findings and adjudicate between 
different possible models, to further explore the effects of different depressive and 
anxious symptom dimensions, and to determine temporal ordering of the 
observed associations in association with cardiovascular disease risk. 
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Supplementary table 1. The relationship between cardiac vagal activity HRV and immunometabolic risk factors in men 
Immunometabolic risk factors 
Triglycerides HDL cholesterol SBP Glucose 
HRV n β p β p β p β p 
HF-HRVa  807 -.090 .016 .080 .034 .022 .55 -.068 .065 
HF-HRVb -.081 .027 .078 .034 .023 .53 -.071 .053 
LF-HRVa 807 -.086 .016 .061 .092 -.009 .80 -.073 .040 
LF-HRVb -.076 .030 .046 .19 -.012 .72 -.076 .031 
SDNNa 807 -.156 <.001 .119 .001 -.058 .11 -.133 <.001 
SDNNb -.136 <.001 .104 .004 -.052 .16 -.128 <.001 
MSDa 807 -.190 <.001 .170 <.001 -.047 .21 -.144 <.001 
MSDb -.167 <.001 .159  <.001 -.040 .28 -.137 <.001 
Note: HDL = high density lipoprotein. SBP = systolic blood pressure. BMI = body mass index. CRP = C-reactive protein. IL-6 =  
variability. SDNN = standard deviation of normal to normal R-R intervals. MSD = the mean of absolute and successive differences  
+ additionally adjusted for smoking, alcohol use, physical activity, presence/absence of medical conditions, and use of 
Supplementary table 2. The relationship between cardiac vagal activity HRV and immunometabolic risk factors in women 
Immunometabolic risk factors 
Triglycerides HDL cholesterol SBP Glucose 
HRV n β p β p β p β p 
HF-HRVa  889 -.049 .16 .010 .78 -.060 .071 -.052 .13 
HF-HRVb -.040 .24 -.002 .96 -.055 .091 -.044 .19 
LF-HRVa 889 -.071 .035 -.016 .64 -.019 .55 -.045 .18 
LF-HRVb -.061 .064 -.034 .30 -.013 .68 -.035 .29 
SDNNa 889 -.088 .011 .002 .96 -.077 .021 -.068 .051 
SDNNb -.077 .024 -.010 .77 -.073 .027 -.060 .076 
MSDa 889 -.088 .011 .031 .37 -.077 .020 -.078 .024 
MSDb -.075 .026 .019 .57 -.074 .024 -.072 .031 
Note: HDL = high density lipoprotein. SBP = systolic blood pressure. BMI = body mass index. CRP = C-reactive protein. IL-6 =  
variability. SDNN = standard deviation of normal to normal R-R intervals. MSD = the mean of absolute and successive differences  
+ additionally adjusted for smoking, alcohol use, physical activity, presence/absence of medical conditions, and use of 
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Immunometabolic risk factors 
Insulin Waist BMI CRP IL-6 
β p β p β p n β p n β p 
-.048 .20 -.102 .005 -.122 .001 718 -.030 .44 673 -.010 .79 
-.049 .18 -.103 .004 -.125 .001 -.033 .40 -.008 .82 
-.055 .13 -.102 .004 -.131 <.001 718 -.040 .29 673 .051 .16 
-.048 .18 -.099 .004 -.134 <.001 -.040 .29 .054 .13 
-.128 .001 -.188 <.001 -.216 <.001 718 -.078 .043 673 .009 .82 
-.114 .002 -.174 <.001 -.209 <.001 -.076 .048 .013 .74 
-.157 <.001 -.214 <.001 -.208 <.001 718 -.085 .031 673 -.073 .056 
-.144 <.001 -.197 <.001 -.198 <.001 -.088 .024 -.074 .051 
interleukin-6. HRV = heart rate variability. HF-HRV = high-frequency heart rate variability.  LF-HRV = low-frequency heart rate  
in inter-beat intervals. aRegression analyses were adjusted for age, sex, education, race, study, and respiration rate. bAdjustmenta 
antihypertensive or lipid-lowering medications.  
Immunometabolic risk factors 
Insulin Waist BMI CRP IL-6 
β p β p β p n β p n β p 
-.051 .14 -.002 .95 -.005 .88 773 -.037 .33 730 -.006 .87 
-.043 .21 .010 .75 .006 .85 -.028 .46 .006 .87 
-.046 .17 -.011 .73 .004 .89 773 -.056 .12 730 -.015 .67 
-.034 .29 .002 .95 .018 .59 -.047 .19 -.004 .90 
-.072 .038 -.011 .75 .005 .89 773 -.061 .10 730 -3.4E-4 .99 
-.064 .057 .003 .94 .017 .62 -.051 .17 .014 .70 
-.121 <.001 -.035 .30 -.016 .64 773 -.099 .008 730 -.039 .30 
-.113 .001 -.019 .57 -.001 .97 -.085 .023 -.016 .66 
interleukin-6. HRV = heart rate variability. HF-HRV = high-frequency heart rate variability.  LF-HRV = low-frequency heart rate  
in inter-beat intervals. aRegression analyses were adjusted for age, sex, education, race, study, and respiration rate. bAdjustmenta 
antihypertensive or lipid-lowering medications.  
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SUMMARY OF MAIN FINDINGS 
This thesis aimed to unravel the role of cardiac autonomic activity in the pathway 
from poor mental health to CVD risk, with specific focus on influences of 
antidepressant use, genetics, and lifestyle.  
In Chapter 2, we showed within NESDA (n=2183) that persons with 
depression and anxiety had a hyporeactivity of HR, RMSSD, and RSA compared to 
controls during the n-back task, a cognitively challenging stressor. In contrast, 
during the psychiatric interview, a personal-emotional stressor, they showed a 
hyperreactivity of these measures. No significant differences were found in PEP 
reactivity.  
In Chapter 3, findings within NESDA (n=1383) suggested that persons 
with depression and anxiety do not show a significantly different TWA or QTc, two 
measures of cardiac repolarization, compared to controls. In addition, 
antidepressant use was not associated with a lower TWA or a prolonged QTc.  
In Chapter 4, NESDA results across a nine-year follow-up period (no. 
observations = 6994) indicated that cardiac autonomic dysregulation was not 
phenotypically or genetically associated with depression and anxiety across 
waves. No evidence was found for moderation by polygenic risk scores for high HR 
and low HRV on the relationship of cardiac autonomic activity with depression and 
anxiety. In contrast, a robust association was found between antidepressant use 
and cardiac autonomic activity across all waves. This association was not 
moderated by a genetic risk for high HR or low HRV.  
In Chapter 5, we combined baseline (n=2618) and 2-year follow-up 
(n=2010) data from NESDA and showed that high physical activity, high frequency 
of sport activities and mild/moderate alcohol use were related to low HR. Heavy 
smoking was related to high HR. High frequency of sport activities was associated 
with high RSA and moderate smoking with longer PEP. Furthermore, 2-year 
change in frequency of sport activities and number of smoked cigarettes/day was 
accompanied by 2-year change in HR. 
Chapter 6 used NESDA data from baseline (n=2379), 2- (n=2245), and 6-
year (n=1876) follow-up, and indicated that temporal stability was good for HR, 
excellent for RSA, and moderate for PEP over 2 years. Stability decreased for a 4- 
and 6-year interval. The most important determinants for increase in HR were 
(increase in) smoking, increase in body mass index (BMI) and (starting) the use of 
antidepressants. Beta-blocking/antiarrhythmic drug use led to a decrease in HR. 
Decrease in RSA was associated with age, smoking and (starting) antidepressant 
use. Decrease in PEP was associated with age and (increase in) BMI.  
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In Chapter 7, 2- (n=1922) and 6-year (n=1616) data from NESDA 
suggested that higher basal HR, lower basal values of RSA and PEP, and higher RSA 
reactivity during cognitive challenge were cross-sectionally related to less 
favorable values of almost all metabolic components. Longitudinal analyses 
showed that higher basal HR and shorter basal PEP predicted 4-year increase in 
many metabolic abnormalities. Higher RSA stress reactivity during cognitive 
challenge predicted 4-year increase in number of metabolic components.  
In Chapter 8, NESDA results from baseline (n=2823), 2-year (n=2099), and 
6-year (n=1774) data, showed that higher HR and lower RSA were cross-sectionally 
associated with higher inflammatory levels. Higher HR predicted higher levels of 
C-reactive protein (CRP) and interleukin(IL)-6 at follow-up. Higher CRP levels
predicted lower RSA at follow-up. NTR results confirmed that higher HR was 
associated with higher CRP and IL-6 levels 5 years later (n=356). In contrast to
NESDA results, higher IL-6 levels predicted higher HR and lower RSA at follow-up 
(n=472).
Finally, in Chapter 9, we demonstrated within AHAB (n=1785) that higher 
Beck Depression Inventory-II (BDI-II) scores were associated with increased 
metabolic and inflammatory dysregulations and decreased HRV. Decreased HRV 
was also associated with increased metabolic and inflammatory dysregulations. 
Structural equation models indicated that BDI-II scores may relate to metabolic 
and inflammatory dysregulations via cardiac vagal activity or to vagal activity via 
metabolic and inflammatory dysregulations. No significant results were found for 
the Center for Epidemiological Studies Depression Scale (CES-D) or the State-Trait 
Anxiety Inventory (STAI-T). 
DISCUSSION OF MAIN FINDINGS 
Is poor mental health associated with cardiac autonomic dysregulation? 
Basal cardiac autonomic activity 
There has been considerable debate on the nature of the relationship between 
poor mental health and cardiac autonomic dysregulation. Most of these studies 
have been conducted with basal levels of cardiac autonomic activity measured 
during a rest or neutral condition, as opposed to autonomic reactivity during 
stressful tasks. Within nine-year longitudinal data from NESDA and multiple waves 
of data, we found little evidence that depressive and anxiety disorders are 
independently associated with basal levels of cardiac autonomic activity (Chapter 
2, 4, 6). This is in line with previous studies conducted within NESDA,1–4 as well as 
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with other studies.5–8 However, up until now the literature remains ambiguous, as 
there are also studies that suggest there is a direct association of depression and 
anxiety with autonomic dysregulation.9–13 These inconsistent findings are possibly 
due to disorder heterogeneity and discrepant control of confounding factors. That 
this may be the case is illustrated by one of our own studies that attempted to 
replicate NESDA findings within AHAB, a general population study (Chapter 9). For 
this study, we only found the BDI-II – but not the CES-D – to be significantly 
associated with HRV. We hypothesize that these scales may capture different 
symptom profiles. For instance, it has been suggested that the CES-D may not be 
specific for depression, but may be a measure of general distress.14 Additionally, in 
contrast to the BDI-II, the CES-D includes some idiosyncratic items, such as ‘people 
were unfriendly’ or ‘I felt that people disliked me’, and does not specifically address 
suicidal ideation.14,15 These findings stress the possibility that disorder 
heterogeneity and the use of different metrics may be an important factor causing 
the ambiguous findings in this field. Despite this possibility, we find it difficult to 
reconcile the contradicting findings in AHAB with NESDA results. The significant 
results within AHAB may be a chance finding, as only one of two depression scales 
was cross-sectionally associated with HRV, while within NESDA there is rather 
consistent longitudinal evidence that depressive and anxiety disorders are not 
directly related to cardiac autonomic dysregulation. In conclusion, although there 
might be a direct association between poor mental health and basal cardiac 
autonomic activity, we find more evidence suggesting that this association is 
negligible. Hence, we sought for other mechanisms through which depression and 
anxiety may be associated with the autonomic nervous system.  
 
 
Cardiac autonomic stress reactivity and cardiac repolarization  
It is possible that, instead of the most commonly investigated variables of basal 
cardiac autonomic activity, there may be other aspects of autonomic activity that 
are altered in depression and anxiety and in part explain the association with CVD 
risk, such as stress reactivity or cardiac repolarization.  
 Regarding stress reactivity, previous studies have suggested both 
hyporeactivity16–23 and hyperreactivity24–28 in depression and anxiety. When we 
investigated whether persons with depression and anxiety showed a differential 
autonomic stress reactivity compared to controls, we found that the direction of 
the effect depended on the type of stressor (Chapter 2). For measures of HR and 
We did not find strong, consistent evidence for a direct association of 
depression and anxiety with basal levels of cardiac autonomic activity. 
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HRV, a hyporeactivity was seen for a cognitively challenging stressor, whereas a 
hyperreactivity was seen for a personal-emotional stressor related to the 
occurrence of symptoms of depression and anxiety. We hypothesize that people 
with depression and anxiety show disengagement from commitments to difficult 
to reach goals29,30 and may be less motivated31,32 to perform well in a cognitively 
challenging task, explaining the resulting hyporeactivity in our study. These 
findings are in line with research by Brinkmann and Gendolla33 indicating that 
dysphoric participants showed lower systolic blood pressure reactivity than non-
dysphoric participants when facing a difficult cognitive task. In contrast, our 
second stressor – a psychiatric interview during which participants described 
depressing and anxious events – may better capture the experiences of the 
personal-emotional stress that especially people with depression and anxiety 
experience in daily life, resulting in a heightened stress reactivity in patients 
compared to controls. However, no significant differences were found for PEP, 
suggesting that sympathetic stress reactivity is less affected in depression and 
anxiety. In addition, the found differences in the reactivity of the other measures 
were rather small. More structured stress tasks eliciting a stronger response should 
be tested to confirm a true differential effect of personal-emotional stress in 
persons with depression and anxiety compared to controls. Nonetheless, our study 
implies that, in contrast to basal cardiac autonomic activity, a modest differential 
autonomic stress reactivity is associated with depression and anxiety. The direction 
of the altered stress reactivity seems to be dependent on the type of stressor: only 
the more ecologically valid stressors may evoke hyperreactivity in patients with 
depression and/or anxiety.  
 
 
 
Studies investigating the association between poor mental health and cardiac 
autonomic activity have often neglected measures of cardiac repolarization, such 
as TWA and QTc. These measures are affected by sympathetic activity and 
associated with cardiac morbidity and mortality.34,35 Therefore, a relationship 
between depressive/anxiety disorder with TWA and QTc may explain part of the 
comorbidity between poor mental health and CVD. However, when we 
investigated these relationships, we did not find evidence for their existence 
(Chapter 3). Our findings are in line with research by Kamphuis and colleagues,36 
indicating that there were no significant associations between QTc and depressive 
People with depression and anxiety show differences in cardiac 
autonomic stress reactivity compared to healthy controls. 
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symptoms, and with previous NESDA research claiming that depressive and 
anxiety disorders do not directly influence sympathetic activity.2 In short, 
depressive and anxiety disorders are likely not associated with measures of cardiac 
repolarization.  
Confounding or moderating influences of antidepressant use, genetic risk, and lifestyle 
Poor mental health may not be directly associated with basal cardiac autonomic 
dysregulation, but there are many factors that can explain why this relationship is 
often found in the literature. Here we discuss our findings for confounding or 
moderating effects of antidepressant use, genetic risk, and lifestyle.  
As mentioned before, the most important debate revolves around 
findings from several studies indicating that the relationship between poor mental 
health and cardiac autonomic activity might be attributable to antidepressant 
use.5,6,8 Indeed, we found antidepressant use to be robustly associated with cardiac 
autonomic activity across nine-year longitudinal data (Chapter 4 & 6). In line with 
previous NESDA studies across shorter time spans,2,3 we found a detrimental effect 
on cardiac autonomic activity of TCA use, followed by SNRI use, and SSRI use. The 
latter might even have a slightly beneficial effect on sympathetic activity. It is 
interesting to note that, in spite of their known sympathomimetic effects, we did 
not find TCA and SNRI use to be associated with measures of cardiac repolarization 
(Chapter 3). These findings may be explained by the biological knowledge that 
different mechanisms of cardiac autonomic activity are in play concerning these 
measures.37 Nonetheless, this thesis adds to the increasing evidence that virtually 
all antidepressants negatively affect cardiac autonomic activity.5,38 Although the 
mechanisms through which they do so are not entirely understood, it is thought 
that antidepressants influence relay nuclei of the parasympathetic nervous system 
in the brain stem,39 inhibit cardiac vagal tone by exerting anticholinergic activity,40 
and/or inhibit the reuptake of norepinephrine in the heart.41  
Despite the compelling evidence that antidepressant use explains a large 
part of the relationship of depression and anxiety with cardiac autonomic 
dysregulation, this is still disputed by studies that found lowered HRV in 
unmedicated patients with psychiatric disorders.9–11 Hence, we entertained the 
possibility of the existence of an as yet unaccounted for factor that moderates the 
relationship of depression and anxiety with cardiac autonomic dysregulation, such 
as a genetic vulnerability. An example of a gene-by-exposure interaction regarding 
Persons with depression and anxiety show no differences in cardiac 
repolarization compared to healthy controls. 
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cardiac autonomic activity has been demonstrated by twin studies finding that 
genetic effects contributing to cardiac autonomic traits at rest become stronger 
under stress.42–44 Because depressive and anxiety disorders are associated with 
high levels of stress, we expected that these psychiatric disorders might also 
interact with genetic risk for cardiac autonomic dysregulation. The presence of 
such an interaction effect may explain the ambiguous findings in this field, as 
studies might have applied exclusion criteria that inadvertently selected samples 
with differential genetic risk for cardiac autonomic dysregulation. However, when 
investigating this, we did not find evidence for a gene-by-exposure interaction 
effect (Chapter 4). We conclude that genetic moderation does not explain 
discrepant findings in the literature regarding the association of depression and 
anxiety with cardiac autonomic activity.  
In the absence of genetic moderation, previous findings of a significant 
relationship of cardiac autonomic dysregulation with depression and anxiety likely 
resulted from other confounding factors, including lifestyle. In the next chapters of 
this thesis, we investigated the association between several lifestyle factors on 
cardiac autonomic activity. These studies showed that high physical activity, 
moderate alcohol use, and non-smoking had a positive effect on cardiac 
autonomic activity (Chapter 5). Factors contributing to cardiac autonomic 
deterioration over time were older age, (increase in) smoking and BMI, and 
(starting) the use of antidepressants. (Starting) the use of cardiac medication, in 
contrast, improved cardiac autonomic activity (Chapter 6). The influences of the 
majority of these factors are well-established in the literature45–52 and our results 
stress the importance of taking them into account when researching the 
association of depression and anxiety with cardiac autonomic activity. This holds 
true especially when comparing a psychiatric sample with healthy controls, as 
many of these factors are known to differ between these populations.53,54  
Is cardiac autonomic dysregulation associated with CVD risk factors? 
As NESDA includes a rather young sample, the incidence of CVD was too low to 
investigate the association of cardiac autonomic dysregulation with cardiovascular 
morbidity and mortality. However, we had access to an abundance of data on 
known CVD risk factors: metabolic syndrome components55 and inflammatory 
The association of depression and anxiety with basal cardiac autonomic 
dysregulation is likely caused by confounding effects of antidepressant 
use and lifestyle, but not by genetic moderation.  
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markers.56,57 In addition, we were able to support the NESDA findings with results 
from two independent cohorts: NTR and AHAB. Within these studies, we confirmed 
previous findings of a strong cross-sectional association of cardiac autonomic 
dysregulation with metabolic (Chapter 7 & 9) and inflammatory (Chapter 8 & 9) 
components.58–78 Longitudinally, higher sympathetic activity predicted increases 
in metabolic dysregulations over time. Unfortunately, at that time, the data was 
not available to test reverse associations. For inflammatory markers, we were able 
to investigate bidirectional prospective associations, and found that high HR 
predicted subsequent higher levels of CRP and IL-6. Some evidence was found that 
inflammatory markers might also predict future cardiac autonomic activity, but 
these findings were less consistent. Longitudinal studies aimed at disentangling 
directionality between these biological systems are scarce, but some of them 
suggest, in line with the current findings, that autonomic dysfunction may precede 
metabolic abnormalities79,80 and increased levels of systemic inflammation.81 It is 
thought that the autonomic nervous system may impact on the metabolic 
syndrome and systemic inflammation by modulating glucose, fat, and liver 
metabolism,82–84 and through the cholinergic anti-inflammatory pathway: the 
neural mechanism that inhibits the inflammatory response by vagal acetylcholine 
secretion.71,74,85 However, according to some studies, reverse causality between 
autonomic activity and immune or metabolic physiology is also plausible.81,86 Or 
perhaps these systems may be best conceptualized as indicators of a broader, 
aggregate, and correlated clustering of systemic risk factors that mutually 
influence one another through bidirectional or feedback pathways. The findings in 
this thesis provide an empirical basis for future work designed to adjudicate 
between the above possibilities.  
   
 
 
Is cardiac autonomic activity in the pathway from poor mental health to CVD risk? 
This question, the holy grail of this thesis, is remarkably difficult to answer. When 
we formally tested this question within AHAB (Chapter 9), the answer was: yes, 
perhaps cardiac vagal activity is a mediator in the pathway from depressive 
symptoms to CVD risk factors. However, these results only held for BDI-II scores in 
contrast to the CES-D, suggesting that these depression scales capture different 
symptom profiles14,15 that are differentially related to biological systems. In 
addition, our results suggest that the found pathway is not fully explanatory and 
that there may be other underlying mechanisms, as a significant direct pathway 
Cardiac autonomic dysregulations are robustly associated with and 
predictive for CVD risk factors over time.  
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remained between depressive symptoms and CVD risk factors. Furthermore, as 
cross-sectional data was used, how can we establish the temporal ordering of this 
pathway? Indeed, alternate statistical mediation testing also suggested that 
cardiovascular risk factors may be in the pathway from depressive symptoms to 
low cardiac vagal activity. Model fit was comparatively poorer for pathways where 
depressive symptoms were treated as the mediator or outcome variable. The latter 
finding is in contrast to results of the Whitehall II study, suggesting that cardiac 
autonomic dysregulations may precede onset of depression rather than the other 
way around.12 As illustrated in the previous paragraph, observational studies – 
even within a longitudinal design – are limited as they do not allow for a definitive 
statement of causality. The question of temporal ordering, however, is almost an 
inconsiderable issue compared to the contrary findings within NESDA, suggesting 
that depressive and anxiety disorders are not even cross-sectionally associated 
with cardiac autonomic activity. Sample heterogeneity, methodological discrepancies, 
and lurking confounding factors, despite the best efforts to control for them, will always 
affect studies of an observational nature. Future interventional and mechanistic 
studies are warranted to shed more light on the question whether cardiac 
autonomic activity is in the pathway from poor mental health to CVD risk. But to 
indulge the faithful reader of this thesis, who has come all this way to seek an 
answer, I will provide my own speculative notions: poor mental health may lead to 
cardiovascular disease risk, perhaps through increased cardiac autonomic stress 
reactivity, and/or through antidepressants and lifestyle factors that influence basal 
cardiac autonomic activity, and/or through other mechanisms that are not a 
consequence of autonomic activity.  
METHODOLOGICAL CONSIDERATIONS 
This thesis is mainly based on NESDA: one of the largest and longest followed 
cohorts with data on mental health, cardiac autonomic activity, and metabolic and 
inflammatory components. One of the strengths of NESDA is the use of DSM-IV 
based clinical diagnoses of depression and anxiety, allowing for the investigation 
of more severe mental health problems compared to general population studies 
based on depressive or anxious symptomatology. Another major strength is that 
we had data on multiple waves, enabling us to verify the consistency of our 
findings. Furthermore, we used two renowned studies to replicate and extend our 
Real knowledge is to know the extent of one’s ignorance ~ Confucius  
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results within NESDA: NTR and AHAB. Despite the richness of these databases, 
there are some general limitations that ought to be considered.  
First, methodological differences compromise the comparability between 
the studies. In contrast to the population-based NTR and AHAB studies, NESDA was 
designed to include a large sample of people with (a history of) depression and/or 
anxiety. In addition to sample discrepancies, there are differences in data-
collection between the studies, as confounding factors have been measured 
differently and cardiac autonomic variables were recorded in various ways. 
Regarding the latter, data for NTR was collected during 24-hours of a regular day, 
data for NESDA was assessed during a 100-min recording of several conditions in 
a laboratory setting, and data for AHAB was assessed with a different device during 
a 5-min rest period. One could argue that the NTR data is more ecologically valid 
but also more prone to interpersonal variability than the NESDA data. In turn, 
NESDA data may be more susceptible to interpersonal variability than AHAB data, 
as the different laboratory conditions may have caused a different physiological 
response in some individuals compared to others. However, the combined 
findings of the three studies allowed us to investigate whether the pattern 
of results in this thesis holds across diverse settings. 
As NESDA is the main source of data for the articles in this thesis, the 
following limitations are solely directed to this dataset. Cardiac autonomic 
measures were recorded during several conditions, but not during a true rest 
condition, rendering these measures prone to all sources of variability. 
Contrariwise, measurement of cardiac autonomic activity during rest or laboratory 
conditions may not be as ecologically valid as 24-hour measurements in real life, 
which presumably more reliably predict future disease.87 However, Chapter 6 
showed that the average of the conditions has good temporal stability for HR and 
RSA, suggesting that we have assessed robust and reliable variables. PEP showed 
a substantially lower temporal stability, possibly due to the difficulty in the scoring 
of ICG wave forms and the use of different raters. These factors might have 
contributed to some of the null-findings for PEP.  
Many of the measured variables, such as lifestyle and the presence of 
disease, are based on self-report, which are more prone to inaccuracy and bias than 
objective measures. However, data was available on cotinine levels at baseline and 
these levels showed strong correlations with self-reported number of smoked 
cigarettes/day, enhancing our confidence in the reliability and validity of the used 
lifestyle measures. In addition, previous research has shown that self-reported 
disease and general practitioners information are in good agreement.88 
Finally, as mentioned before, all of the studies in this thesis are based on 
observational data. Although prospective studies provide a better stab at causality 
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than cross-sectional studies, they are still imperfect. For instance, many 
confounders can influence a relationship and it is not possible to properly control 
for all of them. If these confounders affect the predictor and outcome variables at 
different time points in life, this can create the false impression of causality. These 
and other factors that may influence the results of observational studies warrant 
caution when making any inferences about directionality in this thesis.  
CLINICAL IMPLICATIONS 
Like many other biological measures, the effect sizes found for cardiac autonomic 
activity in most of our studies are rather modest and not suitable as a clinically 
useful marker of a dysfunctional stress system on the level of an individual. 
However, cardiac autonomic activity can be non-invasively and unobtrusively 
measured and has shown adequate validity and stability in research. On a 
population level, cardiac autonomic dysregulation may be considered as an early 
warning sign for serious somatic problems later on, and knowledge about factors 
that influence changes in this system are important for prevention and 
intervention strategies. Our research contributed to the increasing evidence that 
poor lifestyle and antidepressant use, both important consequences of depression 
and anxiety, affect cardiac autonomic dysregulation, which on its turn is associated 
with increased CVD risk factors. The lack of evidence for a direct relationship gives 
hope that depressive and anxiety disorders do not inevitably lead to cardiac 
autonomic dysregulations, but that this association may be broken by 
interventions targeting modifiable risk factors, such as lifestyle. Moreover, the 
robust findings of detrimental effects of antidepressant use on cardiac autonomic 
activity ought to be taken into account by clinicians, especially when treating 
patients with poor cardiovascular health. For these patients, prescription of SSRIs 
may be preferable to TCAs or SNRIs, and physical health should be monitored as 
thoroughly as mental health. Better yet, other therapy options should be explored 
that render less adverse side effects.   
FUTURE DIRECTIONS 
Like this thesis ‘stands on the shoulder of giants’, the hope is that future research 
can build upon the knowledge gathered in this thesis. A magnifying glass can be 
taken to look closely at disorder heterogeneity and symptomatology and their 
relationship with different aspects of cardiac autonomic (re)activity. More 
longitudinal research can be performed, investigating long-term bidirectional 
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effects of autonomic, metabolic, and inflammatory systems on one another. In 
addition, long-term studies may determine the association of these systems with 
incident CVD. More (replication) studies are needed to examine the role of genetic 
risk and genetic correlation in the relationship between poor mental health and 
autonomic, metabolic, and inflammatory dysregulations in larger samples. Such 
research will provide us with stronger empirical evidence for the (absent) causal 
associations considered in this thesis. A next step is to attempt to verify or falsify 
these observations by conducting experiments. Such experiments may include 
intervention studies, much like the MOod Treatment with Antidepressant or 
Running (MOTAR) study – currently being conducted by our research group – that 
compares the effect of antidepressant use versus exercise on mental and physical 
health, including cardiac autonomic activity. Intervention studies will be better 
able to answer questions of causality than observational studies. But if we really 
want to understand the role of the autonomic nervous system in the association 
between poor mental health and CVD, we will have to adopt a mechanistic 
approach. For instance, what are the exact effects of specific antidepressants? 
What effects do they exert on receptors, neurotransmitters, cells, organs, and 
systems? Can we deepen our understanding about the mechanisms through 
which the autonomic nervous system influences the metabolic and inflammatory 
systems and vice versa? Can we further identify genetic variants for basal 
autonomic tone and stress-induced reactivity and unravel their specific biological 
functional impact to really answer questions of causality? Such studies may proof 
invaluable for informing preventive interventions, pharmaceutical manufacturing, 
and treatment strategies that genuinely make a difference in a society burdened 
with mental and cardiovascular health issues.  
CONCLUDING REMARKS 
This thesis adds to the evidence that depressive and anxiety disorders are not associated 
with basal cardiac autonomic dysregulation, and that previous found associations may 
have been caused by confounding effects of lifestyle and antidepressant use. As robust 
associations are established between cardiac autonomic dysregulation and CVD risk 
factors, studies investigating factors that have detrimental or beneficial influences on the 
autonomic nervous system are paramount for clinical practice and public health. 
As many a song, this thesis revolves around the heart. The autonomic nervous system is 
to the heart as a maestro is to the orchestra – when conducting badly, the heart will suffer, 
but when conducting well, it may beat in harmony. 
226
REFERENCES 
1  Licht CMM, De Geus EJC, Zitman FG, Hoogendijk WJG, Van Dyck R, Penninx BWJH. Association 
between major depressive disorder and heart rate variability in the Netherlands Study of 
Depression and Anxiety (NESDA). Arch Gen Psychiatry 2008; 65: 1358–1367. 
2  Licht CMM, Penninx BWJH, De Geus EJC. Effects of antidepressants, but not psychopathology, 
on cardiac sympathetic control: a longitudinal study. Neuropsychopharmacology 2012; 37: 
2487–2495. 
3  Licht CMM, De Geus EJC, van Dyck R, Penninx BWJH. Longitudinal evidence for unfavorable 
effects of antidepressants on heart rate variability. Biol Psychiatry 2010; 68: 861–868. 
4  Licht CMM, De Geus EJC, Van Dyck R, Penninx BWJH. Association between anxiety disorders 
and heart rate variability in The Netherlands Study of Depression and Anxiety (NESDA). 
Psychosom Med 2009; 71: 508–518. 
5  O’Regan C, Kenny RA, Cronin H, Finucane C, Kearney PM. Antidepressants strongly influence 
the relationship between depression and heart rate variability: findings from The Irish 
Longitudinal Study on Ageing (TILDA). Psychol Med 2015; 45: 623–636. 
6  Davidson J, Watkins L, Owens M. Effects of paroxetine and venlafaxine XR on heart rate 
variability in depression. J Clin Psychopharmacol 2005; 25: 480–484. 
7  Udupa K, Thirthalli J, Sathyaprabha T. Differential actions of antidepressant treatments on 
cardiac autonomic alterations in depression: A prospective comparison. Asian J Psychiatr 
2011; 4: 100–106. 
8  Noordam R, Van den Berg ME, Niemeijer MN, Aarts N, Hofman A, Tiemeier H et al. 
Antidepressants and heart-rate variability in older adults: a population-based study. Psychol 
Med 2015; 46: 1239–1247. 
9  Yeh TC, Kao LC, Tzeng NS, Kuo TBJ, Huang SY, Chang CC et al. Heart rate variability in major 
depressive disorder and after antidepressant treatment with agomelatine and paroxetine: 
findings from the Taiwan Study of Depression. Prog Neuro-Psychopharmacology Biol 
Psychiatry 2016; 64: 60–67. 
10  Kemp AH, Quintana DS, Felmingham KL, Matthews S, Jelinek HF. Depression, Comorbid 
Anxiety Disorders, and Heart Rate Variability in Physically Healthy, Unmedicated Patients: 
Implications for Cardiovascular Risk. PLoS One 2012; 7: e30777. 
11  Alvares GA, Quintana DS, Hickie IB. Autonomic nervous system dysfunction in psychiatric 
disorders and the impact of psychotropic medications: a systematic review and meta-analysis. 
J psychiatry Neurosci 2016; 41: 89–104. 
12  Jandackova VK, Britton A, Malik M, Steptoe A. Heart rate variability and depressive symptoms: 
a cross-lagged analysis over a 10-year period in the Whitehall II study. Psychol Med 2016; 46: 
2121–2131. 
13  Brown L, Karmakar C, Gray R, Jindal R, Lim T, Bryant C. Heart rate variability alterations in late 
life depression: A meta-analysis. J Affect Disord 2018; 235: 456–466. 
14  Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck Depression 
Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric 
Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health 
Questionna. Arthritis Care Res (Hoboken) 2011; 63: S454–S466. 
15  Fried EI. The 52 symptoms of major depression: Lack of content overlap among seven 
common depression scales. J Affect Disord 2017; 208: 191–197. 
16  Phillips AC, Hunt K, Der G, Carroll D. Blunted cardiac reactions to acute psychological stress 
predict symptoms of depression five years later: evidence from a large community study. 
Psychophysiology 2011; 48: 142–148. 
General discussion     227
17  Schmitz J, Tuschen-Caffier B, Wilhelm FH, Blechert J. Taking a closer look: autonomic 
dysregulation in socially anxious children. Eur Child Adolesc Psychiatry 2013; 22: 631–640. 
18  Brindle RC, Ginty AT, Conklin SM. Is the association between depression and blunted 
cardiovascular stress reactions mediated by perceptions of stress? Int J Psychophysiol 2013; 
90: 66–72. 
19  Fisher AJ, Newman MG. Heart rate and autonomic response to stress after experimental 
induction of worry versus relaxation in healthy, high-worry, and generalized anxiety disorder 
individuals. Biol Psychol 2013; 93: 65–74. 
20  York KM, Hassan M, Li Q, Li H, Fillingim RB, Sheps DS. Coronary artery disease and depression: 
patients with more depressive symptoms have lower cardiovascular reactivity during 
laboratory-induced mental stress. Psychosom Med 2007; 69: 521–528. 
21  Salomon K, Clift A, Karlsdóttir M, Rottenberg J. Major depressive disorder is associated with 
attenuated cardiovascular reactivity and impaired recovery among those free of 
cardiovascular disease. Heal Psychol 2009; 28: 157. 
22  Salomon K, Bylsma LM, White KE, Panaite V, Rottenberg J. Is blunted cardiovascular reactivity 
in depression mood-state dependent? A comparison of major depressive disorder remitted 
depression and healthy controls. Int J Psychophysiol 2013; 90: 50–57. 
23  Rottenberg J, Clift A, Bolden S, Salomon K. RSA fluctuation in major depressive disorder. 
Psychophysiology 2007; 44: 450–458. 
24  Hughes JW, Stoney CM. Depressed mood is related to high-frequency heart rate variability 
during stressors. Psychosom Med 2000; 62: 796–803. 
25  Sheffield D, Krittayaphong R, Cascio WE, Light KC, Golden RN, Finkel JB et al. Heart rate 
variability at rest and during mental stress in patients with coronary artery disease: differences 
in patients with high and low depression scores. Int J Behav Med 1998; 5: 31–47. 
26  Carney RM, Freedland KE, Veith RC. Depression, the autonomic nervous system, and coronary 
heart disease. Psychosom Med 2005; 67: S29–S33. 
27  Kibler JL, Ma M. Depressive symptoms and cardiovascular reactivity to laboratory behavioral 
stress. Int J Behav Med 2004; 11: 81–87. 
28  Light KC, Kothandapani R V, Allen MT. Enhanced cardiovascular and catecholamine responses 
in women with depressive symptoms. Int J Psychophysiol 1998; 28: 157–166. 
29  Nesse RM. Is depression an adaptation? Arch Gen Psychiatry 2000; 57: 14–20. 
30  Norem JK, Cantor N. Defensive pessimism: harnessing anxiety as motivation. J Pers Soc 
Psychol 1986; 51: 1208. 
31  Brackney BE, Karabenick SA. Psychopathology and academic performance: The role of 
motivation and learning strategies. J Couns Psychol 1995; 42: 456. 
32  Lonigan CJ, Carey MP, Finch AJ. Anxiety and depression in children and adolescents: negative 
affectivity and the utility of self-reports. J Consult Clin Psychol 1994; 62: 1000. 
33  Brinkmann K, Gendolla GHE. Does depression interfere with effort mobilization? Effects of 
dysphoria and task difficulty on cardiovascular response. J Pers Soc Psychol 2008; 94: 146. 
34  Okuda K, Watanabe E, Sano K, Arakawa T, Yamamoto M, Sobue Y et al. Prognostic Significance 
of T-Wave Amplitude in Lead aVR in Heart Failure Patients with Narrow QRS Complexes. Ann 
Noninvasive Electrocardiol 2011; 16: 250–257. 
35  Mozos I, Serban C. The relation between QT interval and T-wave variables in hypertensive 
patients. J Pharm Bioallied Sci 2011; 3: 339–44. 
36  Kamphuis MH, Geerlings MI, Dekker JM, Giampaoli S, Nissinen A, Grobbee DE et al. Autonomic 
dysfunction: a link between depression and cardiovascular mortality? The FINE Study. Eur J 
Prev Cardiol 2007; 14: 796–802. 
37  Van Lien R, Neijts M, Willemsen G, De Geus EJC. Ambulatory measurement of the ECG T-wave 
228
amplitude. Psychophysiology 2015; 52: 225–237. 
38  Kemp AH, Brunoni AR, Santos IS, Nunes MA, Dantas EM, Carvalho de Figueiredo R et al. Effects 
of Depression, Anxiety, Comorbidity, and Antidepressants on Resting-State Heart Rate and Its 
Variability: An ELSA-Brasil Cohort Baseline Study. Am J Psychiatry 2014; 171: 1328–1334. 
39  Raul L. Serotonin2 Receptors in the Nucleus Tractus Solitarius: Characterization and Role in 
the Baroreceptor Reflex Arc. Cell Mol Neurobiol 2003; 23: 709–726. 
40  Lavretsky H, Lesser IM, Wohl M, Miller BL. Relationship of age, age at onset, and sex to 
depression in older adults. Am J Geriatr Psychiatry 1998; 6: 248–56. 
41  Esler MD, Hasking GJ, Willett IR, Leonard PW, Jennings GL. Noradrenaline release and 
sympathetic nervous system activity. J Hypertens 1985; 3: 117–29. 
42  De Geus EJC, Kupper N, Boomsma DI, Snieder H. Bivariate genetic modeling of cardiovascular 
stress reactivity: does stress uncover genetic variance? Psychosom Med 2007; 69: 356–364. 
43  Neijts M, Van Lien R, Kupper N, Boomsma D, Willemsen G, De Geus EJC. Heritability and 
Temporal Stability of Ambulatory Autonomic Stress Reactivity in Unstructured 24-Hour 
Recordings. Psychosom Med 2015; 77: 870–881. 
44  Wang X, Ding X, Su S, Li Z, Riese H, Thayer JF et al. Genetic influences on heart rate variability 
at rest and during stress. Psychophysiology 2009; 46: 458–465. 
45  Rennie KL, Hemingway H, Kumari M, Brunner E, Malik M, Marmot M. Effects of moderate and 
vigorous physical activity on heart rate variability in a British study of civil servants. Am J 
Epidemiol 2003; 158: 135–143. 
46  Ohira T, Tanigawa T, Tabata M, Imano H, Kitamura A, Kiyama M et al. Effects of habitual alcohol 
intake on ambulatory blood pressure, heart rate, and its variability among japanese men. 
Hypertension 2009; 53: 13–19. 
47  Middlekauff HR, Park J, Moheimani RS. Adverse effects of cigarette and noncigarette smoke 
exposure on the autonomic nervous system: Mechanisms and implications for cardiovascular 
risk. J Am Coll Cardiol 2014; 64: 1740–1750. 
48  Molfino A, Fiorentini A, Tubani L, Martuscelli M, Rossi Fanelli F, Laviano A. Body mass index is 
related to autonomic nervous system activity as measured by heart rate variability. Eur J Clin 
Nutr 2009; 63: 1263–5. 
49  MacFadyen RJ. Aldosterone blockade reduces vascular collagen turnover, improves heart rate 
variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 
1997; 35: 30–34. 
50  Harada K, Nomura M, Nishikado A, Uehara K, Nakaya Y, Ito S. Clinical Efficacy of Efonidipine 
Hydrochloride, a T-type Calcium Channel Inhibitor, on Sympathetic Activities. Circ J 2003; 67: 
139–145. 
51  Pfeifer MA, Weinberg CR, Cook D, Best JD, Reenan A, Halter JB. Differential changes of 
autonomic nervous system function with age in man. Am J Med 1983; 75: 249–258. 
52  Aeschbacher S, Bossard M, Ruperti Repilado FJ, Good N, Schoen T, Zimny M et al. Healthy 
lifestyle and heart rate variability in young adults. Eur J Prev Cardiol 2016; 23: 1037–1044. 
53  Penninx BWJH. Depression and cardiovascular disease: Epidemiological evidence on their 
linking mechanisms. Neurosci Biobehav Rev 2017; 74: 277–286. 
54  Molarius A, Berglund K, Eriksson C, Eriksson HG, Lindén-Boström M, Nordström E et al. Mental 
health symptoms in relation to socio-economic conditions and lifestyle factors – a population-
based study in Sweden. BMC Public Health 2009; 9: 302. 
55  Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and 
management of the metabolic syndrome: an American Heart Association/National Heart, 
Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–52. 
56  Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–1428. 
General discussion     229
57  Marsland AL, McCaffery JM, Muldoon MF, Manuck SB. Systemic Inflammation and the 
Metabolic Syndrome among Middle-aged Community Volunteers. Metabolism 2010; 59: 
1801. 
58  Koskinen T, Kähönen M, Jula A, Mattsson N, Laitinen T, Keltikangas-Järvinen L et al. Metabolic 
syndrome and short-term heart rate variability in young adults. Diabet Med 2009; 26: 354–
361. 
59  Min K-B, Min J-Y, Paek D, Cho S-I. The Impact of the Components of Metabolic Syndrome on 
Heart Rate Variability: Using the NCEP-ATP III and IDF Definitions. Pacing Clin Electrophysiol 
2008; 31: 584–591. 
60  Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW et al. Multiple metabolic 
syndrome is associated with lower heart rate variability: the Atherosclerosis Risk in 
Communities Study. Diabetes Care 1998; 21: 2116–2122. 
61  Kimura T, Matsumoto T, Akiyoshi M, Owa Y, Miyasaka N, Aso T et al. Body fat and blood lipids 
in postmenopausal women are related to resting autonomic nervous system activity. Eur J 
Appl Physiol 2006; 97: 542–547. 
62  Licht CMM, Vreeburg SA, Van Reedt Dortland AKB, Giltay EJ, Hoogendijk WJG, DeRijk RH et al. 
Increased sympathetic and decreased parasympathetic activity rather than changes in 
hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin 
Endocrinol Metab 2010; 95: 2458–2466. 
63  Vrijkotte TGM, Van den Born B-JH, Hoekstra CMCA, Gademan MGJ, Van Eijsden M, De Rooij SR 
et al. Cardiac Autonomic Nervous System Activation and Metabolic Profile in Young Children: 
The ABCD Study. PLoS One 2015; 10: e0138302. 
64  Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M et al. Adrenocortical, 
autonomic, and inflammatory causes of the metabolic syndrome nested case-control study. 
Circulation 2002; 106: 2659–2665. 
65  Ljung T, Holm G, Friberg P, Andersson B, Bengtsson B, Svensson J et al. The activity of the 
hypothalamic-pituitary-adrenal axis and the sympathetic nervous system in relation to 
waist/hip circumference ratio in men. Obes Res 2000; 8: 487–495. 
66  Stein PK, Barzilay JI, Domitrovich PP, Chaves PM, Gottdiener JS, Heckbert SR et al. The 
relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and 
the metabolic syndrome: the Cardiovascular Health Study. Diabet Med 2007; 24: 855–63. 
67  Grassi G, Dell’Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F et al. Neuroadrenergic 
and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359–
65. 
68  Licht CMM, De Geus EJC, Penninx BWJH. Dysregulation of the autonomic nervous system 
predicts the development of the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 
2484–2493. 
69  Carney RM, Freedland KE, Stein PK, Miller GE, Steinmeyer B, Rich MW et al. Heart rate variability 
and markers of inflammation and coagulation in depressed patients with coronary heart 
disease. J Psychosom Res 2007; 62: 463–7. 
70  Lampert R, Bremmer JD, Su S, Miller A, Lee F, Cheema F et al. Decreased heart rate variability 
is associated with higher levels of inflammation in middle-aged men. Am Heart J 2008; 156: 
759.e1-7. 
71  Cooper TM, McKinley PS, Seeman TE, Choo TH, Lee S, Sloan RP. Heart rate variability predicts 
levels of inflammatory markers: Evidence for the vagal anti-inflammatory pathway. Brain 
Behav Immun 2015; 49: 94–100. 
72  Haensel A, Mills PJ, Nelesen RA. The relationship between heart rate variability and inflammatory 
markers in cardiovascular diseases. Psychoneuroendocrinology 2008; 33: 1305–1312. 
230
73  Tateishi Y, Oda S, Nakamura M, Watanabe K. Depressed heart rate variability is associated with 
high IL-6 blood level and decline in the blood pressure in septic patients. Shock 2007; 28: 549–
553. 
74  Thayer JF. Vagal tone and the inflammatory reflex. Cleve Clin J Med 2009; 76: 23–26. 
75  Haarala A, Kähönen M, Eklund C, Jylhävä J, Koskinen T, Taittonen L et al. Heart rate variability 
is independently associated with C-reactive protein but not with Serum amyloid A. The 
Cardiovascular Risk in Young Finns Study. Eur J Clin Invest 2011; 41: 951–957. 
76  Kon H, Nagano M, Tanaka F, Satoh K, Segawa T, Nakamura M. Association of Decreased 
Variation of R-R Interval and Elevated Serum C-Reactive Protein Level in a General Population 
in Japan. Int Heart J 2006; 47: 867–876. 
77  Araújo F, Antelmi I, Pereira AC, Latorre M do RDO, Grupi CJ, Krieger JE et al. Lower heart rate 
variability is associated with higher serum high-sensitivity C-reactive protein concentration in 
healthy individuals aged 46 years or more. Int J Cardiol 2006; 107: 333–337. 
78  Aeschbacher S, Schoen T, Dörig L, Kreuzmann R, Neuhauser C, Schmidt-Trucksäss A et al. Heart 
rate, heart rate variability and inflammatory biomarkers among young and healthy adults. 
Ann Med 2017; 49: 32–41. 
79  Wulsin L, Herman J, Thayer JF. Stress, autonomic imbalance, and the prediction of metabolic 
risk: A model and a proposal for research. Neurosci Biobehav Rev 2018; 86: 12–20. 
80  Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma 
norepinephrine concentrations predict subsequent weight gain and blood pressure 
elevation. Hypertension 2003; 42: 474–80. 
81  Singh P, Hawkley LC. Autonomic tone and C-reactive protein: a prospective population-based 
study. Clin Auton Res 2009; 19: 367–374. 
82  Romijn J, Fliers E. Sympathetic and parasympathetic innervation of adipose tissue: metabolic 
implications. Curr Opin Clin Nutr Metab Care 2005; 8: 440–444. 
83  Kyrou I, Tsigos C. Stress hormones: physiological stress and regulation of metabolism. Curr 
Opin Pharmacol 2009; 9: 787–793. 
84  Yi C, Fleur S La, Fliers E, Kalsbeek A. The role of the autonomic nervous liver innervation in the 
control of energy metabolism. Biochim Biophys Acta - Mol Basis Dis 2010; 1802: 416–431. 
85  Tracey KJ. The inflammatory reflex. Nature 2002; 420: 853–9. 
86  Tentolouris N, Argyrakopoulou G, Katsilambros N. Perturbed autonomic nervous system 
function in metabolic syndrome. Neuromolecular Med 2008; 10: 169–178. 
87  Zanstra YJ, Johnston DW. Cardiovascular reactivity in real life settings: Measurement, 
mechanisms and meaning. Biol Psychol 2011; 86: 98–105. 
88  Kriegsman DMW, Penninx BWJH, Van Eijk JTM, Boeke AJP, Deeg DJH. Self-reports and general 
practitioner information on the presence of chronic diseases in community dwelling elderly: 
a study on the accuracy of patients’ self-reports. J Clin Epidemiol 1996; 49: 1407–1417. 
General discussion     231


ACHTERGROND 
 
Mensen met een depressie of angststoornis hebben een verhoogd risico op hart- 
en vaatziekten. Om dit verband te begrijpen en wellicht zelfs te kunnen 
doorbreken, is het belangrijk om de onderliggende mechanismes te onderzoeken. 
Het autonome zenuwstelsel is een van de systemen waarvan wordt gedacht dat 
het op de route ligt van slechte mentale gezondheid naar lichamelijke klachten.  
 Het autonome zenuwstelsel is betrokken bij de acute menselijke 
stressreactie en bestaat uit twee delen: het sympathisch deel en het 
parasympathisch deel. Het sympathische zenuwstelsel wordt geactiveerd door 
stressvolle en gevaarlijke situaties bedoeld om het lichaam klaar te maken voor 
actie, ook wel de ‘vecht of vlucht’ reactie genoemd. Dit zorgt voor een verhoogde 
hartslag, bloeddruk, pupilverwijding, ademhaling, zweetproductie en 
energieverdeling naar de spieren. Het parasympathische zenuwstelsel zorgt juist 
voor een toestand van rust en herstel, o.a. door activatie van de spijsvertering en 
verlaging van de hartslag en de bloeddruk. Omdat het autonome zenuwstelsel een 
groot effect heeft op het hart, wordt autonome activiteit vaak gemeten middels de 
werking van het hart. Één aspect van de hartwerking is natuurlijk de hartslag, maar 
er zijn veel meer aspecten, waarvan sommige meer beïnvloed worden door het 
sympathische zenuwstelsel en andere meer door het parasympathische 
zenuwstelsel. Om die reden kunnen wij in ons onderzoek een onderscheid maken 
tussen deze twee delen. Over het algemeen wordt gedacht dat een lagere 
sympathische activiteit en een hogere parasympathische activiteit gunstig is voor 
de mentale en fysieke gezondheid. 
 Het is aannemelijk dat depressie en angststoornissen – gekarakteriseerd 
door stress – kunnen leiden tot een ontregeling van het autonome zenuwstelsel – 
dat een grote rol speelt in de werking van het hart – en dat ontregeling van dit 
systeem kan leiden tot hart- en vaatziekten. Uit eerder onderzoek blijkt inderdaad 
dat mensen met een depressie of angststoornis een andere autonome activiteit in 
rust hebben dan mensen zonder die stoornissen. Echter, niet alle studies vinden 
dit verband en er blijven nog veel vragen onbeantwoord. Hoe zit het bijvoorbeeld 
met autonome reactiviteit gedurende een stressvolle situatie, is dat anders bij 
mensen met depressie en angst? En hoe zit het met repolarisatie van het hart (hoe 
snel en goed het hart terugkeert naar een rusttoestand)? Daar is ook weinig 
onderzoek naar gedaan. Daarbij zijn er veel factoren die de relatie tussen mentale 
gezondheid en het autonome zenuwstelsel kunnen verklaren of beïnvloeden, 
zoals antidepressivagebruik, genetische kwetsbaarheid en leefstijl. Er is meer 
onderzoek nodig naar de invloed van deze factoren.  
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Ook de relatie tussen het autonome zenuwstelsel en het risico op hart- en 
vaatziekten behoeft verder onderzoek. Er zijn veel studies gedaan naar het 
verband tussen autonome ontregeling en het metabool syndroom en verhoogde 
ontstekingswaarden (lichamelijke problemen die een verhoogd risico op hart- en 
vaatziekten aanduiden). Meestal werden deze studies op één tijdstip uitgevoerd, 
waardoor het niet duidelijk is wat de richting van het verband is: komt autonome 
ontregeling vóór het metabool syndroom/verhoogde ontstekingswaarden of vice 
versa? Onderzoek met meerdere metingen over de tijd zijn nodig om iets te 
kunnen zeggen over deze richting. Bovendien – terugkomend op de hoofdvraag – 
meer onderzoek moet uitwijzen of het autonome zenuwstelsel daadwerkelijk op 
de route ligt, en dus de relatie kan verklaren, tussen slechte mentale gezondheid 
en een verhoogd risico op hart- en vaatziekten.  
ONDERZOEKSPOPULATIES 
Dit proefschrift is voornamelijk gebaseerd op de Nederlandse Studie naar 
Depressie en Angst (NESDA), een longitudinale cohort studie gericht op het lange 
termijn beloop van depressie en angststoornissen. De NESDA populatie bestaat 
uit 2981 deelnemers met een leeftijd tussen de 18 en 65 jaar die op dit moment of 
in het verleden een depressie of angststoornis hadden, en een 
vergelijkingsgroep zonder deze psychiatrische stoornissen. De deelnemers zijn 
gerekruteerd vanuit de algemene populatie, eerstelijns zorg en gespecialiseerde 
geestelijke gezondheidsinstellingen in Nederland. De basismeting vond plaats 
tussen september 2004 en februari 2007 en vervolgmetingen vonden plaats na 
twee, vier, zes en negen jaar. De metingen werden uitgevoerd door speciaal 
getraind onderzoekspersoneel, waarbij een uitgebreid interview werd afgenomen, 
lichamelijk onderzoek werd gedaan en bloed- en speekselmonsters werden 
verzameld.  
Omdat NESDA voornamelijk uit mensen met een depressie en/of 
angststoornis bestaat, hebben we  naast NESDA twee algemene populatie studies 
gebruikt om een aantal bevindingen in dit proefschrift te bevestigen en verder te 
onderzoeken. Het Nederlandse Tweelingen Register (NTR) bestaat uit 828 
deelnemers waarvan er data beschikbaar is over het autonoom zenuwstelsel en 
ontstekingswaarden. De ‘Adult Health and Behavior’ (AHAB) studie bevat 
gedragsdata en biologische metingen van 1785 deelnemers.  
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ONDERZOEKSDOEL 
Het hoofddoel van dit proefschrift is om te onderzoeken wat de rol van het 
autonome zenuwstelsel is in de relatie tussen slechte mentale gezondheid en 
risico op hart- en vaatziekten, met een specifieke focus op invloeden van 
antidepressiva, genetica en leefstijl. Dit doel is opgedeeld in de volgende vragen: 
Is er een verband tussen slechte mentale gezondheid en autonome ontregeling 
(Hoofdstuk 2 – 6, 9)? Is er een verband tussen autonome ontregeling en risico op 
hart- en vaatziekten (Hoofdstuk 7 – 9)? En kan het autonome zenuwstelsel de 
relatie verklaren tussen slechte mentale gezondheid en een verhoogd risico op 
hart- en vaatziekten (Hoofdstuk 9)?   
HOOFDBEVINDINGEN 
Is er een verband tussen slechte mentale gezondheid en autonome ontregeling? 
In dit onderzoeksveld wordt veel discussie gevoerd over of er een direct 
verband bestaat tussen slechte mentale gezondheid en autonome activiteit in 
rust (zonder stress), of dat dit verband wordt verklaard door andere 
factoren, zoals antidepressivagebruik. Hoofdstuk 2, 4 & 6 laten zien dat binnen 
het negenjarige onderzoek in NESDA weinig bewijs is van een directe relatie 
tussen depressie en angststoornissen met autonome activiteit in rust. Echter, 
toen wij deze relatie onderzochten in de AHAB studie, vonden wij dat één 
van de twee gebruikte depressieschalen wel een verband liet zien met 
parasympathische activiteit (Hoofdstuk 9). Dit vinden wij moeilijk om te 
verklaren, maar we denken dat we in AHAB wellicht een toevalsbevinding 
hebben gehad. Kortom, er zou een direct verband kunnen zijn tussen slechte 
mentale gezondheid en het autonome zenuwstelsel in rust, maar het 
onderzoek in dit proefschrift suggereert dat dit verband verwaarloosbaar is.  
Hoe zit het met andere aspecten van autonome activiteit, zoals stress 
reactiviteit en repolarisatie van het hart? Zijn die anders in mensen met depressie 
of angst? In Hoofdstuk 2 hebben we binnen NESDA aangetoond dat mensen met 
een depressie en angststoornis over het algemeen een verminderde autonome 
stress reactiviteit hadden bij een cognitieve taak. Daarentegen vonden we een 
verhoogde stressreactiviteit bij een psychiatrisch interview dat mogelijk meer 
persoonlijke emotionele stress oproept. Onze hypothese is dat mensen met 
depressie en angst zich afsluiten voor doelen die moeilijk te bereiken zijn en 
wellicht minder gemotiveerd zijn om goed te presteren tijdens een cognitieve 
taak. Dit zou de verminderde stressreactiviteit verklaren. Tijdens het psychiatrische 
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interview beschrijven de deelnemers depressieve en angstige situaties. Dit zou, in 
tegenstelling tot een cognitieve taak, een meer waarheidsgetrouwe reflectie van 
stress zijn, die vooral psychiatrische patiënten in het dagelijks leven ervaren. 
Daarom denken wij dat deze stressor wel tot een verhoogde stressreactiviteit heeft 
geleid. We concluderen dat mensen met een depressie en angststoornis een 
andere autonome stressreactiviteit vertonen dan mensen zonder deze 
stoornissen. Repolarisatie van het hart bekeken we in Hoofdstuk 3. Uit NESDA-
bevindingen bleek dat deze maten hetzelfde waren voor mensen met een 
depressie en angststoornis vergeleken met mensen zonder deze stoornissen. 
Repolarisatie van het hart wordt beïnvloed door het sympathische zenuwstelsel. 
Dat we in deze studie geen verschil vinden, komt dus overeen met de eerdere 
conclusie dat depressie en angststoornissen geen directe relatie vertonen met het 
autonoom zenuwstelsel in rusttoestand.  
 Slechte mentale gezondheid is misschien niet direct verbonden met 
autonome ontregeling in rust, maar er zijn veel factoren die kunnen verklaren 
waarom dit verband wel vaak wordt gevonden. We bekeken de effecten van 
antidepressivagebruik, genetische kwetsbaarheid en leefstijl. Binnen NESDA 
vonden we dat antidepressivagebruik op alle tijdspunten gerelateerd was aan 
autonome ontregeling (Hoofdstuk 4 & 6). De grootste ontregeling werd 
veroorzaakt door het gebruik van de zwaardere, klassieke tricyclische 
antidepressiva (TCAs), gevolgd door serotonerg- en noradrenerg-werkende 
antidepressiva (SNRIs). Het kleinste, maar nog steeds slechte, effect vonden we 
voor de lichtere, moderne antidepressiva (serotonine heropname remmers 
(SSRIs)). Aangezien vooral mensen met een psychiatrische stoornis deze 
medicijnen nemen, zou antidepressivagebruik dus kunnen verklaren waarom veel 
studies depressieve en angstige stoornissen aan autonome ontregeling koppelen. 
Maar ook studies naar patiënten die deze medicijnen niet gebruiken, vinden het 
bovenstaande verband soms. Daarom zochten we naar meer verklarende factoren, 
zoals genetische kwetsbaarheid. Genen en omgeving beïnvloeden elkaar. In 
Hoofdstuk 4 was onze hypothese dat slechte mentale gezondheid vooral 
autonome ontregeling zou uitlokken in mensen die een genetisch hoger risico op 
autonome ontregeling hadden, en minder invloed zou hebben op de mensen 
zonder deze genetische kwetsbaarheid. Stel dat de ene studie veel mensen bevat 
met een genetische risico op autonome ontregeling en een andere studie juist 
minder. Dat zou kunnen verklaren waarom de eerste studie wel een direct verband 
vindt tussen depressie/angst en autonome activiteit en de tweede studie niet. 
Echter, ons onderzoek vond geen bewijs voor een dergelijke gen-
omgevingsinteractie. We zochten daarom verder naar verklarende factoren en 
onderzochten het effect van leefstijl. In Hoofdstuk 5 vonden we dat hoge fysieke 
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activiteit, gematigd alcoholgebruik en niet-roken een positief effect hadden op 
autonome activiteit. Factoren die bijdroegen aan een verslechtering van het 
autonome zenuwstelsel over de tijd waren (toename in) roken en BMI en 
(beginnen met) antidepressivagebruik. (Beginnen) met hartmedicatie zorgde juist 
voor verbetering van autonome activiteit (Hoofdstuk 6). Het is bekend dat 
mensen met een slechte mentale gezondheid vaak ook een slechte leefstijl 
hebben. Het is dus mogelijk dat depressie en angst niet op zichzelf leiden tot 
autonome ontregeling, maar dat de leefstijl die gepaard gaat met deze stoornissen 
dit verband veroorzaken.  
 
Is er een verband tussen autonome ontregeling en risico op hart- en vaatziekten? 
De bovenstaande vraag onderzochten we binnen NESDA, NTR en AHAB. 
Samengenomen lieten deze studies zien dat autonome ontregeling sterk 
verbonden was met het metabool syndroom (Hoofdstuk 7 & 9) en met verhoogde 
ontstekingswaarden (Hoofdstuk 8 & 9). Over de tijd heen, zagen we dat hogere 
sympathische activiteit voorspellend was voor een toename in metabole 
ontregeling. Het omgekeerde verband konden we destijds helaas niet bekijken. 
Het verband tussen autonome activiteit en ontstekingswaarden konden we wel in 
beide richtingen onderzoeken. Uit de resultaten bleek dat een hogere hartslag 
voorspellend was voor toekomstige hogere ontstekingswaarden. Het bewijs voor 
het omgekeerde verband (dat ontstekingswaarden voorspellend zijn voor 
autonome ontregeling), was minder sterk. Dit onderzoek geeft ons meer inzicht in 
de richting van de relatie tussen het autonome zenuwstelsel en risico op hart- en 
vaatziekten, maar meer onderzoek is nodig om echt iets te zeggen over oorzaak 
en gevolg.  
 
Kan het autonome zenuwstelsel de relatie verklaren tussen slechte mentale 
gezondheid en een verhoogd risico op hart- en vaatziekten? 
Deze vraag, de ‘heilige graal’ van dit proefschrift, is moeilijk om te beantwoorden. 
Toen we dit onderzochten in de AHAB studie in Hoofdstuk 9, was het antwoord: 
ja, misschien ligt autonome ontregeling in de weg van depressieve symptomen 
naar risico op hart- en vaatziekten. Echter, er zijn veel kanttekeningen bij deze 
bevinding te maken. We vonden deze resultaten bijvoorbeeld slechts voor één van 
de twee depressieschalen. Ook hebben we hierbij gebruik gemaakt van data 
gemeten op één tijdspunt en kunnen we daarom weinig zeggen over oorzaak en 
gevolg. Niet te vergeten dat we in NESDA überhaupt geen bewijs vonden voor een 
verband tussen slechte mentale gezondheid en het autonome zenuwstelsel. Het 
antwoord is dus: we weten het niet en er is meer (interventioneel en mechanistisch) 
onderzoek nodig. Omdat ik begrijp dat dit een erg onbevredigend antwoord is, zal ik 
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hier toch mijn gedachten opschrijven, met de kanttekening dat dit louter speculaties 
zijn: slechte mentale gezondheid zou kunnen leiden tot risico op hart- en vaatziekten, 
misschien door verhoogde autonome stressreactiviteit en/of via antidepressivagebruik 
en leefstijlfactoren die het autonoom zenuwstelsel beïnvloeden en/of via andere 
mechanismes die niets te maken hebben met autonome activiteit.  
 
CONCLUSIE 
 
Dit proefschrift versterkt het bewijs dat depressie en angststoornissen niet gepaard 
gaan met autonome ontregeling in rust en dat eerder gevonden verbanden wellicht 
veroorzaakt zijn door de effecten van leefstijl en antidepressivagebruik. Aangezien we 
een sterk verband vinden tussen autonome ontregeling en verhoogd risico op 
hart- en vaatziekten, is het belangrijk voor de klinische praktijk en de 
volksgezondheid om factoren te onderzoeken die een goede of slechte invloed 
hebben op autonome activiteit. Behandelaren van mensen met depressie en angst 
behoren voorzichtiger te zijn met het voorschrijven van antidepressiva, vooral 
TCAs. Zij zouden alternatieven kunnen overwegen, zoals leefstijlverandering, die 
een positief effect hebben op mentale en fysieke gezondheid. Toekomstig 
interventioneel en mechanistisch onderzoek is nodig om diepere kennis te 
verwerven over de relatie tussen depressie/angst, het autonoom zenuwstelsel en 
hart- en vaatziekten. Deze kennis is noodzakelijk voor vroegtijdige interventies, 
medicijnontwikkeling en behandelstrategieën die werkelijk een verschil kunnen 
maken in een samenleving die steeds meer te maken heeft met problemen van het 
hoofd en het hart.   
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